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ABSTRACT 
 
Cutaneous fatty acid-binding protein (C-FABP) or FABP5, is a FABP family 
member that can bind to long chain fatty acids with high affinity. C-FABP was 
identified by our research group as a gene involved in malignant progression of 
prostate cancer and able to promote the growth of primary tumours and induce 
metastasis when transfected into rat benign Rama 37 model cells. It was 
demonstrated that C-FABP was a prognostic marker for patient outcome and a target 
of tumour-suppression for prostate cancer. As an initial step to understanding the 
complex molecular mechanisms involved in the cancer promoting activity of C-
FABP, this study investigated the possible relationship between tumorigenicity-
promoting activity of C-FABP and its fatty acid-binding capability. After single and 
double mutations were generated in the fatty acid binding motif of the C-FABP 
cDNA, wild type and mutant C-FABP cDNAs were excised from the mammalian 
vector pIRES2-EGFP and inserted into pBluescript cloning vector to generate a 
complimentary restriction sites at both ends of the cDNAs. The C-FABP cDNAs 
were excised from the pBluescript vector with KpnI and PstI and inserted into pQEs 
expression vector to form three constructs that express the wild type and two mutant 
C-FABPs (C-FABP-WT, C-FABP-R109A and C-FABP-R109/129A), respectively. 
SDS-PAGE and sequence analysis confirmed the correct insertion of C-FABPs into 
expression vector pQE. The pure recombinant proteins were subsequently produced 
and purified. The importance of fatty acid-binding activity to the cancer promoting 
function was assessed by comparing the cancer promoting abilities exerted by C-
FABPs with different fatty acid-binding capabilities. 
To test whether the recombinant proteins produced were biological active, the fatty 
acid binding ability of wild type and mutant C-FABPs were tested. When fatty acid 
binding ability of the wild type C-FABP is set at 1, the average fatty acid binding 
ability the C-FABP-R109A and C-FABP-R109/129A were significantly reduced to 
0.32% and 0.09%, respectively (Student t-test, P<0.005).  These results suggested 
that fatty acid binding ability of C-FABP depends on the structured integrity of the 
binding motif. Thus, changing one amino acid in the motif significantly reduced the 
fatty acid binding ability by 68%, and changing two amino acids almost completely 
abolished the fatty acid binding ability of C-FABP. 
To access the importance of the structural integrity of the fatty acid binding motif to 
the tumorigenicity-promoting activity of C-FABP in prostate cancer, the effect of 
wild type and mutant C-FABPs on cell proliferation, invasion and colony formation 
as indication of tumourigencity were analysed. The average growth rate of cells 
stimulated with C-FABP-WT was significantly increased by 17% (Student t-test, 
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P<0.05) when compared to control cells. Whereas, the average growth rate of cells 
stimulated with C-FABP-R109A and C-FABP-R109/129A were significantly 
reduced by 33% and 47%, respectively (Student t-test, P<0.005) when compared to 
control cells. The invasiveness of cells stimulated with C-FABP-WT, C-FABP-
R109, C-FABP-R109/129A and the control cells were 256±40, 163±32, 80±26 and 
96.6±15.2, respectively. The number of invaded cells stimulated with C-FABP-WT 
was the highest in all cell lines and more than 2.6-fold higher than the number of 
invaded cells from control (Student t-test, P<0.05). The average number of colonies 
produced in the soft agar by selected cells stimulated with C-FABP-WT, C-FABP-
R109A, C-FABP-R109/129A and control were 1050±132.29, 283±76.38, 157±38.1 
and 155±68.74, respectively. In comparison with the control, the average number of 
colonies produced by C-FABP-R109A stimulated cells was increased by 45% 
(Student t-test, P<0.01) whereas the average number of colonies produced by C-
FABP-R109/129A stimulated cells was at same level as the control cells (Student t-
test, P>0.5). The most significant change occurred in C-FABP-WT stimulated cells 
that produced more than a 6.7-fold (85%) increase in the number of colonies formed 
in soft agar when compared to controls (Student t-test, P<0.001). These results 
showed that the increased wild type C-FABP stimulation in prostate cell line 
significantly increased cell proliferation, invasiveness, and tumorigenicity. Whereas, 
the increased expression of both mutant forms of C-FABP did not significantly affect 
these characteristics. 
Overall, this study has confirmed that the biological potential of C-FABP to promote 
tumourigencity of prostate cancer cells depends on its ability of binding to fatty 
acids. Thus, C-FABP may facilitate cancer development through a mechanism 
involving transportation of intracellular fatty acids into cells. These results were 
supported by our recent data obtained from in-vivo studies performed in a nude 
mouse model.   
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1.1 Epidemiology of prostate cancer  
1.1.1 Incidence  
Prostate cancer is the most frequently diagnosed non-cutaneous male malignancy and 
is the second cause of cancer-related death in men in most Western countries. In 
2008, there were 37,051 new cases of prostate cancer diagnosed in the UK (Table 
1.1). Worldwide, it is estimated that 913,000 men were diagnosed with prostate 
cancer in 2008, and more than two-thirds of cases were diagnosed in developed 
countries (Figure 1.1). The highest rates were in Australia/New Zealand, Western 
Europe and USA while the Asian countries have the lowest rates (Figure 1.1) (Jemal 
et al, 2008). Different screening methods, diet and environment, family history and 
genetic factors all contribute to this variation.  
The apparent rise in incidence rates is almost certainly of the introduction of serum-
based assays for prostate specific antigen (PSA) together with other clinical 
examinations. PSA is normally present in blood at very low levels up to 4.0 ng/ml. 
PSA is usually used as one of the primary methods to diagnose the disease at an early 
stage. As a result, survival rate has improved in recent decades, mostly because the 
improved diagnosis and screening procedures have lead to discovery of organ-
confined tumours (Tanaka et al, 2010). However, elevated levels of PSA (more than 
4.0 ng/ml) may suggest although not confirmed the presence of prostate cancer. In 
addition, tumour metastasis also occurs in patients with prostate cancer who have 
normal PSA level.    
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Table 1.1: Prostate cancer: number of new cases and European-age standardised 
incidence rate (ASR), countries of the UK, 2008 (Baade et al, 2009). 
  
England Scotland Wales 
Northern 
Ireland 
United 
Kingdom 
Cases 30,893 2,716 2,480 962 37,051 
Crude Rate 122 108.6 169.9 110.5 122.9 
ASR 97.5 85.7 119.9 103.8 97.9 
ASR - LCL 96.4 82.5 115.2 97.2 96.9 
ASR - UCL 98.6 88.9 124.6 110.3 98.9 
  
 
 
Figure 1.1: prostate cancer, world age-standardised incidence and mortality 
rates, by world regions, 2008 (Jemal et al, 2008). 
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1.1.2 Mortality 
Prostate cancer accounts for around 12% of male deaths from cancer in the UK and 
is the second most common cause of cancer death in men after lung cancer. Ninety-
three Percent of prostate cancer deaths occur in men aged 65 and over (Figure 1.2) 
(Edwards et al, 2005). 
Prostate cancer mortality in the UK was fairly stable during the 1970s but began to 
increase in the early 1980s (Figure 1.3). Mortality peaked in the early 1990s when 
the European age-standardised death rate reached 30 per 100,000 in 1992. Since then 
there has been a slight fall in the rates and in 2008 the European age-standardised 
rate was 24 per 100,000. This was the first sustained decrease in annual death rates 
for thirty years (Bosetti et al, 2008).  
 
Figure 1.2: number of deaths and age-specific mortality rates, prostate Cancer, 
UK, 2008 (Schroder et al, 2009).  
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Figure 1.3: Age-standardised (European) mortality rates, prostate cancer 1971-
2008 (Bosetti et al, 2008).  
 
1.1.3 Survival 
Five year survival rates for prostate cancer have improved from around 31% for 
patients diagnosed in 1971-75 to 77% in 2001-2006 in England and Wales (Figure 
1.4) (Rachet et al, 2009). The latest survival statistics for Scottish men show that 
five-year relative survival rates have increased from 37% for patients diagnosed in 
1977-81 to 60% for patients diagnosed in 1996-2000 (Brewster et al, 2000).     
0
5
10
15
20
25
30
35
1
9
7
1
1
9
7
4
1
9
7
7
1
9
8
0
1
9
8
3
1
9
8
6
1
9
8
9
1
9
9
2
1
9
9
5
1
9
9
8
2
0
0
1
2
0
0
4
2
0
0
7
R
a
te
 p
e
r 
1
0
0
,0
0
0
Chapter 1: Introduction           P a g e  | 36 
 
 
 
 
 
Figure 1.4: prostate cancer Age standardised five-year survival rates in England 
and Wales (Rachet et al, 2009).  
 
1.2 Risk Factors  
1.2.1 Age 
Age is an important risk factor for prostate cancer (Figure 1.2). Prostate cancer is 
rarely seen in men younger than 40 years, the incidence rises rapidly with each 
decade thereafter. The possibility of developing prostate cancer varies with age, 
being 13.7% for the age group of 60-79 years, 2.2% for those aged 40-59 and 
0.005% in those younger than 39 years (Merrill & Bird, 2002). In addition, the 
probability of finding prostate cancer when performing autopsies in deceased people 
is much higher, at about 20% in men between the age of 50 and 60 years and 
increasing to 50% in men between 70 and 80 years old (Lunenfeld, 2002).  
0
20
40
60
80
100
1971-
1975
1976-
1980
1981-
1985
1986-
1990
1991-
1995
1996-
1999
2001-
2006*
Chapter 1: Introduction           P a g e  | 37 
 
 
 
 
1.2.2 Race 
Variations in both incidence and death rates around the world from prostate cancer 
have been reported amongst different races. In the UK, the risk of being diagnosed or 
dying from prostate for black Caribbean and black African men is approximately two 
to three times higher than that for white men, while Asians annually have the lowest 
incidence rate of prostate cancer (Jemal et al, 2008). The differences in prostate 
cancer risk by race may reflect genetic variation, dietary habit, and even the methods 
used to detect the cancer and determine the incidences. In recent years, prostate 
cancer incidence has risen considerably in many countries, including countries in 
which prostate cancer was previously considered low. Although changes in lifestyle 
cannot be excluded, the rate of change is too fast to be concerned solely by 
alterations in life style.  
1.2.3 Family history 
There is an increase in incidence of prostate cancer in persons with a history of 
prostate cancer in their family (about two to four times higher than in control 
population). Those with a family history of prostate cancer tend to have their disease 
diagnosed six years earlier than control (Bratt, 2002). Family history and hereditary 
factors are estimated to be important in 5-10% of all prostate cancers, and 40% of 
those cancers diagnosed below the age of 55. However, the clinical presentation of a 
family history of prostate cancer does not indicate cancer presenting at an early age, 
and there is no difference in stage or grade.  
Some of the genetic loci identified by linkage studied include hereditary prostate 
cancer gene 1 (HPC1) on chromosome 1q23-25, predisposing to prostatic cancer 
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(PCAP) on chromosome 1q42-43, cancer of the prostate and brain (CAPB) on 
chromosome 17p, locus on chromosome 8p22-23 and HPC2 on chromosome 17p 
(Makridakis & Reichardt, 2004). In a study of Scandinavian twins, higher prostate 
cancer concordance rates were found for monozygotic twins versus dizygotic twins, 
suggesting a genetic influence on risk (Lichtenstein et al, 2000). 
Prostate cancer was also reported to occur at a higher rate in families with other 
cancers such as breast cancer. Carriers of the breast cancer 1 (BRCA1) gene had 
twice the incidence of prostate cancer of non-carriers (Tulinius et al, 1992). Those 
families with hereditary prostate cancer also had higher incidence of central nervous 
system tumours (Isaacs et al, 1995). 
1.2.4 Hormones  
Androgens play an important role both in development and growth of the prostate 
gland and its over-expression also play an important role of prostate cancer 
development. It has been suggested that altered hormone metabolism may play a role 
in the progression of prostate cancer from histologic to clinically significant (Attar et 
al, 2009). Indeed, Hsing (2001) showed that testosterone levels was higher in 
patients with prostate cancer than control (Hsing, 2001), although, another study has 
been unable to confirm this (Shaneyfelt et al, 2000). It has been found that the level 
of  serum testosterone in young black men is approximately 15% higher than that in 
their white counterparts, and this difference may explain the increased risk of 
prostate cancer in black men (Sasagawa & Nakada, 2001). It has also been shown 
that testosterone metabolism is different in American/European men when compared 
with Japanese men (Sasagawa & Nakada, 2001). Japanese men have a lower 5-alpha 
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reductase activity, which may help explain their lower incidence of clinical prostate 
cancer. Although, hormones play an important role in normal and cancerous prostate 
physiology, their relationship to risk of prostate cancer remains undefined.    
1.2.5 Other factors 
The association of prostate cancer with other risk factors have been evaluated in a 
number of studies. However, the statistic data for risk factors such as socioeconomic 
status, occupation, cigarette smoking, alcohol consumption and vasectomy were not 
convincing that these risk factors resulted in an increasing incidence of prostate 
cancer. In contrast, some studies have shown increase in risk of prostate cancer with 
an increase in number of sexual partners (Rosenblatt et al, 2001).   
 
1.3 The Pathology of Prostate Cancer 
1.3.1  Anatomy of the prostate  
The prostate gland is an ovoid shaped gland located at the base of the bladder, 
surrounding the proximal urethra. The human prostate consists of four morphological 
regions comprising of two peripheral zones, a central zone and a fibromuscular zone 
(Figure 1.5). The peripheral zones together consist of approximately 70% of the total 
tissue mass of the gland. They are very susceptible to inflammation and it is within 
these zones that mature prostate tumour cells are commonly located. The central 
zone makes up 25% of the total tissue mass of the prostate gland and it is very 
resistant to inflammation and to prostatic carcinoma. The transitional zone, making 
up 5% of the total prostate tissue mass and it is the most common site of Benign 
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Prostatic Hyperplasia (BPH) while the fibromuscular zone is responsible for 
secretion of prostatic fluids during ejaculation by initiating muscular contractions 
(Abate-Shen & Shen, 2000).  
 
Figure 1.5: The anatomy and zones of prostate gland (Abate-Shen and Shen, 
2000). 
 
1.3.2 Prostate Architecture 
The normal prostate composes of different cell types that can be distinguished by 
their cytokeratin (CK) and cluster differentiation (CD) expression pattern. Three 
main cell types are discernible within normal, mature prostatic epithelium-basal, 
secretory luminal and neuroendocrine. The luminal or glandular cells constitute the 
exocrine compartment of the prostate, secreting prostate specific antigen (PSA) and 
prostatic acid phosphate (PAP) into the glandular lumina. They express high levels of 
the androgen receptor (AR), and depend on androgens for their survival (Collins & 
Maitland, 2006). They also express CK 8 and CK 18. 
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In contrast, basal cells are relatively undifferentiated and lack secretory activity. 
These cells rest on the basement membrane and are able to express CKs 5 and 14 as 
well as CD44 (Bonkhoff & Remberger, 1996). A study by Collins and Maitland 
(2006) reported that basal cells express low/undetectable levels of AR and are 
independent of androgens for their survival (Collins & Maitland, 2006). However, 
they do express autocrine factors such as Bcl-2 which has a protective function 
against DNA damage (Rizzo et al, 2005).  
The third cell type is neuroendocrine cells. These cells are found in the epithelium of 
the acini and in ducts of all parts of the gland. The major type of neuroendocrine 
cells contains serotonin, thyroid stimulating hormone and chromogranin A. 
neuroendocrine cells are terminally differentiated, post-mitotic cell types that are 
androgen insensitive (Bui & Reiter, 1998), and can also express neuropeptide Y. 
Therefore, the immunoreactivity to neuropeptide Y was demonstrated in up to 75% 
of prostate cancer, suggesting a role in growth and expansion of prostate cancer 
(Ruscica et al, 2007).  
 
1.4 Prostate cancer initiation  
1.4.1 Benign Prostatic Hyperplasia (BPH) 
Benign Prostatic Hyperplasia (BPH) defines as non malignant overgrowth of prostate 
tissue. BPH and prostate cancer are often found concurrently, and there are some 
similarities between these two lesions. Both are age related disease and both require 
androgen stimulation. However, BPH is not a precursor of prostate cancer (Sausville 
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& Naslund, 2010). BPH develops in the transition zone, a ring of tissue around the 
urethra and its growth is inward toward the prostate's core, constantly tightening 
around the urethra and associated with lower urinary tract symptoms (LUTS). Most 
of prostate carcinomas, on the other hand, begin in the outer peripheral zone of the 
prostate and invade the surrounding tissues. Although the pathogenesis of BPH is 
still poorly understood, some studies indicated that BPH is related to hormonal 
changes that occur as men ageing (Wise & Ostad, 2001).  
1.4.2 Prostatic Intraepithelial Neoplasia (PIN) 
Prostatic Intraepithelial Neoplasia (PIN) refers to a sub stage of cellular 
transformation from a normal to a malignant prostatic epithelium (Foster et al, 1999). 
In the UK, over a million biopsies are studied to detect 198,500 new cases of prostate 
cancer annually. PIN represents abnormal proliferation of malignant cells without 
invasion into surrounding stroma, and can be characterized by a variety of 
architectural and cytological aspects (Foster & Ke, 1997) resulting in minimal 
changes to modifications that make it undistinguishable from carcinoma (Montironi 
et al, 2000).  
A study by Berry et al (2008) identified PIN lesions by histological studies of 
prostate cancer tissues (Berry et al, 2008). These lesions were grouped into a series 
of four architectural types: Tufting, Micropapillary, Cribriform and flat and are 
mainly located in the peripheral zone of the prostate. Likewise, the morphological 
appearances can be as low grade or high grade PIN. A low grade PIN lesion is often 
a well differentiated early invasive tumour with a high percentage of basal cells 
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whereas the high grade lesions form poorly differentiated tumours with a secretory 
luminal cell population (Bonkhoff & Remberger, 1996). 
Chromosomal mutation studies (Ayala & Ro, 2007; Joniau et al, 2005) have shown 
that high grade PIN is multifocal and endures the same chromosomal mutations 
observed in early invasive carcinoma. The appearance of high grade PIN generally 
precedes the manifestation of carcinoma by approximately 20 years and is an 
important morphological marker for detection of potential carcinoma of the prostate. 
1.4.3 Gleason Score  
Gleason Score (GS), the histological grading system of prostate cancer proposed by 
Dr. David Gleason in 1966 as a method for evaluating the prognosis of men with 
prostate cancer. GS is widely used for morphological tumour grading prostate cancer 
(Molinie, 2008). The GS is a sum of primary (greater 50% of total pattern seen) 
grade which represents the majority of tumour and secondary (less than 50%, but 
greater than 5% of total pattern seen) grade which represents the minority of tumour. 
The Combined GS is a number ranging from 2 – 10 (Molinie, 2008). The Gleason 
grade is a prostate cancer assess system depend on subjective microscopic 
determination, ranges from 1 – 5, representing the degree of loss of normal glandular 
tissue architecture. Thus grade 1 is the least aggressive and Grade 5 is the most 
aggressive cancer (Figure 1.6).       
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Figure 1.6: Gleason grading system diagram (Humphrey, 2004). 
The subjective microscopic determination of the loss of normal prostate glandular 
structure caused by cancer is graded by number ranged from 1 to 5, with 5 being the 
worst grade possible.  
 
1.5 Cell culture models 
The three cell lines DU-145, PC-3 and LNCaP are the most widely used cells in 
prostate cancer research (Table 1.2). These cells have also been used to address 
various problems encountered in understanding and treating cancer progression and 
metastasis.  
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Table 1.2: General characteristics of DU-145, PC-3 and LNCaP parental cell 
lines (Sobel & Sadar, 2005)  
*some sublines have become androgen insensitive 
 
1.5.1 DU-145  
DU-145 was the first prostate cancer cell line to be established in tissue culture. It 
was derived from a moderately-differentiated brain metastasis (Sobel & Sadar, 
2005). DU-145 cell express low level of prostatic acid phosphatase (PAP) and fail to 
express androgen receptor (AR), prostate specific antigen (PSA) and kallikrein (hK2) 
(Sobel & Sadar, 2005). They also express intermediate filament proteins and 
cytokeratins (CKs) 7, 8, 9 and 19, but not cytokeratin 5 and 14 (van Bokhoven et al, 
2003). The cell population doubling time of Du-145 is approximately 34 hours. It 
grows slowly in soft agar but produces sizable colonies when seeded at 1x10
3-5
 cells 
per dish. Animal studies showed that the tumour, when inoculated into SCID mice, 
results in metastases to liver, lung, spleen, adrenals, kidneys and lymph nodes 
(Bastide et al, 2002).  
 
 DU-145 PC-3/PC-3M LNCaP 
Androgen sensitive No No Yes/No* 
PSA No No RNA and protein 
hK2 No No RNA and protein 
AR No No RNA and protein 
Derivation Brain Vertebra Lymph node 
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1.5.2 LNCaP 
LNCaP cells were isolated from a needle aspiration biopsy of a lymph node 
metastatic lesion (Sobel & Sadar, 2005). LNCaP cells express a high affinity nuclear 
androgen receptor and respond to androgens that stimulate their growth. The cell 
population doubling time of LNCaP is 60 hours. Animal studies showed that tumours 
are formed earlier in male than in female mice, indicating a probable androgen-
dependant characteristic (Zheng et al, 2010). LNCaP cells express CK8 and 18, and 
express a wild type TP53. 
1.5.3 PC-3 
The PC-3 cell lines (Figure 1.7) were originally derived from a poorly-differentiated 
prostate cancer metastasis in bone (Sobel & Sadar, 2005). The cells have a doubling 
time of approximately 33 hours and grow readily in female nude mice, indicating 
their androgen-independent character. Treatment with the mitogens insulin or 
parathyroid hormone and growth factors such as EGF and FGF fails to stimulate their 
growth. PC-3 cells express CKs 5, 8 and 18, and contain a frame-shift mutation in 
TP53 that results in a premature stop codon (van Bokhoven et al, 2003). Based on 
PC-3 cell growth in xenografts, PC3-M cells were isolated with more aggressive 
features than their parental cells. Other sublines, including PC3-M2, PC3-M-pro4 
and PC3-M-LN4 with increased levels of malignancy were also generated. All PC-3 
cells and their derivatives (Figure 1.7) are androgen independent, and do not express 
PSA, RNA or protein (Sobel & Sadar, 2005). 
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Figure 1.7: Schematics of original PC-3 cells and their derivatives (Sobel & 
Sadar, 2005).               
 
1.6 Oncogenes and tumour suppressor genes in prostate cancer  
1.6.1 Oncogenes  
Proto-oncogenes are a group of genes that cause normal cells to become cancerous 
when they are mutated. Proto-oncogenes are involved in regulating cell proliferation, 
single transduction, differentiation and execution of mitogenic signals, usually via a 
translated protein product (Weinstein & Joe, 2006).  
Many oncogenes have been implicated in the development of various types of human 
malignancies. In prostate cancer, the most frequently studied oncogenes are genes of 
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Ras family, C-myc, bcl-2, and HER-2. Thus, none of these oncogenes have been 
correlated conclusively with the initiation or progression of prostate cancer. 
1.6.1.1 Ras oncogene  
The Ras family gene, including H-Ras, K-Ras and N-Ras has been widely studied in 
prostate cancer. Ras genes encode the G-protein (21kD) that connect receptor 
tyrosine kinases on the cell surface with their downstream effectors, Raf, MEK 
(mitogen-activated kinas/extracellular signal-regulated kinase) and ERK 
(extracellular signal-regulated kinase) (Gioeli, 2005). Ras oncogene is activated by 
missense point mutation and altered p21 stimulated cell proliferation in the absence 
of external signals. Abnormalities of the signal pathway occur in many cancers, 
although a very limited number of clinical cases have been reported in prostate 
cancer gene mutation in Western countries. There appears to be a racial variation. 
For instance, Ras gene mutation were relatively uncommon in prostate cancer in the 
United States (Gumerlock et al, 1991). In contrast, the rate of mutation is 26% in 
Japanese prostate cancer suggesting that such mutation is racially-distributed. 
Nevertheless, the p21 mediated signalling pathway is a key role in prostate cancer, 
which was activated by growth factors as a portion of their signalling pathway. 
Moreover, activation of Ras can induce androgen independent growth of prostate 
cancer cells and stimulate the activation of androgen-response genes through Raf and 
MEK mediated pathway in androgen-dependent and androgen-independent cells 
(Gioeli, 2005).  
At mRNA level, the increased expression of Ras was reported both in rat prostatic 
dysplasia (Yu et al, 1993) and human primary tumours, as well as prostate cancer 
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cell lines (Shields et al, 2000). However, the Ras mRNA expression was not 
correlated with tumour progression.   
1.6.1.2 C-myc oncogene  
The c-myc oncogene is located on chromosome 8 at 8q24 and plays an important role 
in regulation of cell proliferation, cell differentiation and apoptosis (Grandori et al, 
2000). This well known oncogene, characterised  as a transcription factor, increase 
its copy numbered by amplification or/and chromosomal gain (Ferrara, 2004). A 
number of studies have reported that c-myc mRNA is elevated in prostate cancer, 
compared to normal prostate tissues or BPH, and that there is a trend on  the 
enhanced c-myc expression with increased tumour grades (Gurel et al, 2008; 
Williams et al, 2005). These results indicated that the amplification of c-myc may be 
a potential marker for prostate cancer progression. However, Zhang et al (2000) did 
not detect the over-expression of c-myc gene in prostate cancer by in-situ 
hybridisation (Zhang et al, 2000). 
1.6.1.3 HER-2 (C-ERB-R2, neu) 
The HER kinase family, which includes epidermal growth factor receptor (EGFR) 
and human epidermal growth factor receptor (HER2), are receptor-and receptor- like 
transmembrane proteins that are activated in some human tumours (Hynes & Lane, 
2005). The gene encoding the HER2 protein is amplified in 20% to 25% of breast 
cancer patients and an anti HER2 antibody, trastuzamb, has verified to be useful in 
their treatment (Slamon et al, 2001). It has been reported that over expression of 
HER2 may contribute to androgen independence in prostate cancer (Craft et al, 
1999). They showed that HER2 can activate the androgen receptor pathway in 
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absence of ligands like steroid hormones. In addition, casodex, an androgen 
antagonist, blocks the effects of growth factors but not HER2 on androgen receptor 
functions. This indicates that either HER2 signalling cascade produces a molecule 
that binds at competitively higher affinity than casodex, or HER2 activates androgen 
receptor function on fresh non-optimal androgen receptor ligand binding domains 
rather than to enhance androgen receptor function on high-affinity binding sites. 
Another group found that HER2 expression correlated with advanced stages of 
prostate cancer and higher Gleason scores (Katsumata et al, 1992). Nevertheless, 
reports on frequencies of HER2 over-expression in prostate cancer are controversial.  
1.6.1.4 Bcl-2 Oncogene   
Bcl-2 located on chromosome 18q21.33/18q21.3. It prevents programmed cell death 
and is thought to be a key gene for the regulation of cell life and death (Catz & 
Johnson, 2003). In the prostate gland, Bcl-2 is normally expressed in basal epithelial 
cells which are not affected by androgen deprivation but not in prostatic secretory 
epithelial cells (Matsushima et al, 1996; Raffo et al, 1995). Furthermore, McDonnell 
et al (1992) reported that Bcl-2 is undetectable in 13 of 19 androgen dependent 
prostate tumours. In contrast, 77% of androgen-independent cancers display high 
levels of Bcl-2 reactivity, indicating that Bcl-2 might be involved in the progression 
from androgen –dependence to independence. Abeele et al (2002) suggested that the 
function of Bcl-2 might be associated with its ability to regulate nuclear and systolic 
Ca
2+
 in prostate carcinoma cells (Abeele et al, 2002). Several studies have suggested 
that Bcl-2 expression increase with grade and stage, and is a potential biomarker for 
early prostate cancer (Foster et al, 1999) and in advanced hormone-refectory prostate 
cancer (Quinn et al, 2005). However, low level and high level Bcl-2 expression were 
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also observed in prostate cancer after treatment by radical prostatectomy alone 
(Amirghofran et al, 2005).  
 
1.6.2 Tumour Suppressor genes  
A tumour suppressor gene is a gene can protect normal cells from progressing to 
form a malignant tumour cell through their regulation function in cell. Absence of a 
tumour suppresser gene may allow tumorigenesis with restrained progression to 
metastasis (Knudson, 2001). Unlike oncogene, tumour suppressor genes generally 
follow the ´two-hit hypothesis´, which implies that the mutation in both alleles of 
double stranded DNA, before being permissive for tumorigenesis or metastasis 
(Knudson, 1971). This is due to the fact that if only one allele for the gene is 
damaged, then the second can still produce the correct protein. Hence, mutant tumour 
suppressor´s alleles are usually recessive whereas mutant oncogene alleles are 
typically dominant. 
´Gatekeeper´ genes are tumour suppressor genes that directly regulate the growth of 
tumours by inhibiting cell proliferation or promoting cell death. Mutation or deletion 
of such a gene increase the probability of tumour formation, such as PTEN (Ali, 
2000). ´Caretaker´ genes like BRCA1/BRCA2 (Levitt & Hickson, 2002), are tumour 
suppressor genes that normally repair DNA damage. Individuals with mutation of 
´Gatekeeper´ genes are at great risk of developing tumour. Furthermore, metastasis 
suppressor genes, are considered to be a gene that can prevent tumour cells from 
progressing to metastasis and eventually prevent tumour cells from spreading, such 
as NM23 and CD44 (Liu et al, 2002; Lombardi, 2006).  
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1.6.2.1 Retinoblastoma (RB) 
Retinoblastoma (RB) gene was the first tumour suppressor gene identified and was 
reported by Knudson et al in 1971 (Knudson, 1971). RB is located on the long arm of 
chromosome 13q and has been implicated in tumorigenesis of the DU-145 prostate 
cancer cell line. The RB gene product functions to suppress cell division by 
preventing cells in G1 phase from entering S phase. Replacement of the wild type RB 
gene led to decreased tumorigenesis of the cell line in nude mice (Bookstein et al, 
1990). A study by Taneja et al (2001) reported that 16.4% of RB gene mutations in 
primary human prostate cancer were detected by polymerase chain reaction  (PCR) – 
single stranded conformation  polymorphism (SSCP) analysis, suggesting that 
structural alteration of the RB gene is involved in progression steps of prostate 
carcinogenesis (Taneja et al, 2001).  
1.6.2.2 P53 
P53 is a nuclear phosphoprotein (53 KDa) encoded by gene TP53 located on 
chromosome 17p13. The protein product of P53 gene has been shown to control cell 
cycle progression, DNA repair and cell survival (Shi et al, 2002). P53 has been 
found in three of five prostate cancer cell lines (Isaacs et al, 1991). In the PC-3 cell 
lines, the alteration of P53 gene has been detected on DNA, mRNA and protein 
levels (Rubin et al, 1991). Several studies described that alteration in P53 gene is 
clearly associated with progressive disease, like metastasis to bone and androgen-
independent growth (Burchardt et al, 2001; Shi et al, 2004). However, Brooks et al 
(1996) considered that point mutation of P53 gene may be an infrequent event in the 
oncogenesis of untreated prostate cancer (Brooks et al, 1996).  
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1.6.2.3 Cadherin 
 Cadherin is a member of the family of cell adhesion molecules (CAMs) that include 
occludins, integrins, and a variety of immunoglobulin-like molecules. All are cell-
surface proteins and play a variety of roles in cell recognition, contact inhibition and 
cell-cell adhesion. The E-cadherins encoded by CDH1 located on chromosome 
16g22.1, is a calcium dependent, homophilic cell-cell adhesion molecule that drive 
morphogenetic rearrangements and maintain the integrity of epithelial layers via the 
formation of adherens junction (Lilien et al, 2002). The expression of E-cadherin 
was decreased in a various high grade carcinomas with more aggressive phenotype, 
including prostate cancer (Umbas et al, 1997). N-cadherin is just like E-cadherin a 
type-I cadherin encoded by gene CDH2 located on chromosome 18q11.2. While E-
cadherin is mostly expressed in epithelial cells, N-cadherin is expressed in various 
cell types including nerve, myocardial and mesenchymal cells. It was believed that 
E-cadherin promotes epithelial cell-epithelial cell adhesion by interacting with E-
cadherin molecules on opposing cell surface (Hajra & Fearon, 2002), while N-
cadherin promotes epithelial cell-stromal cell adhesion.  
Controversial gene expression of E-cadherin was found in prostate cancer different 
stages, in which loss of expression of E-cadherin was found in localised prostate 
cancer with increased N-cadherin, while high expression of E-cadherin in metastasis 
(Rubin et al, 2001; Tomita et al, 2000). However, re-expression of E-cadherin was 
also found in primary breast cancer transition to metastasis. Recent studies showed a 
single polymorphism was found on allele A of E-cadherin promoter region with 70% 
decreased transcription of allele A in prostate cancer (Lindstrom et al, 2005), that 
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may explain decreased E-cadherin expression in localised prostate cancer not in 
metastasis. 
Although several studies suggested that a significant effect for E-cadherin expression 
in prostate cancer (Dhanasekaran et al, 2001), it is still difficult to use E-cadherin in 
clinical trial. This is partly due to heterogeneous expression in prostate carcinoma. 
Thus, as a potential marker, E-cadherin may be used in combination with other 
biomarker.  
1.6.2.4 KAI-1 
KAI-1 is a metastasis suppressor gene isolated by Alu-PCR techniques from human 
chromosome 11p11.2 and shown to suppress metastasis when introduced into 
Dunning rat AT6.1 prostate cancer cells. KAI-1 encodes a plasma membrane 
glycoprotein belonging to the TM4 superfamily (Jackson et al, 2003), with four 
transmembrane domains and a large N-glycosylated motif. It is believed to play a 
key role in cell-cell interaction or in extra cellular matrix binding and suggested as a 
tumour suppressor gene. In addition, the protein product of the gene is reported to be 
reduced in human cell lines derived from metastatic prostate cancer (Dong et al, 
1995). Interestingly, Schulz et al (2003) have shown that expression of KAI-1 is 
directly activated by p53, and loss of immunoreactivity of both KAI-1 and p53 
resulted in poor overall survival of prostate cancer patients (reviewed in (Schulz et 
al, 2003)).   
1.6.2.5 NM23  
NM23 located on chromosome 17q21.3, encodes a nucleoside diphosphate kinase 
that was reported to be a tumour suppressor gene (Kauffman et al, 2003), involved in 
Chapter 1: Introduction           P a g e  | 55 
 
 
 
 
the  proliferation and  differentiation of several cancers.  Several studies correlated 
low expression of NM23 with poor prognosis and survival, lymph node infiltration 
and histopathological indicators of high metastatic potential, in a number of cancer 
types (Hartsough & Steeg, 2000). However, the role of NM23 needs to be clarified in 
prostate cancer. Evidence from some studies showed that the high level expression of 
NM23 was found in prostate metastasis sites by immunohistochemical  staining 
analysis (Igawa et al, 1996). Another study displayed over-expression of NM23 in 
PIN suggesting that over-expression of NM23 represents an early event in the 
development of prostate cancer and its decreased expression might be associated 
with later prostate cancer metastases (Myers et al, 1996). 
1.6.2.6 CD44 
The CD44 gene located at 11p13 chromosome encodes a transmembrane 
glycoprotein. It is an important tumour metastasis suppressor gene in prostate cancer 
(Ponta et al, 2003) which also plays a role in normal prostatic epithelial cell 
differentiation. Both protein and mRNA studied demonstrated that CD44 expressed 
strongly in basal cells and moderately in luminal cells in benign acini (Noordzij et al, 
1997; Omara-Opyene et al, 2004). Moreover, CD44 protein has been found in benign 
prostatic tissues and in 60% of primary prostate cancer with about 14% of metastasis 
expressing low level of CD44 (Aaltomaa et al, 2000). De Marzo et al (1998) strongly 
correlated loss of CD44 with high grade and invasive prostate cancer (De Marzo et 
al, 1998). In the AT3.1 rat prostate cancer cell-line, transfection-induced expression 
of CD44 can suppress tumour metastasis but not affect tumorigenesis (Noordzij et al, 
1999). Verkaik et al (2000) suggested that hypermethylation at the promoter region 
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of CD44 may block gene transcription in prostate cancer eventually and, reducing 
protein expression of CD44 (Verkaik et al, 2000).  
1.6.2.7 PTEN 
The gene PTEN (phosphatase and tensin homologue) is a 47-KDa dual-specificity 
phosphatase with homology both to the protein tyrosine phosphatase family and two 
cytoskeleton proteins, tensin and auxilin. The tyrosine phosphatase family plays an 
important role in regulating cell signal transduction and in cell transformation (Tell 
et al, 2004). Homozygous deletions of PTEN have been detected in up to 10% of 
locally confined cancers and metastasis (Verhagen et al, 2006) also in 30% of 
prostate cancer cell lines and xenografts (Vlietstra et al, 1998). PTEN point 
mutations have been demonstrated in 2 to 10% of primary prostate cancer (Dong et 
al, 2001), and 30% to 60% of metastases (Dong et al, 2001; McMenamin et al, 
1999), suggesting that PTEN could be a marker for prostate cancer metastasis, as 
well as for metastatic potential. The mechanism of PTEN acting as a tumour 
suppressor gene may involve inhibition of the phosphatidylinositol-3-kinase- protein 
B (PI3K-ATK) signalling pathway that is important for cell-cycle progression and 
cell- survival (Davies et al, 1999). Further studies demonstrated that the up-
regulation of AKT activation is significantly associated with decreased survival, and 
therefore PTEN loss is a possible route by which this may occur (McCall et al, 
2008).  
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1.7 Prostate Cancer Metastasis  
Metastasis is defined as the process, by which malignant prostatic epithelial cells 
leave the primary tumour and travel to distant sites through circulatory system and 
there establish secondary tumours. This is a multi-step process that consists of a 
series of sequential events involving complex interaction between the cancer cells 
and their environment. After the initial neoplastic transformation of cells, metastasis 
is thought to involve the following steps (Figure 1.8) (Arya et al, 2006). 
 Initial neoplastic transformation of prostate cells 
 
Tumour neoangiogenesis/ lymphangiogenesis and cancer growth 
 
Loss of local cell adhesion and detachment of cells from primary tumour 
 
Local invasion of host stroma (extracellular matrix) 
 
Escape of tumour cells into vasculature or lymphatics 
 
Cancer cell avoidance of immune system attack and turbulence of circulation 
 
The non-random homing of neoplastic cells to specific metastatic sites 
 
Extravasation of tumour cells into secondary organ and proliferation and 
growth at this site 
    
Figure 1.8: The metastatic cascade of prostate cancer 
After the initial neoplastic transformation of cells, metastasis is thought to involve 
multiple steps. The cell has to detach from the local primary tumour tissue 
architecture and invade the surrounding tissue, leading to invasive growth. Motile 
cells then have to enter the bloodstream and travel in the vascular network to reach 
a distant location. Then the cell must be able to leave the bloodstream and invade 
into the target tissue and proliferate at the target site.     
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1.7.1 Mechanisms of bone metastasis in prostate cancer 
The skeleton is a preferred site for prostate and breast cancer metastasis. The studies 
demonstrated that approximately 90% of advanced prostate cancer metastasize to 
bone (Kingsley et al, 2007). Within the skeleton, metastases present as two types of 
lesions: osteoblastic or osteolytic. These lesions result from an imbalance between 
osteoblast-mediated bone formation and osteoclast-mediated bone resorption 
(Kingsley et al, 2007).    
1.7.1.1 Osteoclastic bone resorption 
The first important steps of prostate cancer cells metastasis to the bone is the 
activation of osteoclasts resorption which results in not only allowing the seeding of 
cancer cells but also releasing survival and growth factors that promote prostate 
cancer metastasis (Kingsley et al, 2007). Among these factors, the most prominent is 
the Receptor Activator of Nuclear Factor -  ligand (RANK ligand) produced by 
osteoblastic cells (Figure 1.9). 
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Figure 1.9: Schematic representation of the putative interactions between 
prostate cancer cells and osteoblastic/osteoclastic cells in tumoral bone 
microenvironment (Mori et al, 2007).  
RANK-positive prostate tumour cells preferentially target bone microenvironment 
where it is rich in RANKL. In tumoral bone environment, RANKL produced by 
osteoblasts and bone stromal cells has two potential targets: osteoclasts/osteoclast 
precursors and prostate cancer cells. RANKL acts as a ‘soil’ factor that facilitates 
prostate cancer metastasis development in bone by activating both kinds of RANK-
positive cells. : RANKL, : RANK, : OPG, X: soluble factor(s) produced by 
prostate cancer cells. 
 
 
RANK ligand is mainly located on the surface of osteoblasts and bind to its specific 
receptor (RANKR) which is expressed on the surface of the osteoclastic precursors. 
The studies showed that osteotropic factors such as parathyroid hormone, 1, 25-
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dihydroxyvitamin D3, and parathyroid hormone can induce osteoclast formation and 
activation by up-regulation of RANKR (Penno et al, 2009). Osteoprotegerin, a 
member of tumour necrosis factor receptors, acts as a competitive inhibitor against 
RANK ligand binding RANKR and thus blocks the RANKR - RANK ligand 
interaction (Cairns et al, 1997). On the other hand, some controversial results 
demonstrated that osteoprotegerin also bind to tumour necrosis factor related 
apoptosis inducing ligand results in inhibition of cancer cell apoptosis (Holen et al, 
2002). Nevertheless, osteoprotegerin remarkably decreases prostate cancer metastasis 
to bones because it inhibits bone resorption (Mori et al, 2007). Therefore, the 
development of competitive antibodies, such as recombinant osteoprotegerin, against 
RANK ligand can be potential treatments for bone metastasis (Figure 1.10). 
 
 
Figure 1.10: The ratio of RANK ligand to osteoprotegerin determines the level 
of osteoclastogenesis (Mori et al, 2007).   
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1.7.1.2 Domination of the osteoblastic lesions 
Osteoblasts are bone forming cells which come from mesenchymal stem cells (Arya 
et al, 2006). Many factors can regulate the growth, survival and differentiation of 
osteoblasts, such as Endothelin-1 (ET-1), basic fibroblast growth factor (bFGF), 
Insulin-like growth factor (IGF) and Parathyroid hormone related protein (PTHrP). 
Some of them are also produced by metastatic prostate cancer cells. 
ET-1, a peptide of 21 amino acid residues, is synthesized in vascular endothelial 
cells. It is involved in angiogenesis, the formation of the new bone and osteoblastic 
bone metastasis (Medinger et al, 2003). The previous studies demonstrate that ET-1 
is one of the most over-expressed factors in osteoblast and can increase prostate 
cancer cell proliferation probably by enhancing the mitogenic effects of IGF and 
epidermal growth factor. Recent studies showed that overexpress ET-1 can up-
regulate the vascular endothelial growth factor (VEGF) expression through the 
endothelin receptor A in osteoblast and thus could act as an angiogenic factor in the 
formation of bone metastasis (Medinger et al, 2003). 
IGF-1 plays an important role in cell proliferation and inhibiting cell apoptosis in 
prostate cancer. Insulin-like growth factor binding protein-3 (IFGBP3) together with 
acid-labile subunit (ALS) binds IGF-1(75% - 90% of circulating IGF-1) and the 
ligands binding trigger the downstream pathway of IGF-1 receptor (IGF-1R). The 
ligands binding activate the intrinsic tyrosine kinase of IGF-1R which results in 
phosphorylation  of IGF-1R substrates - insulin receptor substrate-1 (IRS1), Src- and 
collagen-homology (SHC) and growth factor receptor-binding protein 2 (Grb2). 
Then, these phosphorylated factors active with Ras – Raf – mitogen-activated protein 
kinase (MAPK) cascade, which result in increasing cell proliferation (Piqueras et al, 
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2007). The IRS-1 also phosphorylates phosphatidylinositol 3’-kinase (P13K) and 
AKT, which promotes anti-apoptotic survival of the cancer cells as shown in (Figure 
1.11). In addition, it has been reported that elevated concentration of urokinase-type 
plasminogen activator (uPA) which is produced by prostate cancer cells also 
stimulates the local activity of IGF-1, therefore, increasing prostate cancer cells 
proliferation and inducing the osteoblastic reaction. 
 
 
Figure 1.11: IGF-I–IFGBP3–ALS binds to IGF-IR to trigger a series of ligand-
mediated activations including RAS–RAF–MAPK and PI3K–AKT signalling 
pathway, controlling cell proliferation and cell apoptosis, respectively (Piqueras 
et al, 2007).  
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1.7.2  Androgens and Prostate Cancer 
Androgens are male steroid hormones, such as testosterone, that control the 
development and maintenance of masculine characteristics. Androgens are 
synthesized primarily in testes, under the regulation of luteinizing hormone, which is 
itself regulated by the levels of gondotropin-releasing hormone (GnRH). Adrenal 
glands and some peripheral tissues including the prostate, also produce certain 
amount of androgens. Testosterone is the principle androgen and circulates mostly 
(98%) bound to sex hormone-binding globulin and albumin. At intracellular level, 
Testosterone is enzymatically converted to a more potent metabolite 
dihydrotestosterone (DHT); both steroids bind to the androgen receptor (AR), a 
ligand regulated transcription factor in the nuclear hormone receptor super family. 
Liganded-AR binds to the androgen response elements located in the regulatory 
regions of a variety of genes, many of which are involved in the growth, survival and 
differentiation of prostate cells (Attar et al, 2009).                    
1.7.3 Androgen independence and prostate cancer 
Androgens play a major role in promoting the development and progression of 
prostate cancer. As a result, androgen ablation (blockade of androgen action) through 
the androgen receptor (AR) has been the cornstone of treatment of advanced prostate 
cancer (Miyamoto et al, 2004). Therefore, prostate cancer is treated based on a 
unique characteristic, in that it is exquisitely dependent on androgen for 
development, growth and survival (Culig & Bartsch, 2006). Androgen ablation 
triggers cell death or cell cycle arrest of prostate cancer cells (Balk, 2002). Thus, 
androgen ablation remains the primary course of treatment for all patients with 
prostatic cancer (Sowery et al, 2007). The androgen-blockage therapy is initially 
Chapter 1: Introduction           P a g e  | 64 
 
 
 
 
effective, and result in disease remission. However, recurrent tumours arise within a 
median period of 2-3 years, and in these recurrent tumour cells androgen signalling 
has been inappropriately restored (Feldman & Feldman, 2001).  
1.7.4 Progression to androgen independence  
Progression to androgen independence is frequently signalled by a rise of Prostate 
Specific Antigen (PSA) under endocrine treatment and usually followed by cancer 
cell metastasis (Schroder, 2008). However, a total of seven mechanisms can be 
identified that are related to progression to androgen independence (Table 1.3). Five 
of those are dependent on the androgen receptor (AR), which is present or over-
expressed in androgen independent prostate cancer (AIPC) cell (Schroder, 2008). 
 
Table 1.3: Mechanisms of progression of prostate cancer to androgen 
independence (Schroder, 2008) 
Cause of Androgen 
independence 
AR-dependent change 
Example of Mechanisms 
of Androgen 
Independence 
Genetic Change in PC 
cells 
No 
Malignant epithelial stem 
cells 
Bypassing the AR No Inhibition of apoptosis 
Ligand-independent AR 
activation 
Yes GF function as ligands 
AR hypersensitivity Yes 
Amplified AR  
hypersensitivity AR  
increased DHT 
Change of AR 
specificity by mutation 
Yes 
Stimulation by non 
androgens (antagonists) 
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1.7.4.1 Pre-existing genetics changes in prostate cancer stem cells  
Several studies (Coffey & Isaacs, 1981; Isaacs, 1999) postulated that androgen 
independence of prostate cancer was due to a selective growth advantage of pre-
existing hormone-independent clonal populations of pre-existing, hormone-
independent stem cells. The total population of prostate cancer cells in this setting is 
considered to be a mixture of hormone-dependent and hormone-independent cells 
from the time of initiation of the malignancy. Progression to hormone independence 
would then be explained by proliferation the hormone- independent cell population 
due to a growth advantage originating from suppression by androgen ablation of the 
growth of hormone-dependant cancer cells. 
1.7.4.2 Oncogenes and apoptosis inhibition 
Another Androgen and AR-independent mechanism plays an important role in 
clinical settings. This mechanism includes the activation of oncogenes, the 
suppression of tumour suppressor genes, such as the over expression of Bcl-2, which 
is part of a mechanism capable of inhibiting apoptosis. McDonnell et al (1992) found 
that Bcl-2 was undetectable in 13 of 19 cases of AIPC tissue. In contrast, some other 
studies showed high levels of Bcl-2 staining. In normal human prostate Bcl-2 
expression was limited to the basal epithelial cells (McDonnell et al, 1992). 
However, the observation of these findings does not establish a casual relationship. 
In contrast, (Revelos et al, 2005) found that expression of Bcl-2 in prostate cancer 
cells was an independent predictor of treatment failure in localised disease. Bcl-2 has 
been regarded as a therapeutic target in hormone refractory prostate cancer and 
antisense therapy was also developed for the mouse double minute 2 (MDM2) 
oncogene (Chi, 2005).  
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Inactivation of the PTEN tumour suppressor gene was found to be associated with 
locally progressive prostate cancer (Verhagen et al, 2006). Also, knock-down of both 
alleles of PTEN in mouse prostate resulted in successful induction of prostate cancer 
in an animal that did not usually develop this disease. The resulting cell proliferation 
was not accompanied by reduced apoptosis indicating that the proliferative 
mechanism is independent of the Bcl2 cascade (Ma et al, 2005).   
1.7.4.3 Ligand-independent AR activation  
It was suggested (Culig et al, 1994b) that AR can be activated by insulin-like growth 
factor 1 (IGF-1), keratinocyte growth factor (KGF) and the epidermal growth factor 
(EGF). It was also showed that these growth factors were over expressed in some 
prostatic cancers and that antiandrogen bicalutamide blocks the IGF-induced AR 
activation. Receptor tyrosine kinase activated pathways have been targeted by 
several new drugs including Herceptin with limited activity in AIPC (Ziada et al, 
2004). 
Although these described mechanisms appeared to have no direct relation to 
androgen regulation, the intriguing finding that AR is expressed in most AIPC tissue 
suggests that different mechanisms may overlap (Dorff et al, 2006). Other authors 
have shown that the androgen-binding capacity of the AR in AIPC cells is unchanged 
(Ruizeveld de Winter et al, 1994). This leads to review of those potential 
mechanisms of progression to AIPC that are dependent on AR. 
1.7.4.4 AR hypersensitivity  
Amplification of AR leading to increased sensitivity and response to very low levels 
of androgens was found in about a third of tissues derived from hormone-
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independent prostate cancer (Koivisto et al, 1997) and it was positively related to 
increased progression measured by the proliferation marker Ki67 (Haapala et al, 
2007). Hypersensitivity of the AR may also explain the antiandrogens treatment 
failure resulting from an imbalance of the increased number of receptor molecules 
and the available number of competing molecules of the antiandrogen in the nucleus 
(de Jong et al, 1992). Moreover, increased intraprostatic levels of androgens due to 
increased production of DHT in the prostate as suggested by (Labrie et al, 2005) or 
changes of the sensitivity of AR (Gregory et al, 2001) will have the same results; 
stimulation of growth due to activation of AR. 
1.7.4.5 Changes of AR specificity (AR mutations) 
The AR gene is located on the X chromosome. Germline mutations leading to a loss 
of AR function and the clinical androgen insensitivity syndrome are not infrequent. 
Complete loss of AR function is compatible with life (Quigley et al, 1995). 
However, due in part to the heterogeneity of tumours, the incidence of somatic 
mutation is not fully known. What is clear however is that the primary tumours have 
a low level of androgen receptor mutations compared to metastatic tumours after 
androgen ablation therapy (Marcelli et al, 2000). These findings suggest that gaining 
such mutations may be a driving factor leading to androgen independence. These 
results contrast with another study which reported that accumulated mutations during 
androgen deprivation were already acquired in metastatic tumours, and were not 
instigated by androgen ablation (Cher et al., 1996).  
A study by (Veldscholte et al, 1992) discovered a mutation leading to a functional 
change of the AR in the LNCaP cell line. This mutation resulted in substitution of 
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alanine for threonine at position 877 of the AR (the T877A mutation) gene. The 
presence of this mutation changes the growth inhibitory effect of the same substance. 
At, present, it remains uncertain how frequently AR mutation lead to androgen 
insensitivity in a clinical setting. Experiments relating to the use of castration or an 
luteinizing hormone-releasing hormone (LHRH) agonist in combination with an 
antiandrogen as initial treatment in prostate cancer has shown that flutamide 
withdrawal my lead to clinical remission in about 30% of cases with duration of 3 to 
4 months (Feldman & Feldman, 2001). AR mutations seem to be at least in part due 
to the selective pressure exerted by the use of antiandrogens. A study by (Taplin et 
al, 1999) identified the T877a mutation in 5 of 16 patients who received maximal 
androgen blockade using flutamide. Later, in a study of 48 specimens obtained from 
bone marrow metastases of prostate cancer progressing under endocrine treatment, 5 
(10%) had a mutation in the hormone-binding domain (Taplin et al, 2003).   
1.7.4.6 Gene Fusions 
Gene fusion between the androgen-dependant TMPRSS2 gene and oncogenes of the 
ETS family were described by Tomlins et al (Tomlins et al, 2005). Such fusions may 
play a role in the initiation or promotion of prostate cancer and may also provide a 
mechanism for explaining the progression of clinical prostate cancer from the 
hormone dependent to the hormone independent state. The fused gene was formed 
through the binding of the activated AR to the androgen responsive element of 
TMPRSS2. In this way, the activated AR actually mediates the fusion of an 
oncogene. Presence of the fusion mainly between TMPRSS2, and the ERG or ETV1 
members of the ETS oncogenes family were observed in both hormone dependent 
and hormone independent prostate cancer xenograft lines (Hermans et al, 2006).  
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One recent study of 165 patients treated by radical prostatectomy revealed that one of 
the gene fusions was found in every 81 (49.1%) of cases. Also, after adjusting for 
grade, stage and PSA level, the hazard ratio for PSA recurrence of gene-positive 
cases was 8.6%. This is the only large clinical study suggesting that the TMPRSS2-
ERG gene fusion is an independent prognostic parameter in locally confined prostate 
cancer (Nam et al, 2007). In contrast, (Demichelis et al, 2007) showed that the 
TMPRSS2-ERG fusion was present more frequently in lethal prostate cancer 
prospectively treated by watchful waiting (cumulative incidence ratio 2.6, P<0.01). 
The TMPRSS2-ERG gene fusion has also been identified in 21% of 19 evaluated 
high-grade prostatic intraepithelial neoplasia (PIN) lesions (Cerveira et al, 2006).  
Although there is theoretical potential for TMPRSS2-ERG oncogene family gene 
fusions to be related to prostate cancer progression to androgen independence, direct 
causal clinical evidence for the involvement of this mechanism is not available at 
present. 
1.7.4.7 Androgen synthesis in AIPC tissues 
In 1991, van der Kwast et al showed that almost consistently the AR studied by 
immunohistochemistry remained over-expressed in primary prostate cancer tissue 
that was progressive under endocrine treatment (van der Kwast et al, 1991). The 
study was based on freshly obtained and frozen tissue in 17 cases of local 
progression under endocrine treatment requiring transurethral prostatic resection. In 
13 of the 17 examined specimens at least 80% of the nuclei of tumour cells were AR 
positive. Only one case was completely AR negative. Shortly thereafter it was 
confirmed that the AR in AIPC tissue was structurally intact and has a normal 
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binding capacity (Ruizeveld de Winter et al, 1994). The other finding, the fact that 
PSA still serves as a prognostic marker in AIPC despite castration levels of serum 
androgens, has always been suggestive of remaining androgen activity that is not 
counteracted by castration or the use of LHRH agonist. The promoter region of the 
PSA gene contains several androgen-responsive elements (AREs); PSA expression, 
therefore, requires an activated AR.  
These findings provide links to recent developments that show that high androgen 
levels are preserved in tissues derived from metastases of patients with AIPC 
suggesting a high level of endocrine activity. Stanbrough et al (Stanbrough et al, 
2006) studied 33 prostate cancer specimens that were obtained from bone marrow 
metastases and preserved by snap freezing. The study showed an increased 
expression of number genes involved in the androgenic part of the steroid 
metabolism included the genes 3βHSD2, AKR1C3, SRD5A1, as well as AKR1C1, 
C2 and UGT2B15. These genes all encode for enzymes that are involved in the 
androgen synthesis from the level of pregenenolone and progesterone on downward. 
The AR was found to be a 5.8 fold over expressed. Moreover, over-expression was 
also seen for SRD5A1, the gene that encode for 5-α-reductase type 1 but not type 2 
which is predominant in tissue of benign prostatic hyperplasia (BPH). 
More recently these data were confirmed in a study of six cases of AIPC with 
metastases disease. Tissue from bone metastases was obtained by warm autopsy and 
immediately frozen. This study showed levels of DHT that were equivalent to non- 
castrated prostate cancer tissue. Testosterone level, however, was found to be 3.8 
times higher than that in prostate cancer tissue from non-androgen deprived patients. 
The transcripts for enzymes of androgen synthesis including cytochrome P17A, aldo-
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keto reductase 1 C3 (AKR1CK), 3β hydroxysteroid dehydrogenase-2 (3βHSD2) and 
the gene encoding for 5-α-reductase type 2 (5-α-R2) were significantly up regulated 
in the metastatic samples. The data suggest that both the increased synthesis and 
degradation of androgen occurred in AIPC tissues (Mostaghel et al, 2009).  
1.7.5 Androgen receptors and growth factors interactions 
Although AR is playing a key role in all phases of prostate carcinogenesis, a number 
of other signalling pathways, and their interaction with AR signalling, are also 
critically implicated in prostate cancer, especially in advanced cancer cells. 
Several growth factors such as, insulin-like growth factor (IGF), Keratinocyte growth 
factor (KGF) and epidermal growth factor (EGF), can increase AR transactivation 
under absence or low levels of androgen (Culig et al, 1996; Culig et al, 1994a). A 
study by Gregory et.al suggested that EGF increased level of transcriptional 
intermediary factor 2/glucocorticoid receptor interacting protein 1 through mitogen 
activated protein kinase (MAPK) signalling pathway and promote AR transcriptional 
response in prostate cancer cells (Gregory et al, 2004). Another angiogenesis growth 
factor, vascular endothelial growth factor (VEGF), has been frequently studied 
recently. The elevated expression of VEGF, which resulted in promoting vascular 
growth and endothelial cell proliferation, was found in androgen-stimulated prostate 
growth (Joseph et al, 1997). Other reports also showed that functions of VEGF were 
activated through hypoxia-induced factor (HIF) regulated by androgens and/or 
androgen receptor (Boddy et al, 2005). Further studies demonstrated the significant 
correlation between HIF expression with AR and VEGF expression, and provided 
firm support for this control system (Banham et al, 2007). Understanding of such 
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cross-talk between AR cascade and growth factors signalling may provide new 
opportunities for therapy of aggressive prostate cancer. 
 
1.8 Angiogenesis  
Angiogenesis is a process involving the growth of new capillaries from pre-existing 
blood vessels. Angiogenesis repairs damaged tissue when wounds are healing; 
therefore, normal cells can switch on the growth of blood vessel by releasing 
angiogenic factors (Folkman, 2002). In contrast, they also can produce 
antiangiogenic factors which switch blood vessel growth off (Carmeliet & Jain, 
2000). Tumour angiogenesis is defined as: cancer cells stimulate the growth of 
hundreds of capillaries from the nearby blood vessels which grow around and/or into 
the tumour to establish an independent supply of nutrients and oxygen. Angiogenesis 
is not only important to tumour development but also a critical step in tumour 
metastasis. The immature, highly permeable blood vessels, which have little 
basement membrane and few intercellular junctional complexes, provide efficient 
route of exit for tumour cells to leave the primary site, enter the blood stream, travel 
to another part of the body and begin to grow there. 
1.8.1 Vascular endothelial growth factor (VEGF) 
There are at least five members of the vascular endothelial growth factor (VEGF) 
family which exist in man: VEGF-A (usually referred to as VEGF), VEGF-B, 
VEGF-C and VEGF-D and a structurally related molecule, placental growth factor 
(PlGF). All members of VEGF family are crucial important angiogenic factors which 
primarily target vascular endothelial cells. They promote new blood vessel formation 
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by binding tyrosine kinase receptors (also known as VEGF receptors) located on cell 
surface. Three VEGF receptors have been recognized: VEGFR-1 or fms-like tyrosyl 
kinase-1(Flt-1), VEGFR-2 or Kinase insert domain receptor (KDR/Flk-1) and 
VEGFR-3 or Flt-4. Both VEGF and VEGF-B bind to VEGFR-1. VEGFR-1 is 
involved in the organization of development of blood vessel, haematopoiesis and 
enhances VEGF-induced VEGF-2 signaling during abnormal angiogenesis. VEGF 
but not VEGF-2 binds to VEGFR-2 results in promoting cell proliferation, mitosis, 
vascular permeability and angiogenesis, whereas VEGF-C and VEGF-D are ligands 
for VEGFR-3, which stimulates lymphangiogenesis (Ferrara, 2004).  
1.8.2 The isoforms of VEGF 
VEGF is a ~45kDa homodimeric heparin-binding glycoprotein which was firstly 
identified by Senger et al. in 1983. VEGF gene consists of 8 exons separated by 7 
introns and is located at chromosome 6p21.3 (Aragon-Ching & Dahut, 2009). So far, 
there are 12 VEGF isoforms which have been divided into two families according to 
their terminal exon (exon 8) splice site: the proximal splice site, designated as 
VEGFxxx or distal splice site, designated as VEGFxxxb (Nowak et al, 2008). The 
identified multiple proteins of VEGF expressed in human tissues and cells are named 
as VEGF121, VEGF121b, VEGF145, VEGF145b, VEGF165, VEGF165b, VEGF189, 
VEGF189b and VEGF206 according to the different number of amino acids. VEGF121 
is thought to be the most diffusible isoform due to the absence of a heparin-binding 
domain. VEGF165 is the predominant VEGF isoform secreted by different types of 
cells. VEGF165 not only exists in diffusible location but also remains bound to the 
cell surface and the extra cellular matrix (ECM). However, the larger isoforms such 
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asVEGF189 and VEGF206 with high affinity to heparin remain localized within ECM 
(Ferrara, 2004). 
1.8.3 VEGF and prostate cancer 
Most of the tumour cells secrete VEGF in vitro indicating that VEGF may play a 
crucial role in tumour angiogenesis. This has been confirmed by in situ hybridization 
studies which demonstrated that VEGF mRNA is expressed in the majority of human 
carcinomas such as breast cancer, lung cancer, bladder cancer  and ovary cancer 
(Ferrara, 2004). In prostate, VEGF is expressed differently between normal, benign 
and prostate cancer cells. It has been reported that the expression of VEGF mRNA 
was detected in PIN, and poorly differentiated tissues, but not in normal prostate 
tissue (Huss et al, 2001).  Further studies also showed that the microvessel density 
(MVD) was increased significantly in metastatic prostate cancer samples when 
compared with non-metastatic prostate cancer tissues (Kitagawa et al, 2005). In 
addition, higher expression of hypoxia-inducible factor (HIF), a key regulator of 
VEGF expression, was detected in malignant prostate cancer compared with the 
adjacent normal and benign prostate tissue (Du et al, 2003). Clinical studies revealed 
that the level of VEGF expression in serum, plasma or urine was correlated with 
higher Gleason grade, metastasis and disease-specific survival (Bok et al, 2001; 
Duque et al, 1999). On the other hand, inhibition of VEGFR-1 and VEGFR-2 using 
AZD-2171 (Cediranib, AstraZeneca) induced tumour shrinkage in 56.5% of patients 
(13 out of 23 patients with measurable disease) with 4 meeting the criteria
 
for partial 
response (Aragon-Ching & Dahut, 2009). These results indicated that VEGF played 
a dual role in prostate cancer at both the early initiating stage and the later stage for 
tumour progression and metastasis. VEGF interacts with VEGF-2 to stimulate 
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endothelial cell proliferation through the mitogen activated protein kinase (MAPK) 
pathway and promote vascular permeability, and subsequently with VEGFR-1 to 
assist the organization of new capillary tubes. 
1.8.4 Other growth factors in Prostate cancer  
Several growth factors, such as insulin-like growth factor (IGF) and epidermal 
growth factor (EGF) were found to increases the trans-activation potential of AR in 
prostate cancer. Epidemiological studies suggested that there is a correlation between 
the increased risk of developing prostate cancer and the high serum level of IGF-1 or 
low levels of IGFBP-3, a serum protein that regulates the binding of free IGF-1 to 
IGF receptor (IGFR) (Chan et al, 1998). However,  these findings have not been 
successfully demonstrated by some other studies (Chen et al, 2005).  
The EGFR is expressed in 40-80% of malignant prostate cancer cells and this 
increased expression was correlated with high Gleason score and tumour progression 
from an androgen-dependent to an androgen-independent state (Syed & Tolcher, 
2003). EGF was shown to activate the transcriptional activity of AR by either 
increasing the expression levels or stimulating the activity of the AR co-activators in 
prostate cancer cells. Therefore, EGF is thought to promote malignant progression 
and metastasis of advanced prostate cancer (Reddy et al, 2006).  
 
1.9 Peroxisome proliferator-activated receptors 
Peroxisome proliferator-activated receptors (PPARs) are part of the nuclear receptors 
family of transcription factors and identified originally in Xenopus frogs as receptors 
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that induce the proliferation of peroxisome in cells in the early 1990s (Han et al, 
2008). The functional role of these ligand activated transcription factors is involved 
in regulating fatty acid catabolism, lipid storage and glucose metabolism in the body. 
There are three isoforms of PPARs: PPARα, PPARβ/δ and PPARγ. They are 
expressed in various tissues and play different roles.  
1.9.1 Structure of PPAR  
Despite the location and functional differences, PPAR isoforms share similar 
structure and functional domains. Like other nuclear receptors, PPARs are composed 
of four major domains: A/B, C, D and E/F (Figure 1.12).  
 
 
Figure 1.12: The schematic view of the domain structure of PPARs. 
 
 
The N-terminal region of PPARs contains A/B domains which are different in both 
length and amino acid sequences. The A/B domain contains a transactive domain, 
which is independent of the presence, is termed activation function 1 (AF1). The 
activity of this domain can be regulated by protein kinase phosphorylation (Stephen 
et al, 2004). The C domain, which is the most conserved region amongst the PPARs, 
consists of a DNA binding domain (DBD). This domain contains two typical zinc 
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finger motifs which bind to specific sequences of DNA and are responsible for 
binding PPAR to peroxisome proliferator response element (PPRE) within the 
promoter region of the target gene. The D domain is a highly flexible hinge region. 
The C-terminal region of PPAR is an E/F domain which contains ligand binding 
domain (LBD) and ligand dependent activation domain (AF2). The LBD of PPARs 
consists 13 α helices and a β sheet forming a hydrophobic pocket which is about 
twice as large as other nuclear receptors (Peters & Gonzalez, 2009). This region is 
important for activation of PPAR binding to the PPRE and also plays an important 
role in nuclear localization. In addition, some studies demonstrated that PPARs could 
be activated by a variety of fatty acids at certain concentrations (Keller et al, 1993). 
PPARs form heterodimers with the 9-cis retinoic acid receptor (RXR), which result 
in a conformational change of both receptors, allowing the heterodimers to bind to 
the PPRE DNA promoter region containing repeat motifs (AGGTCANAGGTCA) 
and regulate the gene transcription (Figure 1.13). 
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Figure 1.13: Model for PPARs signalling pathway (Harmon et al, 2010). 
 
1.9.2 PPAR β/δ 
PPAR β/δ is expressed ubiquitously throughout the body with different levels in 
different cell types. PPAR β/δ can be activated by natural ligands, such as fatty acids, 
retinoid acids and prostaglandins as well as synthetic ligands including GW501516, 
GW0742 and L165041. Several studies demonstrate that PPAR β/δ plays an 
important role in cell proliferation, differentiation and apoptosis. Activation of PPAR 
β/δ can stimulate cell proliferation in colon cancer, liver cancer, lung cancer and 
breast cancer cell lines (Peters & Gonzalez, 2009). It has also been reported that 
PPAR β/δ increases cell proliferation in PNT2 and LNCaP but not in DU145 and 
PC-3 prostate cancer cell lines (Stephen et al, 2004). However, the data on the role of 
PPAR β/δ in cell proliferation are inconsistent and controversial. In addition, a 
number of recent studies suggest that activation of PPAR β/δ with GW501516 can 
also stimulate angiogenesis by enhancing the expression of VEGF (Han et al, 2008; 
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Piqueras et al, 2007). Strong evidence suggests that ligand activation of PPAR β/δ 
can enhance the expression of 3-phosphoinositide dependent protein kinase 1 
(PDK1) and subsequently activate the downstream protein kinase B (AKT) by 
phosphorylation. Activation of the PDK1/AKT signalling pathway has a direct effect 
on cell apoptosis through phosphorylation of the BCL-2 family member BCL-2 
associated death promoter (BAD) thereby suppressing cell apoptosis and promoting 
cell survival. Schug et al. also suggested that PDK1/AKT anti-apoptosis signalling 
pathway regulated by PPAR β/δ (Schug et al, 2007a). A recent study by Morgan et al 
(2010) showed that PPAR β/δ directly induce the expression of C-FABP through a 
functional PPRE within the promoter region of the C-FABP gene. They also showed 
that activation of the C-FABP/ PPAR β/δ pathway enhances the proliferation of 
malignant prostate cancer cell line PC3M, and that downregulation of either protein 
inhibits growth of these cells (Morgan et al, 2010). Moreover, these results revealed 
the existence of a positive feedback loop that enhances the transcriptional activities 
of the C-FABP/ PPAR β/δ pathway in prostate cancer cells, and they indicate that 
these activities support prostate carcinoma cell proliferation and tumourigencity.    
1.9.3 PPAR γ 
PPARγ has been the most extensively studied isoform of PPAR family. It is mainly 
expressed in adipose tissues and plays a crucial role in adipocyte differentiation and 
lipid metabolism. Previous observation showed that PPARγ ligands promote the 
VEGF production in bladder and prostate cancer cells (Fauconnet et al, 2002; 
Haslmayer et al, 2002). Analogous findings were also reported by Cho et al. who 
detected a significant increase in VEGF and its receptors in epithelial cells treated 
with PPARγ synthetic ligand, thiazolidinediones. In addition, activation of PPARγ 
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also stimulates the tumour formation in colon cancer (Pino et al, 2004). On the other 
hand, there are several lines of evidence to support that PPARγ ligand activations are 
capable of inhibiting angiogenesis progression under certain conditions. It is 
suspected that the various times and doses of PPARγ ligand treatment or the variety 
of organisms and cells examined may lead to such discrepancies. 
 
1.10 Fatty Acid, Fatty Acid Binding Proteins and Prostate Cancer  
1.10.1 Introduction to Fatty Acid  
Fatty acid (FA) trafficking in cells is a complex and dynamic process that affects 
many aspects of cellular function. FAs functioning both as an energy source and as 
signals for metabolic regulation, acting through enzymatic and transcriptional 
networks to modulate gene expression, growth and survival pathways, and 
inflammatory and metabolic responses (Hotamisligil, 2006). Furthermore, FAs, 
particularly linoleic and arachidonic acids, can be metabolized into a diversed large 
family of bioactive lipid mediators called eicosanoids, which may function as pro 
and anti-inflammatory mediators. In particular, the cyclopentenone prostaglandins, 
such as PGA1, PGA2 and PGJ2, have potent anti-inflammatory effects through the 
inhibition of inflammatory kinase pathways (Serhan, 2007). 
1.10.2 Dietary fatty acid and prostate cancer  
The incidence of latent cancer is uniform around the globe. However, western 
developed nations have a higher incidence of clinical prostate cancer. Giving that 
approximately 40% of total energy intake is obtained from fat in a westernised diet, 
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this provides a rational for studying the link between dietary fat intake and prostate 
cancer (Das et al, 2001). 
Epidemiological studies (Maeda et al, 2003; Newberry et al, 2006) showed a link 
between prostate cancer and two main factors; age and diet. Such studies suggested 
that the difference in prostate cancer incidence between western countries and Japan 
was a direct link to the type and quantity of fatty acids ingested. It was showed that 
an increase incidence of an individual from a country of a relatively low prostate 
cancer risk to that from a country of high prostate cancer risk. 
The human body is capable of synthesis certain FAs. Yet those acquired solely 
through diet defined as “essential” fatty acids. These make up precursors of two 
classes of polyunsaturated fatty acids, linoleic acid- an omega 6 fatty acid derived 
from vegetable, seed and corn oils, and linoleic acid- an omega 3 fatty acid derived 
mainly from fish oils. The methods by which polyunsaturated fatty acids (PUFA), 
such as eicosanoids, are thought to influence and promote cancer progression is not 
fully understood, however it is suggested that conversion of the precursor linoleic 
acids into arachidonic acid by desaturation plays an integral part. Arachidonic acid is 
catalysed into prostaglandin and thromboxanes by the cyclooxygenase enzyme. 
Studies have shown the existence of two forms of cyclooxygenase enzyme. Cox-1, 
which is constitutively active and Cox-2, an inducible gene observed to be over 
expressed/up regulated in prostate cancer biopsies (Fosslien, 2000). In contrast, fish 
oils containing eicosapentanioc acid and lipoxygenase, thereby producing series 3 
and 5 prostaglandins which reportedly cause less tissue inflammation, and reduce the 
production of the more active arachidonic acid metabolites (Newberry et al, 2008). 
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1.10.3 Fatty acid binding proteins (FABPs) 
Intracellular lipid chaperones know as FABPs are a group of molecules that 
coordinate lipid responses in cells and are also strongly linked to metabolic and 
inflammatory pathways (Chmurzyńska, 2006). FABPs are abundantly expressed 14-
15 KDa proteins that reversibly bind hydrophobic ligands, such as saturated and 
unsaturated long chain fatty acids, eicosanoids and other lipids, with high affinity 
(Zimmerman & Veerkamp, 2002). FABPs are found a cross species from Drosophila 
melanogaster and Caenorhabditis elegans to mice and humans, demonstrating strong 
evolutionary conservation. However, little is known about their exact biological 
functions and mechanisms of actions. Studies in cultured cells have suggested 
potential action of FABPs in fatty acid import, storage and export as well as 
cholesterol and phospholipid metabolism (Chmurzyńska, 2006; Haunerland & 
Spener, 2004). 
Recently, through the use of various genetic and chemical models in cells as well as 
whole animals, the FABPs have been shown to be central to lipid-mediated processes 
and related metabolic and immune response pathways. In addition, they have also 
highlighted their considerable potential as therapeutic targets for a range of 
associated disorders, including obesity, diabetes and atherosclerosis (Furuhashi & 
Hotamisligil, 2008). 
1.10.3.1 Fatty acid binding proteins (FABPs) family 
Different types of FABPs can be divided into two main groups (Glatz & van der 
Vusse, 1996): those associated with the plasma membrane (FABPpm) and those 
located intracellularly or in cytoplasm (C-FABP). So far nine tissue-specific 
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cytoplasmic FABPs have been identified Table 1.4  (Furuhashi & Hotamisligil, 
2008). 
 
 
Table 1.4: Family of FABPs (Furuhashi & Hotamisligil, 2008).   
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1.10.3.2 Fatty acid binding proteins (FABPs) affinity and structure  
Several FABP isoforms have been structurally investigated through isolated 
recombinant proteins by X-ray crystallography and nuclear magnetic resonance. 
FABPs have an extremely wide range of sequences diversity ranging from 15% to 
70% sequence identity between different members (Chmurzyńska, 2006). However, 
all known FABPs share almost identical three dimensional structures (Figure 1.14). 
Common to all FABPs is a 10-stranded antiparallel β-barrel structure, which is 
formed by two orthogonal five-stranded β-barrels, the opening of which is framed on 
one side by the N-terminal helix-loop-helix “cap” domain, and fatty acids are bound 
to the interior cavity. The conserved fingerprint, providing a signature for all FABPs, 
has recently been revealed as shown in Figure 1.15. 
All FABPs bind long-chain fatty acids with differences in ligand selectivity, binding 
affinity and binding mechanisms as a result of small structural differences between 
isoforms. In general, the more hydrophobic the ligand is the tighter the binding 
affinity with the exception of unsaturated fatty acids. It is also possible that the needs 
of target cells determine the affinity and even selectivity of the major isoforms 
present in different sites. For example, B-FABP is highly selective for very long-
chain fatty acids such as docosahexarnoic acid (Balendiran et al, 2000). On the other 
hand, L-FABP exhibits binding capacity for a broad range of ligands from 
lysophospholipids to haem (Coe & Bernlohr, 1998). 
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Figure 1.14: Crystal structure of ligand-bound FABPs (Furuhashi & 
Hotamisligil, 2008).  
Ligand-binding FABPs are shown above (The figures were created using PyMOL). 
(a) FABP1 (Protein Data Bank (PDB) code: 1lfo); (b) FABP2 (PDB code: 2ifb); (c) 
FABP3 (PDB code: 2hmb); (d) FABP4 (PDB code: 2ifb); (e) FABP5 (PDB code: 
1b56); (f) FABP8: (PDB code: 1pmp); (g) FABP6: (PDB code: 1o1v); (h&i) 
FABP7: (PDB code: 1fe3 & 1fdq). 
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Figure 1.15: Fingerprint for fatty acid binding proteins (Furuhashi & 
Hotamisligil, 2008).  
Three highly conserved motifs are presented with the ribbon diagram. 
FATTYACIDBP1 (blue ribbon) forms part of first β strands (βA). It also includes a 
nuclear localization signal (NLS) and a hormone-sensitive lipase (HSL) binding site. 
The nuclear export signal (NES) domain is located in FATTYACIDBP2 (green 
ribbon) which includes β sheet 4 and 5 (βE). FATTYACIDBP3 (red ribbon) encodes 
β sheet 9 (βI) and 10 (βJ). The key amino acids are also marked with blue, green and 
red respectively. 
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1.10.3.3 Functions of FABPs 
Numerous functions have been proposed for FABPs. As lipid chaperones, FABPs 
may actively facilitate the transport of lipids to specific compartments in the cells, 
such as to the lipid droplet for storage, to the endoplasmic reticulum for signalling, 
trafficking and membrane synthesis, to the mitochondria or peroxisome for 
oxidation, to cytosolic or other enzymes to regulate their activity, to the nucleus for 
lipid-mediated transcriptional regulation, or even to the outside of cells to signal in 
an autocrine or paracrine manner (Figure 1.16). 
FABPs content in most cells is generally promotional to the rates of fatty acid 
metabolisms. FABPs are also involved in conversion of fatty acids to eicosanoid 
intermediates and in stabilizations of leukotrienes (Zimmer et al, 2004). Furthermore, 
a direct protein-protein interaction between hormone-sensitive lipase (HSL) activity 
and A-FABP or E-FABP in adipocytes has been also reported (Hertzel et al, 2002). 
In general, the interacting protein partners for FABPs are poorly understood, and the 
searches for such proteins with conventional approaches have not been fruitful. 
However, movement of FABPs into the nucleus and interaction with nuclear 
hormone receptors is possible, and this mechanism might potentially deliver ligands 
to this protein family (Gillilan et al, 2007). 
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 Figure 1.16: Putative functions of FABPs in the cell (Furuhashi & Hotamisligil, 
2008). 
 
1.10.4 Cutaneous FABP (C-FABP) in prostate cancer 
C-FABP is also called Epidermal FABP (E-FABP) or Psoriasis-associated FABP 
(PA-FABP). C-FABP is a 15 KDa cytosolic protein of the fatty acid binding protein, 
which binds with high affinity to long chain fatty acid. In addition to skin, C-FABP 
expression has been identified in the endothelial cells of the placenta, heart, skeletal 
muscle, small intestine, renal medulla and in the goblet cells of the lung (Masouye et 
al, 1996). In addition to breast tissues, increased levels of C-FABP have also been 
Chapter 1: Introduction           P a g e  | 89 
 
 
 
 
detected in the malignant tumours of bladder and pancreas (Celis et al, 1999; Sinha 
et al, 1999), indicating that C-FABP may also play a role in malignant progression in 
these cells. Although the precise role of C-FABP in these tissues is not clear, it is 
likely to be involved in binding and transporting intracellular fatty acids, some of 
which are signalling molecules reported to be involved in carcinogenesis (Glatz & 
van der Vusse, 1996).  
Our  previous studies (Jing et al, 2000) have found that the C-FABP gene was 
overexpressed in malignant breast and prostate epithelial cell lines, when C-FABP 
gene was transfected into the benign rat Rama 37 model cells and the tranfectants 
subsequently inoculated into Wistar Furth rats, a significant number of animals 
developed metastasis. Further studies demonstrated that C-FABP promoted 
tumorigenesis and metastasis of prostate cancer cells by facilitating angiogenesis 
through up-regulating VEGF gene (Jackson et al, 2002; Soker et al, 2001). These 
results indicated that there may be a fatty acid signalling initiated pathway that leads 
to metastasis in prostate cancer and C-FABP and VEGF are all important factors in 
this possible pathway. 
Suppression of C-FABP expression by antisense transfection in PC-3M cells 
decreased the invasive capacity in vitro and reduced the tumourigencity in vivo. 
Moreover, the suppression of VEGF expression has also been detected in these 
transfected cell lines (Adamson et al, 2003). These results indicated that over-
expression of C-FABP may stimulate the expression of VEGF and subsequently 
promote the angiogenesis to facilitate tumour formation and metastasis. Recent 
studies by Morgan et.al also confirmed that suppressing the expression of C-FABP in 
PC-3M cells using  siRNA silencing technique resulted the significant reduction of 
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tumourigencity both in vitro and in vivo (Morgan et al, 2008). However, how exactly 
C-FABP elevates the expression of VEGF is still unclear. 
 
1.11 Scope of this thesis 
1.11.1 Hypothesis 
This thesis tests hypothesis that the tumour-promoting activity of C-FABP depends 
on its fatty acid binding and transporting function which is dependant of structural 
integrity of fatty acid binding motif.   
 
1.11.2 Aims 
To investigate the relationship between the tumorigenicity-promoting function of C-
FABP and its fatty acid binding ability by performing following set of experiments:   
 Generation of mutation in C-FABP cDNAs and transfected them into LNCaP 
prostate cancer cells.   
 Production of recombinant C-FABPs and testing their fatty acid binding 
ability.  
 Study the effect of over-expression of recombinant wild type and mutant C-
FABPs on tumorigenicity of prostate cancer cells. 
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2 MATERIALS AND METHODS  
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2.1 Materials  
All materials and preparation of stock solutions used in this thesis are summarised in 
Appendices 1 and 2.     
2.2 General molecular biology methods 
2.2.1 Calculation of DNA and RNA concentration 
The DNA or RNA samples were examined for concentration and quality using the 
NanoDrop ND-1000 spectrophotometer. Nucleic acid sample (1µl) was loaded onto 
the lower measurement pedestal. After closing the sampling arm, the spectral 
measurement was initiated using the operating software on the computer. The DNA 
or RNA sample concentration was presented on the screen in ng/µl based on 
absorbance at 260nm using the modified Beer-Lambert equation. The purity of the 
sample was also assessed using ratio of absorbance at 260nm and 280nm. A ratio of 
~1.8 was generally accepted as pure for DNA; a ratio of ~2.0 was generally accepted 
as pure for RNA. 
 
2.2.2 Ethanol precipitation of DNA and RNA 
The DNA or RNA to be precipitated was mixed with 2.5 volumes of chilled 4°C 
temperature absolute ethanol and 10% volumes of 3M sodium acetate (pH5.2). The 
mixture was mixed gently by inversion and incubated at –80oC overnight for DNA or 
RNA to precipitate. The DNA or RNA was pelleted by centrifuging at 16,000 xg at 
4
o
C in a microcentrifuge for 20 minutes. The supernatant was removed and the pellet 
was washed by 100μl of pre-chilled 70% (v/v) ethanol. The DNA or RNA was 
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recentrifuged at 16,000xg at 4
o
C for 15 minutes and the supernatant was decanted. 
The DNA or RNA was air dried and resuspended in sterile DEPC-treated water. 
 
2.2.3 Agarose gel electrophoresis of DNA 
Agarose gel electrophoresis was performed in 1xTBE buffer (0.089M Tris-base, 
0.089M boric acid, 0.002M EDTA pH8.0). The agarose concentration of the gel was 
0.8% to 2.0% (w/v) according to DNA size. The agarose was dissolved in 200ml of 
1xTBE buffer by microwave heating for 2 minutes and cooled to 40-50
o
C. Then, 
10µl of 500ng/ml ethidium bromide was added for visualisation. The gel mixture 
was poured and placed at 4
o
C to solidify. DNA samples were prepared by adding 5x 
agarose gel loading buffer [0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene 
cyanol FF, 30% (v/v) glycerol in water] to a 1x concentration and loaded into the gel 
alongside DNA size marker. The gel was run for 50 minutes at 90V and visualised 
on a UV transilluminator. 
 
2.2.4 Purification of DNA from agarose gels 
DNA fragments were separated using agarose gel electrophoresis (section 2.2.3). The 
required fragments were visualised by ethidium bromide and excised using a sterile 
blade. Each excised gel slice was weighed and three times the volume of buffer QG 
was added. Then, the mixture was dissolved in a 50
o
C water bath for 10 minutes with 
occasional vortex mixing. The melted agarose and DNA solution was applied to a 
QIAquick spin column and centrifuged for 1 minute at 16,000xg in a microcentrifuge 
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and the flow through was discarded. The membrane, bound with DNA, was washed 
by passing through 750 l of buffer PE and re-centrifuged for a further minute to 
remove any residue. The DNA was eluted from the column by adding 30μl of 
distilled water and quantified as described above. The DNA was stored at –20oC 
until needed. 
2.2.5 Restriction Enzyme digestion of plasmid DNA 
Plasmid DNA was digested with two different restriction enzymes (XhoI and PstI) to 
check for the presence of insert or to produce the DNA fragment for ligation. The 
restriction enzyme digest mixture was prepared as shown in Table 2.1. 
 
 
 
 
 
 
 
 
 
 
 
Table 2.1: The restriction enzyme digestion mixture (total volume 50µl) 
 
The restriction enzyme digest mixture was incubated at 37
o
C for 2 hours to allow 
complete digestion of template DNA. Then, the enzyme reaction was inactivated by 
heating to 68
o
C for 10 minutes and the products were analysed by gel 
electrophoresis. 
Water 35µl 
10x NEBuffer 3 5µl 
XhoI 20units/µl 1µl 
PstI 20units/µl 1µl 
BSA 10µg/µl 5µl 
DNA 1µg/µl 3µl 
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2.2.6 DNA ligation 
Fragments of DNA were removed from pBluescript vector using restriction enzyme 
digestion (section 2.1.5) and inserted into transfection vector pIRES2-EGFP by 
ligation reaction using T4 DNA ligase. The ligation mixture was prepared as shown 
in Table 2.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.2: The ligation reaction mixture 
 
After overnight incubation at 4
o
C, 5µl of ligation mixture was transformed into 
competent bacterial cells (section 2.1.8). Recombinant DNA was recovered from 
bacterial cells using a Qiagen miniprep or midiprep kit (section 2.1.9). 
 
Insert DNA (180ng/µl) 2µl 
Vector DNA ( 110ng/µl) 1µl 
2x quick Ligation buffer 10µl 
T4 DNA Ligase  
(400 cohesive end units) 
/µl) 
 
1µl 
H2O 6µl 
Total volume 20µl 
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2.2.7 cDNA sequencing 
Recombinant plasmid DNAs or cDNA sequences generated by reverse transcription 
polymerase chain reaction (RT-PCR) were sent for nucleotide sequencing at the 
School of Tropical Medicine, University of Liverpool. Sequencing was carried out 
by using a big dye terminator cycle sequencing reaction kit with an ABI prism 377 
automated DNA sequencer. Sequence alignment was determined by using BioEdit 
for searching Genbank (BLAST). 
 
2.2.8 Transformation of competent bacteria with plasmid DNA 
2.2.8.1 Preparation of competent bacterial cells 
E.coli (DH5 ) glycerol stock was streaked onto an LB-agar plate and incubated at 
37 C overnight. On the following day, a single colony was inoculated into a conical 
flask containing 10mls LB broth and incubated at 37
o
C overnight with shaking at 
225xg. Then, 1ml of overnight culture was transferred into 100ml of SOB medium 
(2% w/v bactotryptone, 0.5% w/v yeast extract, 10mM NaCl, and 2.5mM KCl) and 
incubated at 37 C with shaking at 225xg until the OD550 reached 0.4.  The culture 
solution was split into 8x 12ml aliquots and placed on ice to cool for 10 minutes. The 
DH5  bacteria were pelletted by centrifuging at 2500xg for 10 minutes at 4
o
C and 
the supernatant was discarded. The bacterial cell pellets were resuspended in 8.25ml 
of pre-cooled RF1 buffer (100mM KCl, 50mM MgCl2.4H20, 30mM KCl, 10mM 
CaCl2 and 15% v/v glycerol, pH6.8) and incubated on ice for 10 minutes. After a 
further centrifuging at 2500xg for 10 minutes at 4
o
C, the cell pellet was resuspended 
in 2ml of RF2 buffer (10mM MOPS, 10mM KCl, 75mM CaCl2.2H2O and 15% v/v 
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glycerol, pH6.8). The DH5  bacteria solution was dispensed into 1ml aliquots in 
cryovials, frozen in liquid nitrogen and transferred immediately to –80oC freezer for 
storage. 
 
2.2.8.2 Transformation 
A vial of DH5  competent cells was removed from the -80  C and thawed on ice. 
Then, 50ng of plasmid DNA or 10μl of the ligation mixture was added to 50µl of 
competent DH5  cells, mixed by flicking gently and incubated on ice for 30 
minutes. The cells were heat shocked at 42 C for exactly 90 seconds and placed on 
ice for a further 2mins followed by adding 800 l of SOC (2% w/v bactotryptone, 
0.5% w/v yeast extract, 10mM NaCl, 10mM MgCl 2, 10mM MgSO4, 2.5mM KCl, 
20mM glucose) and incubated 37 C for 1 hour in a shaking incubator at 225xg. 
Transformed bacteria solution (200 l) was plated onto LB plates containing 50µg/ml 
ampicillin or 30µg/ml kanamycin for antibiotic selection and incubated at 37 C 
overnight. Finally, colonies were picked from the plate and grown in LB broth 
containing antibiotic at 37 C, 225xg overnight and plasmid minipreps were 
conducted. 
 
2.2.8.3 Calculation of transformation efficiency  
 Transformation efficiency is the number of transformed cells (transformants) 
generated by 1 g of supercoild plasmid DNA in a transformation reaction. 
Transformation efficiency is calculated as follows:  
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2.2.9 Isolation of plasmid DNA  
Plasmid DNA was isolated using Qiagen extraction kits.  
2.2.9.1 Miniprep extraction of plasmid DNA 
Overnight cultured bacteria (5ml) in LB medium containing antibiotic harvested by 
centrifuging at 6,000xg for 1min and the supernatant removed.  The cell pellet was 
resuspended in 250 l of suspension buffer P1 (50mM Tris-HCl pH8.0, 10mM EDTA 
and 100μg/ml RNaseA) by vortexing, followed by adding 250 l of cell lysis buffer 
P2 (200mM NaOH and 1% w/v SDS) and mixed by gentle inversion of the 
microcentrifuge tube six times.  Then, 350 l of neutralisation buffer N3 (4.2M Gu-
HCl, 0.9M potassium acetate pH4.8) was added and mixed by gentle inversion of the 
microcentrifuge tube six times. The mixture was centrifuged at 13,000xg for 10 
minutes and the supernatant was loaded to a miniprep spin column. The column was 
centrifuged at 13,000xg for 1 minute and the flow through was discarded. The 
column was then washed by adding 750 l of wash buffer PE (10mM Tris-HCl pH7.5 
and 80% ethanol) and centrifuged at 13,000xg for 1 minute. After removing the flow 
through, the spin column was centrifuged for an additional minute to remove residual 
wash buffer. The column was placed in a clean 1.5ml microcentrifuge tube and 30 l 
of distilled water was added to the centre. After 1min incubation at RT, the plasmid 
DNA was eluted by centrifuging at 13,000xg for 1 minute.  The concentration and 
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quality of the DNA were examined as described in section 2.1.1 and isolated plasmid 
DNA was stored in a -20 C freezer. 
 
2.2.9.2 Midiprep extraction of plasmid DNA 
A single colony of transformed DH5  bacteria was transferred into flasks containing 
10ml of LB medium with antibiotic and left to grow overnight at 37 C, 225xg. The 
overnight cultured bacterial cells (5ml) were then transferred to 200ml LB medium 
containing antibiotic and incubated for 5 additional hours at 37 C, 225xg. The 
transformed bacterial cells were harvested by centrifuging at 6,000xg for 10min at 
4oC and the supernatant was removed. The cell pellet was resuspended in 4ml of 
buffer P1 (50mM Tris-HCl pH8.0, 10mM EDTA, 100μg/ml RNase A) by vortexing 
until no clump remained. The bacterial cells were lysed by adding 4ml of lysis buffer 
P2 (200mM NaOH, 1% w/v SDS), gently mixed by six times inversion. After 
incubation at RT for 5mins, 4ml of pre-chilled P3 neutralising buffer (3.0M 
potassium acetate pH5.5) was added and the mixture was mixed by inverting six 
times, incubated on ice for 15mins and then centrifuged at 16,000xg, 11 C for 
30mins. The supernatant containing plasmid DNA was transferred to a clean 30ml 
centrifuge tube and re-centrifuged at 16,000xg, 11 C for further 15mins. In the mean 
while, a Qiagen midiprep column was equilibrated by applying 4ml of equilibration 
buffer QBT (750mM NaCl, 50mM MOPS pH 7.0 and 15% v/v isopropanol) and 
allowed to empty by gravity flow. Once the Qiagen midiprep column was 
equilibrated, the cleared supernatant containing plasmid DNA was loaded into the 
column and allowed to flow under gravity. The column was washed twice with 10ml 
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of wash buffer QC (1.0M NaCl, 50mM MOPS pH 7.0, 15% v/v isopropanol) and the 
plasmid DNA was eluted from the column using 5ml of elution buffer QF (1.25 M 
NaCl, 50mM Tris-HCl pH 8.5, 15% v/v isopropanol). The eluted DNA was 
precipitated by adding 3.5ml of isopropanol, mixed and centrifuged at 4 C, 11,000xg 
for 30mins. The supernatant was carefully removed and the pellet was washed with 
2ml of 70% (v/v) ethanol and centrifuged at RT, 11,000xg for 10mins. After 
removing the supernatant, the pellet was air-dried for 10mins and the plasmid DNA 
was then dissolved in 200 l of nuclease-free water. The concentration and quality of 
the DNA were examined as described in section 2.1.1 and the isolated plasmid DNA 
was stored at -20 C 
 
2.3 Mutagenesis of C-FABP gene and construction of C-FABPs 
transfection vectors 
A 436 base pair fragment of the protein coding region of C-FABP was amplified by 
RT-PCR from total mRNA isolated from PC-3M cells. The amplified C-FABP 
product was T-A cloned into a PGEM-Teasy plasmid and then transferred into 
pBluescript II SK vector as shown in Figure 2.1. Transformer
tm 
Site-Directed 
Mutagenesis Kit was used to generate one or two point mutations to the C-FABP 
gene. The transformer mutagenesis strategy, as shown in Figure 2.2, can not only 
introduce single or multiple specific base mutations with high efficiencies (70-90%) 
but also has the advantage of avoiding subcloning and using single-stranded vectors 
or specialized double-stranded plasmids. Furthermore, the use of T4 DNA 
polymerase instead of PCR reduces the risk of generating spurious mutations.  
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First, the mutagenic primer and the selection primer containing a mutation in a 
restriction enzyme site were annealed to one strand of the denatured double-stranded 
plasmid. 
Second, after DNA extension, ligation and a primary selection by restriction digest 
the mixture of mutated and unmutated plasmids is transformed into a mutS E.coli 
strain defective in mismatch repair. 
Third, the DNA was isolated from pooled transformants and digested with the 
selective restriction enzyme. 
Finally, the digested DNA was transformed into DH5α bacterial cells and the 
mutated plasmid was recovered by midiprep extraction. 
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Figure 2.1: Circular maps and lists of features for the pBluescript II SK vector 
The pBluescript II SK vector contains an ampicillin selection marker which is 
essential for Transformer site-directed mutagenesis kit because the bacterial strain 
BMH 71-18 mutS has a Tn10 transposon and therefor is tetracycline resistant. The 
efficiency of the chosen restriction enzyme digestion has been examined at a low 
DNA concentration (0.1µg/30µl) before the mutagenesis assay procedure. 
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Figure 2.2: Transformer site-directed mutagenesis strategy  
(The picture is taken from Clontech transformer site-directed mutagenesis kit user 
manual).  
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2.3.1 Selection and mutagenic primers 
Selection primer:  5’- CAAGATCTCGATGGCGGTGGCG-3’ 
Mutagenic primer (R109A): 5’- CGTGTTATGTCGTTTTAACTTTC -3’ 
Mutagenic primer (R129A): 5’- GTGGACATGACGCTAGATAC -3’ 
The changed base pairs of the selection and mutagenic primers are underlined. All 
primers were synthesized with an incorporated 5’ phosphate. 
 
2.3.2 Generation of the mutant plasmid DNA  
The primer/plasmid annealing reaction mixture was prepared with 2µl of 10x 
annealing buffer (200mM Tris-HCl pH7.5, 100mM MgCl2, 500mM NaCl), 0.1µg 
plasmid DNA, 2µl of 0.1µg/µl selection primer, 2µl of 0.1µg/µl mutagenic primer 
(the selection and mutagenic primers are listed in section 2.2.1.) and nuclease-free 
water (adjust to a total volume of 20µl). After denaturation at 100
o
C for 3 minutes, 
the reaction mixture was immediately placed on ice for 5 minutes. Then, the reaction 
mixture was supplemented with 3µl of 10x synthesis buffer, 1µl of T4 DNA 
polymerase (3units/µl), 1µl of T4 DNA ligase (2.84 WEISS units/µl), 5µl of 
nuclease-free water and incubated at 37
o
C for 2 hours to synthesize the mutant DNA 
strand. The reaction was stopped by heating at 70
o
C for 8 minutes and cool to RT. 
 
2.3.3 Selection by restriction digestion 
The DNA in synthesis/ligation mixture was ethanol precipitated (section 2.2.2) and 
resuspended in restriction enzyme digestion mixture with 0.5µl of NotI (20units/µl), 
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3µl of 10x NEBuffer3 and 26.5µl of nuclease-free water for primary selection. The 
reaction mixture was incubated at 37
o
C for 2 hours and heated at 70
o
C for 5 minutes 
to stop the digestion. Then, 11µl of the digested plasmid DNA was used to transform 
BMH 71-18 mutS competent cells (section 2.2). The mixed plasmid pool was 
isolated using miniprep (section 2.1.9) and digested with NotI restriction enzyme. 
The digested plasmid DNA was used to transform DH5α competent cells followed 
the same procedure as for the first transformation. The mutant DNA was recovered 
by miniprep or midiprep and the mutation was verified by directly sequencing the 
mutagenized region as previously described in section 2.2.1 The mutagenic primer 
(R109A) was applied to introduce single mutation and the double mutations were 
generated using both mutagenic primer (R109A) and mutagenic primer (R129A). 
 
2.4 Cell culture 
2.4.1 Routine cell culture 
All routine cell culture manipulations took place in a tissue culture hood located in 
the Tissue Culture Laboratory. Cells were cultured in 75cm
2
 cell culture flasks and 
maintained at 37
o
C in a humidified incubator which contains 5% (v/v) CO2. LNCaP 
cells were cultured in XGI1640 nutrient medium supplemented with 10% (v/v) 
Foetal calf serum (FCS), 2mM L-glutamine, 1mM Sodium pyruvate, 100IU 
penicillin/streptomycin (PEN-STREP), 5µg/ml 5- dihydroxytestosterone and 
5µg/ml hydrocortisone. LNCaP-C42 and 22RV-1 cells were cultured in XGI1640 
nutrient medium supplemented with 10% (v/v) Foetal calf serum (FCS), 2mM L-
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glutamine and 100IU penicillin/streptomycin (PEN-STREP). All routine culture 
media were replaced every alternate day.  
 
2.4.1.1 Thawing of cells 
Cryogenic vials of cells were defrosted in a water bath at 37
o
C and immediately 
transferred into a universal tube with 20ml of complete cell culture medium. The 
cells were then pelleted by centrifugation at 900xg lasting for 3 minutes. Then, the 
supernatant was discarded and the pellet was resuspended in a suitable volume of 
complete medium containing 10% FCS. Finally, cells were plated out in a 75cm
2
 cell 
culture flask and maintained within a controlled atmosphere of 5% CO2 at 37
o
C. 
 
2.4.1.2 Sub-culture of cell lines 
Cells cultured to approximately 70-80% confluence were passaged to allow 
continuous growth. Medium was completely removed from the flasks. Cell cultures 
were washed by phosphate buffered saline (PBS) and incubated at 37
o
C with 3.5ml 
of 2.5% (v/v) trypsin/versene solution for a period 4 minutes or until the cells had 
rounded up and were starting to detach from the culture dish. The trypsin/versene 
solution was inactivated by adding 10ml of complete medium. The cells were then 
transferred to a universal tube and centrifuged at 900xg for 3 minutes. The 
supernatant was removed and cells were resuspended in cell culture medium.  The 
cells were aliquotted at the required concentration and maintained within a controlled 
atmosphere of 5% CO2 at 37
o
C.  
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2.4.1.3 Counting cells 
The number of cells was calculated by using an improved Neubauer double counting 
chambers haemocytometer. Cells were detached as described previously. After 
thoroughly mixed, 10µl of cell suspension was loaded to a counting chamber of 
haemocytometer with 9 (3x3) squares. Then, cells were counted in four corner 
squares under the microscope. The total number of cells is calculated using the 
equation listed below: 
 
Total number of cells = Average cell count per square x Dilution x 10
4
 x Total 
volume (ml) 
 
2.4.1.4 Freezing cells 
Cells were selected for freezing when they were approximately 70-80% confluence. 
Before freezing, the cell culture medium was replaced with fresh medium for 24 
hours. The cells were detached as described in 2.4.1.2 and resuspended in 10ml of 
completed medium. Then, the total number of cells was counted as mentioned in 
2.4.1.3. The cells were re-centrifuged at 900 xg for 3 minutes. The supernatant was 
removed and the cell pellet was broken up by repeated pipetting with freezing 
medium (Complete medium with 7.5% (v/v) DMSO) to give a concentration of 
1x10
6
 cells/ml. Aliquots (1ml) of the cell suspension were pipetted into cryogenic 
vials and placed into a nalgene cryo-preserver box containing 250ml of isopropyl 
alcohol. The box stored in a freezer at –80oC overnight before cryogenic vials 
transferred for long term storage in liquid nitrogen. 
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2.5 Cell transfection 
2.5.1 Stable transfection of the LNCaP cell line using GeneJammer 
A polyamine based method of transfection (GeneJammer) was used to insert pIRES2-
EGFP into LNCaP cells. Prior to transfection, LNCaP cells (2x10
5
) were seeded in a 
6-well tissue culture plate and the cells were grown overnight in complete LNCaP 
culture medium to reach 50-70% confluence. In the mean time, 97µl of sterile, room 
temperature (RT), serum-free, antibiotic-free XGI medium was transferred to a 1.5ml 
eppendorf tube and supplemented with 3µl GeneJammer transfection reagent. After 
incubation for 5mins at RT, 2µg of DNA was added to the diluted GeneJammer 
transfection reagent and mixed gently. The mixture was incubated at RT for 30 
minutes and added dropwise to the wells of the 6-well tissue culture plate. Then, the 
transfection mixture was distributed evenly by rock the plate back and forth. The 
control transfections were also performed as shown in Figure 2.3. After incubation in 
standard growth conditions for 48 hours, cells were split into 5 separate 9cm cell 
culture plate and cultured in selective medium containing 0.5mg/ml Geneticin for 10 
days. The Geneticin was removed and the surviving transfected clones were allowed 
to recover in routine medium for one week. 
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Figure 2.3: Three mock-transfection controls 
Three mock-transfection controls were performed by putting cells through the 
transfection procedure without adding GeneJammer transfection reagent or DNA or 
both of them. 
 
2.5.2 Transfected clone selection by cell image 
Cells were then re-cultured in selective medium for a further 3-4 weeks until the cells 
in control transfection died out and healthy cell clones had formed in the cell culture 
plate. As pIRES2-EGFP vector (Figure 2.4) contained the enhanced green fluorescent 
protein (EGFP) coding region, successfully transfected cell colonies with the 
expression of fluorescent marker were detected under a fluorescence microscope. 
Because the proportion of cells transfected within a population is relatively low (less 
than 10%), the ring cloning methodology was used to isolate colonies. For each batch 
transfectants, 5 colonies with best expression of EGFP were marked on the down-
side of 9cm plate for ring cloning. 
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Figure 2.4: Circular maps and lists of features for the pIRES2-EGFP vector 
(The vector map is taken from Clontech transformer site-directed mutagenesis kit 
user manual).  
 
2.5.3 Ring cloning of transfected cells 
The tops of 1ml pipette tips were cut to enlarge the cloning rings and sterilised by 
autoclaving. The selective medium from the transfectant plates was removed and the 
plates were washed with PBS. Using forceps, cloning rings were dipped in silicon 
grease and placed over the colonies. The small amount of silicon grease allowed the 
rings to adhere to the plate and formed a watertight seal around the colony. Then, 
100µl of 2.5% (v/v) trypsin/versene solution was added to isolated colonies and 
incubated for 6 minutes or until the cells were rounded-up. The detached cells were 
transferred to a 1.5ml Eppendorf tube and the trypsin inactivated by adding an equal 
volume of routine cell culture medium. The cells were centrifuged for 3 minutes at 
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900xg. After remove of supernatant, the cell pellet was resuspended in 1ml selective 
culture medium containing 0.5mg/ml geneticin and plated into a 24-well plate and 
maintained within a controlled atmosphere of 5% CO2 at 37
o
C. 
 
2.6 Molecular cloning 
Cloning technique is a powerful tool for the in-vitro studies of gene expression, 
structure and function. In this study, a fragment of the C-FABP-WT, C-FABP-
R109A (single mutant) and C-FABP-R109/129A (Double mutant) were inserted into 
an expression vector. The vector-gene construct was transformed into the host E.coli 
cells for further manipulation of the C-FABPs fragments.  
 
2.6.1 Phase 1:      
2.6.1.1 Cloning into pBluescript II SK (+/-) Phagemids 
The pIRES2-CFABP-WT, pIRES2-CFABP-R109, C-FABP-R109/129A and 
pIRES2-EGFP (vector only) were inserted in to a plasmid vector, the vector used 
was pBluescript II SK (+/-) Phagemids supplied by Qiagen. The pBluescript II SK 
(+/-) Phagemids victor is circular and contains multiple unique restriction enzymes 
recognition sites as well as  T7 and T3 promoters, the choice of promoter used to 
initiate transcription determines which strand of the insert cloned into the victor will 
be transcribed. The vector contains ampicillin and β-galactosidase resistance genes. 
The restriction map of the poly cloning region of the vector is shown in Figure 2.1. 
Ligation of the pIRES2-CFABP wild type and mutants into the pBluescript vector 
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and subsequent transformation of the E.coli bacteria cells were carried out according 
to the manufacturer’s the QIAexpressionist (Qiagen, Duesseldorf, Germany) Figure 
2.5. The molar ratio of vector insert used for the reaction was 10:1. The ligation 
reaction described in Table 2.4 was incubated overnight at 14°C. A self ligation 
reaction containing all the above components except for the pIRES2-EGFP (vector 
only) was used as a positive control. After completion of the ligation reaction 
mixtures were stored at -20°C until further use.  
 
 
Figure 2.5: Construction of QIAexpress expression vector.  
(The picture is taken from QIAexpress Ni-NTA Fast Start Handbook)  
*R1 and R2: restriction sites.   
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2.6.1.2 Ethanol precipitation of DNA  
The DNA to be precipitated was mixed with 2.5 volumes of chilled state temperature 
absolute ethanol and 10% volumes of 3M sodium acetate (pH5.2). The mixture was 
mixed gently by inversion and incubated at –80oC freezer overnight for DNA to 
precipitate. The precipitated DNA was pelleted by centrifuge at 16,000 xg at 4
o
C in a 
microcentrifuge for 20 mins. The supernatant was removed and the pellet was 
washed by 100μl of pre-chilled 70% (v/v) ethanol. The DNA was recentrifuged at 
16,000xg at 4
o
C for 15 mins and the supernatant was decanted. The DNA was air 
dried and resuspended in sterile DEPC-treated water. 
2.6.1.3 Restriction Enzyme digestion of plasmid DNA 
Plasmid DNA was digested with two different restriction enzymes (XhoI and PstI) to 
check for the presence of insert and to produce DNA fragment for ligation. The 
restriction enzyme digest mixture was prepared as shown in Table 2.3. 
 
 
 
Table 2.3: The restriction enzyme digestion mixture (total volume 25µl).  
 WT 
Single 
Mutant (R) 
Double 
Mutant (RR) 
PBluescript 
Water 13.5µl 14.8µl 13µl 13µl 
10x NEBuffer 3 2.5µl 2.5µl 2.5µl 2.5µl 
XhoI 20units/µl 1µl 1µl 1µl 1µl 
PstI 20units/µl 1µl 1µl 1µl 1µl 
DNA 1.5µg 7µl 5.7µl 7.5µl 7.5µl 
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The restriction enzyme digest mixture was incubated at 37
o
C for 2 hours to allow 
complete digestion of the template DNA. Then, the enzyme reaction was inactivated 
by heating to 68
o
C for 10 minutes and the products were analysed by gel 
electrophoresis. 
 
 
2.6.1.4 Agarose gel electrophoresis of DNA 
Agarose gel electrophoresis was carried out in 1xTBE buffer (0.089M Tris-base, 
0.089M Boric acid, 0.002M EDTA pH8.0). The agarose concentration of the gel was 
0.8% to 2.0% (w/v) according to DNA size. The agarose was dissolved in 200ml of 
1xTBE buffer by microwave heating for 2mins and cooled to 40-50
o
C. Then, 10µl of 
500ng/ml ethidium bromide was added for visualisation. The gel mixture was poured 
and placed at 4
o
C to solidify. DNA samples were prepared by adding 5x agarose gel 
loading buffer (0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol FF, 30% 
(v/v) glycerol in water) to a 1x concentration and loaded into the gel alongside DNA 
size marker. The gel was run for 50mins at 90V and visualised on a UV 
transilluminator. 
 
2.6.1.5 Purification of DNA from agarose gels 
DNA fragments were separated using agarose gel electrophoresis as described 
previously in section 2.5.1.4. The required fragments were visualised by ethidium 
bromide and excised using a sterile blade. Each excised gel slice was weighed and 
three times the volume of buffer QG was added. Then, the mixture was dissolved in a 
50oC water bath for 10 mins with occasional vortex mixing. The melted agarose and 
DNA solution was applied to a QIAquick spin column and centrifuged for 1 minute 
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at 16,000 xg in a microcentrifuge and the flow through was discarded. The 
membrane, bound with DNA, was washed by passing through 750 l of buffer PE 
and re-centrifuged for a further minute to remove any residue. The DNA was eluted 
from the column by adding 30μl of distilled water and quantified as described above. 
The DNA was stored at –20oC until needed 
 
2.6.1.6 Calculation of insert/vector ratio 
The insert to vector molar ratio can have a significant effect on the outcome of a 
ligation and subsequent transformation step. Molar ratios can vary from a 1:1 insert 
to vector molar ratio to 10:1. In this study, 10:1 insert to vector molar ratio has been 
the most suitable according to formula below: 
 
   
 
  
 
2.6.1.7 DNA ligation 
Fragments of DNA were removed from pBluescript vector using restriction enzyme 
digestion as described in section 2.5.1.3 and inserted into transfection vector 
pIRES2-EGFP by ligation reaction using T4 DNA ligase. The ligation mixture was 
prepared as shown in Table 2.4. 
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Table 2.4: The ligation reaction mixture   
WT: C-FABP-WT, R: C-FABP-R109A and RR: C-FABP-R109/129A. Undigested 
pBluescript used as a control. 
 
After overnight incubation at 4
o
C, 5µl of ligation mixture was transformed into 
competent bacterial cells as described in section 2.5.1.8. The recombinant DNA was 
recovered from bacterial cells using a Qiagen miniprep or midiprep kit as described 
in section 2.5.1.9. 
 
2.6.1.8 Transformation of competent bacteria with plasmid DNA 
2.6.1.8.1 Preparation of competent bacterial cells 
E.coli (DH5 ) glycerol stock was streaked onto LB-agar plate and incubated at 37 C 
overnight. On the following day, a single colony was inoculated into a conical flask 
containing 10mls LB broth and incubated at 37oC overnight with shaking at 225xg. 
Then, 1ml of overnight culture was transferred into 100ml of SOB medium (2% w/v 
 WT R RR 
Insert DNA (180ng/µl) 9µl 9µl 9µl 
Vector DNA ( 110ng/µl) 1µl 1µl 1µl 
10x quick Ligation buffer 2µl 2µl 2µl 
T4 DNA Ligase  
( 400 cohesive end units 
/µl) 
 
1µl 1µl 1µl 
H2O 7µl 7µl 7µl 
Total volume 20µl 20µl 20µl 
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bactotryptone, 0.5% w/v yeast extract, 10mM NaCl, and 2.5mM KCl) and incubated 
at 37 C with shaking at 225xg until the OD550 reached 0.4.  The culture solution 
was split into 8x 12ml aliquots and placed on ice to cool for 10mins. The DH5  
bacteria were pelletted by centrifuging at 2500xg for 10mins at 4oC and the 
supernatant was discarded. The bacterial cell pellets were resuspended in 8.25ml of 
pre-cooled RF1 buffer (100mM KCl, 50mM MgCl2.4H20, 30mM KCl, 10mM 
CaCl2 and 15% v/v glycerol, pH6.8) and incubated on ice for 10mins. After a further 
centrifuging at 2500xg for 10mins at 4oC, the cell pellet was resuspended in 2ml of 
RF2 buffer (10mM MOPS, 10mM KCl, 75mM CaCl2.2H2O and 15% v/v glycerol, 
pH6.8). The DH5  bacteria solution was dispensed into 1ml aliquots in cryovials, 
frozen in liquid nitrogen and transferred immediately to –80oC for storage. 
 
2.6.1.8.2 Transformation 
A vial of DH5  competent cells was removed from the -80  C and thawed on ice. 
Then, 50ng of plasmid DNA or 10μl of the ligation mixture was added to 50µl of 
competent DH5  cells, mixed by flicking gently and incubated on ice for 30mins. 
The cells were heat shocked at 42 C for exactly 90 seconds and placed on ice for a 
further 2mins followed by adding 800 l of SOC (2% w/v bactotryptone, 0.5% w/v 
yeast extract, 10mM NaCl, 10mM MgCl 2, 10mM MgSO4, 2.5mM KCl, 20mM 
glucose) and incubated 37 C for 1 hour in a shaking incubator at 225xg. 
Transformed bacteria solution (200 l) was plated onto LB plates containing 50µg/ml 
ampicillin or 30µg/ml kanamycin for antibiotic selection and incubated at 37 C 
overnight. Finally, colonies were picked from the plate and grown in LB broth 
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containing antibiotic at 37 C, 225xg overnight and plasmid minipreps were 
conducted. Transformation efficiency was calculated (section 2.1.8.3). 
 
2.6.1.9 Isolation of plasmid DNA  
Plasmid DNA was isolated using Qiagen extraction kits.  
2.6.1.9.1 Miniprep extraction of plasmid DNA 
The overnight cultured bacteria (5ml) in LB medium containing antibiotic was 
harvested by centrifuging at 6,000xg for 1min and the supernatant was removed.  
The cell pellet was resuspended in 250 l of cell suspension buffer P1 (50mM Tris-
HCl pH8.0, 10mM EDTA and 100μg/ml RNaseA) by vortexing, followed by adding 
250 l of cell lysis buffer P2 (200mM NaOH and 1% w/v SDS) and mixed by gentle 
inversion of the microcentrifuge tube six times.  Then, 350 l of neutralisation buffer 
N3 (4.2M Gu-HCl, 0.9M potassium acetate pH4.8) was added and mixed by gentle 
inversion of the microcentrifuge tube six times. The mixture was centrifuged at 
13,000xg for 10 minutess and the supernatant was loaded to a miniprep spin column. 
The column was centrifuged at 13,000xg for 1min and the flow through discarded. 
The column was then washed by adding 750 l of wash buffer PE (10mM Tris-HCl 
pH7.5 and 80% ethanol) and centrifuged at 13,000xg for 1 minute. After removing 
the flow through, the spin column was centrifuged for an additional minute to 
remove residual wash buffer. The column was placed in a clean 1.5ml 
microcentrifuge tube and 30 l of distilled water was added to the centre. After 1 
minute incubation at RT, the plasmid DNA was eluted by centrifuging at 13,000xg 
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for 1 minute.  The concentration and quality of the DNA were examined as described 
in section 2.1.1 and isolated plasmid DNA was stored in a -20 C. 
 
2.6.1.9.2 Midiprep extraction of plasmid DNA 
A single colony of transformed DH5  bacteria was transferred into flasks containing 
10ml of LB medium with antibiotic and left to grow overnight at 37 C, 225xg. The 
overnight cultured bacterial cells (5ml) were then transferred to 200ml LB medium 
containing antibiotic and incubated for 5 additional hours at 37 C, 225xg. The 
transformed bacterial cells were harvested by centrifuging at 6,000xg for 10 minutes 
at 4
o
C and the supernatant was removed. The cell pellet was resuspended in 4ml of 
buffer P1 (50mM Tris-HCl pH8.0, 10mM EDTA, 100μg/ml RNase A) by vortexing 
until no clump remained. The bacterial cells were lysed by adding 4ml of lysis buffer 
P2 (200mM NaOH, 1% w/v SDS), gently mixed by six times inversion. After 
incubation at RT for 5 minutes, 4ml of pre-chilled P3 neutralising buffer (3.0M 
potassium acetate pH5.5) was added and the mixture was mixed by inverting six 
times, incubated on ice for 15 minutes and then centrifuged at 16,000xg, 11 C for 
30mins. The supernatant containing plasmid DNA was transferred to a clean 30ml 
centrifuge tube and re-centrifuged at 16,000xg, 11 C for further 15 minutes. In the 
mean while, a Qiagen midiprep column was equilibrated by applying 4ml of 
equilibration buffer QBT (750mM NaCl, 50mM MOPS pH 7.0 and 15% v/v 
isopropanol) and allowed to empty by gravity flow. Once the Qiagen midiprep 
column was equilibrated, the cleared supernatant containing plasmid DNA was 
loaded into the column and allowed to flow under gravity. The column was washed 
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twice with 10ml of wash buffer QC (1.0M NaCl, 50mM MOPS pH 7.0, 15% v/v 
isopropanol) and the plasmid DNA was eluted from the column using 5ml of elution 
buffer QF (1.25 M NaCl, 50mM Tris-HCl pH 8.5, 15% v/v isopropanol). The eluted 
DNA was precipitated by adding 3.5ml of isopropanol, mixed and centrifuged at 
4 C, 11,000xg for 30mins. The supernatant was carefully removed and the pellet was 
washed with 2ml of 70% (v/v) ethanol and centrifuged at RT, 11,000xg for 10mins. 
After removing the supernatant, the pellet was air-dried for 10 minutes and the 
plasmid DNA was then dissolved in 200 l of nuclease-free water. The concentration 
and quality of the DNA were examined as described in section 2.1.1 and the isolated 
plasmid DNA was stored at -20 C. 
 
2.6.1.10 cDNA sequencing 
Recombinant plasmid DNAs were sent for nucleotide sequencing at the Cogenics 
Technolgies
TM
 (Essex, UK), 100ng/µl (10µl) of each purified DNA was analysed. 
Appropriate primers were used according to Cogenics Technologies protocol. 
Sequence alignment was determined by using BioEdit for searching Genbank 
(BLAST). 
 
2.6.2 Phase 2: 
2.6.2.1 Cloning into pQE vectors 
The CFABP-WT, CFABP-R109A and C-FABP-R109/129A cDNAs were excised 
from pBluescript cloning vector and inserted into pQEs expression vector (pQE-30, 
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pQE-31 and pQE-32). The high-level expression of 6xHis-tagged proteins in E.coli 
using pQE vectors is based on the T5 promoter transcription-translation system. The 
pQE vectors are circular and contain 6xHis-tag coding sequence either 5' or 3' to the 
cloning region as well as T5 promoter (optimized promoter) and two lac operator 
sequences which increase lac repressor binding and ensure efficient repression of the 
powerful T5 promoter. The vector contains β-lactamase (bla) conferring resistance to 
ampicillin at 100µg/ml. The restriction map of the poly cloning region of the vector 
is shown in Figure 2.6. Ligation of the pBluescript-CFABP wild type and mutants 
into the pQE vectors and subsequent transformation of the E.coli bacteria (BL21) 
cells were carried out according to the manufacturer’s the QIAexpressionist (Qiagen, 
Duesseldorf, Germany). The molar ratio of vector insert used for the reaction was 
10:1. The ligation reaction described in Table 2.6 was incubated overnight at 14°C. 
A self ligation reaction containing all the above components except for the pQE 
(vector only) was used as a positive control. After completion of the ligation reaction 
mixtures were stored at -20°C until further use. 
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Figure 2.6: PQE vectors for N-terminal 6xHis tag constructor.  
(The vector map is taken from QIAexpress Ni-NTA Fast Start Handbook) PT5: T5 
promoter, lac O: lac operator, ATG: start codon, MCS: multiple cloning sites with 
restrictions site indicated.   
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2.6.2.2 Restriction Enzyme digestion of plasmid DNA 
Plasmid DNA was digested with two different restriction enzymes (PstI and Kpn1) to 
check for the presence of insert or to produce the DNA fragment for ligation. The 
restriction enzyme digest mixture was prepared as shown in Table 2.5. 
 
 
 
 
 
 
Table 2.5: The restriction enzyme digestion mixture (total volume 25µl).  
 
 
pBlue-
CFABP-WT 
pQE-30  pQE-31 pQE-32 
Water 15µl 14.5µl 2.3µl 2.3µl 
10x NEBuffer 1 3µl 3µl 3µl 3µl 
KpnI 20units/µl 1.5µl 1.5µl 1.5µl 1.5µl 
PstI 20units/µl 1.5µl 1.5µl 1.5µl 1.5µl 
DNA 1.5µg 4µl 4.5µl 16.7µl 16.7µl 
 
pBlue-CFABP-
R109A 
pBlue-CFABP-
R109/129A 
pQE-32 
Water 17µl 17µl 12µl 
10x NEBuffer 1 3µl 3µl 3µl 
KpnI 20units/µl 1.5µl 1.5µl 1.5µl 
PstI 20units/µl 1.5µl 1.5µl 1.5µl 
DNA 1.5µg 2µl 2µl 7µl 
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The restriction enzyme digest mixture was incubated at 37
o
C for 2 hours to allow 
complete digestion of the template DNA. Then, the enzyme reaction was inactivated 
by heating to 68
o
C for 10 minutes and the products were analysed by gel 
electrophoresis. 
 
2.6.2.3 Agarose gel electrophoresis of DNA 
Agarose gel electrophoresis was performed as described in section 2.6.1.4. 
 
2.6.2.4 Purification of DNA from agarose gels 
DNA fragments were separated using agarose gel electrophoresis as described 
previously in section 2.6.1.5. 
 
2.6.2.5 Calculation of insert/vector ratio 
The insert to vector molar ratio can have a significant effect on the outcome of a 
ligation and subsequent transformation step. Molar ratios can vary from a 1:1 insert 
to vector molar ratio to 10:1. In this study, 10:1 insert to vector molar ratio has been 
the most suitable according to formula below: 
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2.6.2.6 DNA ligation 
Fragments of DNA were removed from pBluescript-CFABPs (wild type and 
mutants) vector using restriction enzyme digestion as described in section 2.5.2.2 and 
inserted into transfection vectors pQE by ligation reaction using T4 DNA ligase. The 
ligation mixture was prepared as shown in Table 2.6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.6: The ligation reaction mixture.  
WT: wild type, R: Single Mutant and RR: double mutant. Undigested pBluescript 
used as a control. 
After overnight incubation at 4
o
C, 5µl of ligation mixture was transformed into 
competent bacterial cells as described in section 2.5.2.7. The recombinant DNA was 
recovered from bacterial cells using a Qiagen miniprep or midiprep kit as described 
in section 2.5.1.9. 
 WT R RR 
Insert DNA  6µl 16µl 16µl 
Vector DNA (PQE-30, 31 
& 32) 
2µl 2µl 1µl 
10x quick Ligation buffer 2µl 1µl 2µl 
T4 DNA Ligase  
( 400 cohesive end units 
/µl) 
 
1µl 1µl 1µl 
H2O 9µl - - 
Total volume 20µl 20µl 20µl 
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2.6.2.7 Transformation of competent bacteria with plasmid DNA 
2.6.2.7.1 Preparation of competent bacterial cells 
E.coli (BL21) glycerol stock obtained from Qiagen was streaked onto LB-agar plate 
and incubated at 37 C overnight. On the following day, a single colony was 
inoculated into a conical flask containing 10mls LB broth and incubated at 37
o
C 
overnight with shaking at 225xg. Then, 1ml of overnight culture was transferred into 
100ml of SOB medium (2% w/v bactotryptone, 0.5% w/v yeast extract, 10mM NaCl, 
and 2.5mM KCl) and incubated at 37 C with shaking at 225xg until the OD550 
reached 0.4.  The culture solution was split into 8x 12ml aliquots and placed on ice to 
cool for 10mins. The DH5  bacteria were pelletted by centrifuging at 2500xg for 
10mins at 4
o
C and the supernatant was discarded. The bacterial cell pellets were 
resuspended in 8.25ml of pre-cooled RF1 buffer (100mM KCl, 50mM MgCl2.4H20, 
30mM KCl, 10mM CaCl2 and 15% v/v glycerol, pH6.8) and incubated on ice for 
10mins. After a further centrifuging at 2500xg for 10mins at 4
o
C, the cell pellet was 
resuspended in 2ml of RF2 buffer (10mM MOPS, 10mM KCl, 75mM CaCl2.2H2O 
and 15% v/v glycerol, pH6.8). The BL21 bacteria solution was dispensed into 1ml 
aliquots in cryovials, frozen in liquid nitrogen and transferred immediately to –80oC 
for storage. 
2.6.2.7.2 Transformation 
A vial of BL21 competent cells was removed from the -80  C freezers and thawed on 
ice. Then, 50ng of plasmid DNA or 10μl of the ligation mixture was added to 50µl of 
competent DH5  cells, mixed by flicking gently and incubated on ice for 30mins. 
The cells were heat shocked at 42 C for exactly 90 seconds and placed on ice for a 
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further 2mins followed by adding 800 l of SOC (2% w/v bactotryptone, 0.5% w/v 
yeast extract, 10mM NaCl, 10mM MgCl 2, 10mM MgSO4, 2.5mM KCl, 20mM 
glucose) and incubated 37 C for 1 hour in a shaking incubator at 225xg. 
Transformed bacteria solution (200 l) was plated onto LB plates containing 50µg/ml 
ampicillin and 25µg/ml kanamycin for antibiotic selection and incubated at 37 C 
overnight. Finally, colonies were picked from the plate and grown in LB broth 
containing antibiotic at 37 C, 225xg overnight and plasmid minipreps were 
conducted. Transformation efficiency was calculated as described is section 2.1.8.3. 
 
2.6.2.8 Isolation of plasmid DNA  
The isolation of plasmid DNA was conducted using extraction kits provided by 
Qiagen. 
Miniprep and Midiprep extraction of plasmid DNA were examined as described in 
section 2.5.1.9. 
 
2.6.2.9 cDNA sequencing 
The recombinant plasmid DNAs were sent for nucleotide sequencing at the Cogenics 
Technolgies
TM
 (Essex, UK), 100ng/µl (10µl) of each purified DNA was analysed. 
Appropriate primers were used according to Cogenics Technologies protocol. 
Sequence alignment was determined by using BioEdit for searching Genbank 
(BLAST). 
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2.6.3 Expression and purification of recombinant C-FABP proteins  
The expression and purification of C-FABP recombinant proteins conducted using 
QIAexpress Ni-NTA Fast Start kits provided by Qiagen (for purification and 
detection of recombinant 6xHis-tagged proteins).  
 
2.6.3.1 Growing E. coli and inducing expression  
 Using a sterile toothpick, a single colony was picked from selective antibiotic 
LB agar plate and inoculated into a 10ml LB medium containing 50µg/ml 
ampicillin in a 50ml flask and   incubated at 37 C overnight.  
 250ml of pre-warmed media with ampicillin was inoculated with 10ml of the 
overnight bacterial culture and grow at 37°C with vigorous shaking until an 
OD600 of 0.6 was reached (30-60 minutes). 0.5ml sample was taken 
immediately before induction (this sample was the non-induced control).    
 Expression was induced by adding IPTG (Isopropylthiogalactoside) 
(Appendix 1 & 2) to a final concentration of 1mM. A second 0.5ml was 
collected (this sample was the induced control).  
 Culture was incubated for an additional 4 hours. 
 Cells were harvested by centrifugation at 4000xg for 20 minutes. 
 Cell pellets were stored overnight at -20°C until further use.    
 
2.6.3.2 Protein purification 
Purification of 6xHis-tagged proteins under denaturing condition was conducted 
according to Ni-NTA Fast Start kits provided by Qiagen (Figure 2.7). 
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Figure 2.7: purification of 6xHis-tagged proteins using QIAexpress. 
(The picture is taken from QIAexpress Ni-NTA Fast Start Handbook)   
 
Protocol 
The material used for the purification process and solution preparations are 
summarised in Appendix 1 & 2.    
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Step 1 Cell pellets were resuspended in 10ml denaturing lysis buffer (pH 8.0) 
Step 2 
Cell suspensions were incubated at RT (15-25°C) for 60 min. After an 
hour cell suspensions were mixed 2-3 times by gently swirling the 
suspensions (lysis was completed when the suspension is translucent). 
Step 3 
Lysates were centrifuged at 14000xg for 30 min at RT to pellet the 
cellular debris (the supernatants contain the recombinant protein). 5µl 
2x SDS-PAGE sample buffer was added to a 5µl aliquot of the 
supernatant and stored at -20°C for SDS-PAGE analysis 
Step 4 
The resin in a fast star column was gently resuspended by inverting it 
several times. The seal at the outlet of the column was broken, screw 
cap was opened, and the storage buffer allowed draining out. 
Step 5 
The cell lysate supernatants were applied to the column. The flow-
through fractions were collected and 5µl 2x SDS-PAGE sample buffer 
was added to a 5µl aliquot of the flow-through fractions and stored at -
20°C for SDS-PAGE analysis 
Step 6 
Columns were washed 2 times with 4ml of denaturing wash buffer (pH 
6.3) and both wash fractions were collected. 5µl 2x SDS-PAGE 
sample buffer was added to a 5µl aliquot of each wash fraction and 
stored at -20°C for SDS-PAGE analysis 
Step 7 Bound 6xHis-tagged proteins were eluted with 1ml aliquots of 
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denaturing elution buffer (pH 4.5) and each elution fraction was 
collected in a separate tube. 5µl 2x SDS-PAGE sample buffer was 
added to a 5µl aliquot of each elution fractions and stored at -20°C for 
SDS-PAGE analysis 
Step 8 All fractions were analysed by SDS-PAGE. 
 
 
 
2.7 Analysis of protein expression using Western blot 
2.7.1 Isolation of protein extracts from cultured cells 
Cells were selected for protein isolation when they were grown to approximately 
80% confluence. The cells were detached (section 2.4.1.3) and suspended in 10ml of 
completed medium to inactive the trypsin. Cells suspension was transferred to a 25 
ml sterile universal tube and centrifuged at 900 xg for 3 minutes. The supernatant 
was decanted and the cells were washed with PBS which was removed by 
centrifuging. The cells was lysed by adding CelLytic-M reagent and incubated on a 
roller mixer for 15 minutes at RT (5x10
6
cells / 100µl). The mixture was transferred 
into a 1.5ml microcentrifuge tube and then centrifuged for 20 minutes at 10,000xg to 
pellet the cellular debris. The supernatant was harvested into a fresh microcentrifuge 
tube and the pellet was discarded.  
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2.7.2 Determination of protein concentration 
The concentration of protein extract was quantified using the Bradford dye-binding 
assay. The dye reagent was diluted 5-fold by adding distilled water (Bradford 
reagent: H2O = 1:4) and filtered through Whatman 540 paper. A concentration 
standard curve was created by measuring the absorbance (595nm) of a serial dilution 
of BSA standards (from 50µg/µl to 500µg/µl) after 20 minutes incubation with 
Bradford reagent. Protein samples were also diluted by PBS and incubation with 
Bradford reagent for 15 minutes before measuring the absorbance at 595nm. The 
sample concentration was calculated using the equation from established standard 
curve. 
 
2.7.3 Equalization of protein samples for loading 
Protein samples were quantified before loading using Bradford dye-binding assay as 
described in section 2.7.2. Distilled water was added to samples to make sure an 
equal amount of total protein in all samples. After equalization 5x sample loading 
buffer was added and the protein samples were heated for 10 minutes, chilled on ice 
for 2 minutes and centrifuged before loading in to the SDS gel. 
 
2.7.4 Sodium dodecyl sulphate polyacrylamide protein gel 
electrophoresis (SDS-PAGE) 
The apparatus used for SDS-PAGE was the Bio-Rad Mini Protein II cell (Bio-Rad 
Laboratories Ltd, UK). The 10.2cm x 8.3cm glass plate was placed on a clean dry 
surface. Two 0.75mm spacers were placed along the edges of the plate and the 
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10.2cm x 7.3cm plate was placed on top of the spacers so that it was flush with one 
end of the long plate. Plates were secured with the sandwich clamps and the 
assembled gel sandwich placed in the alignment slot of the casting stand ensuring 
that plates and spacers were flush at the bottom and that a good seal was obtained. 
A 12.5% resolving gel was made by adding 10mls of Next Gel (Appendix 2) to 60µl 
of 10% ammonium persulphate (APS) and 6µl TEMED and the gel immediately 
poured using a glass pipette and an electric pipette filler (Drummond laser) until 
approximately the edge of the plastic comb. At this stage it was very important to 
pour the solution smoothly in order to avoid air bubbles. The 10 well x 0.75mm 
comb was immediately placed in the gel until all teeth were completely covered by 
the solution. The gel was allowed to polymerise for 40 minutes and the comb 
removed by slowly pulling it vertically upwards. The newly formed wells were then 
carefully rinsed with distilled water. The gel was released from the casting stand and 
inserted into the buffer chamber securely. Approximately about 500mls of running 
buffer (Appendix 2) were added to the chamber. 
Five minutes before the loading gel was ready equal amounts of each sample protein 
along with a positive control were placed into separate thin walled Eppendorf tubes 
and lowered into heater. At the end of this period the samples were carefully loaded 
using a Hamilton microliter 700 series syringe, (Hamilton Company, Reno, USA) 
which was thoroughly rinsed with boiling water between each sample. Pre-stained 
electrophoresis standards of various molecular weights were added to the first well 
(Bio-Rad Laboratories Ltd, Harts, UK). The lid was placed on the lower buffer 
chamber, the cell connected to the BioRed power pack 200 (Bio-Rad Laboratories 
Ltd, Harts, UK) and electrophoresis was performed in 500ml 1x next gel running 
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buffer (25ml next gel running buffer and 500ml distilled water ) at 200 volts until the 
dye front had reached the end of the next gel.  
2.7.5 Transfer of proteins from SDS gel to nitrocellulose membrane 
Separated Proteins were transferred from SDS gel to a nitrocellulose membrane 
using the BioRad mini trans-blot system. Six sheets of Whatman 3mm filter paper 
and the nitrocellulose membrane were cut according to the size of the SDS gel and 
soaked in 1x transfer buffer for 5 minutes. The cassette, with black side down, was 
placed on a tray containing transfer buffer and assembles the cassette in following 
order (from black side): a pre-wet fiber pad, three sheets of Whatman filter paper, 
equilibrated SDS gel, nitrocellulose membrane, three sheets of Whatman filter paper 
and another pre-wet fiber pad. The air bubbles were removed from each step using a 
glass roller. The transfer was performed at 100V, 4
o
C for 1.5 hours in pre-chilled 1x 
transfer buffer.  
 
2.7.6 Coomassie blue and PONCAUS staining 
After transfer, the gel was stained with coomassie blue (Severn Biotech Ltd, UK) for 
an hour and washed with distilled water shaking slowly overnight, then dried using a 
vacuum gel-drier (Flowgen, Nottingham, UK) at 70°C for 4-5 hours.  
After transfer, the membrane was stained with 10% PONCEUS solution (Sigma, 
USA) for 2 minutes and washed with TBST for 10 minutes to visualise the protein 
bands. Efficiency of the transfer was assessed through both staining methods. 
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2.7.7 Immunoblotting for detection of protein expression 
The nitrocellulose membrane containing the proteins was blocked with 10ml of 5% 
blocking solution (5g Milk dissolved in 100ml TBST) for an hour at room 
temperature on a gentle agitation to prevent non-specific binding of the primary 
antibody. The membrane was then incubated on a shaker with a primary antibody in 
an appropriate concentration (Table 2.7) at 4
o
C overnight. The following day, the 
membrane was washed with 1x T-TBS 4 times for 10 minutes each time to remove 
unbound primary antibody and incubated with a secondary antibody in an 
appropriate concentration (Table 2.7) for an hour at room temperature. Then, the 
membrane was washed with 1x T-TBS 4 times for 10 minutes each time again. The 
probed antigens on the membrane were visualized by incubation in ECL reagents 
(2ml of Reagent A was mixed with 50µl of solution B) for 5 minutes at room 
temperature. Chemiluminescent images were recorded on Kodak films with 0.5-10 
minute’s exposure. The films were developed and fixed in the dark room. 
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Table 2.7: Primary and secondary antibodies used in Western blot. 
 
 
2.7.8 Immunoblotting for detection of β-actin expression  
Consistently expressed β-actin antibody was used to normalise any loading 
variations.  
After target protein expression detection by ECL, the membrane washed in 1x T-
TBS, agitated overnight. Then the membrane was incubated in 10ml of 5% blocking 
solution for 30 minutes before incubation with β-actin antibody in a 1:5000 dilution 
for 30 minutes at room temperature. This was followed by three washes with 1x T-
TBS for 10 minutes each then the secondary antibody was added and incubated for 
Target Protein  Primary Antibody  Secondary Antibody  
C-FABP 
Monoclonal Rabbit Anti-human  
C-FABP (1:500) (Hycult
R 
Biotech) 
Polyclonal Swine Anti-
rabbit  
Immunoglobulins/HRP 
(1:5000) (Abcam)  
6xHis-tagged protein   
Penta-his antibody Binding 
(1:1000) (Qiagen)  
Polyclonal Swine Anti-
rabbit  
Immunoglobulins/HRP 
(1:5000) (Abcam)  
β-Actin 
Monoclonal Mouse  
Anti-β-Actin (1:5000) (Abcam) 
Polyclonal Rabbit Anti-
mouse 
Immunoglobulins/HRP 
(1:20000) (Abcam)  
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30 minutes at room temperature in 1:20000 dilution. Blots were washed three times 
with 1x T-TBS again and bound β-actin probes were visualised using the advanced 
ECL detection system.   
 
To standardize the loading difference, the level of β-actin expression was examined. 
The expression level (EL) of each target protein was calibrated using the formula 
listed below: 
 
 
 
 
2.8 Total RNA isolation 
Total RNA was isolated from cultured cells using the RNAeasy Mini Kit. Two 
75cm
2
 flasks cells were cultured to 70-80% confluence and harvested as described in 
section 2.4.1.2. The cells were washed with PBS which was removed by centrifuging 
at RT, 900xg for 3 minutes and 350µl buffer RLT containing 3.5µl -
Mercaptoethanol was added to lyse the cells. The cell lysate was then homogenised 
by centrifuging through a PrepEase filter unit at 16,000xg for 1 minute and 
precipitated in one volume of 70% ethanol. The resulting solution was transferred to 
an RNAeasy mini column sitting in a 2ml collection tube and centrifuge for 30 
seconds at 11,000xg. The column was then washed by 700μl buffers RW1 and twice 
with 500μl RPE buffer by centrifuging at 11,000xg for 30 seconds. The RNeasy spin 
column was centrifuged again at 16,000xg for 1 minute to eliminate any carryover 
buffer. After 30μl of RNase free water was added, the RNeasy spin column was 
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incubated at RT for 1 minute. Finally, the total RNA was eluted by centrifuging the 
column for 1 minute at 16,000xg. The total RNA yield and purity was determined by 
NanoDrop ND-1000 spectrophotometer as mentioned in section 2.2.1. 
2.8.1 Reverse transcription polymerase chain reaction 
2.8.1.1 First strand cDNA synthesis 
First strand cDNA was synthesized using total RNA isolated from LNCaP cells as 
described in section 2.7. Total RNA (3μg) was mixed with 1μl of 50μM Oligo (dT)20 
primer and 2μl of dNTP mixture (10mM each dATP, dCTP, dGTP, dTTP at neutral 
pH). After the volume was adjusted to 13μl with nuclease-free water, the mixed 
solution was incubated at 65°C for 5 minutes and chilled on ice for 1 minute. Then, 
the solution was mixed with 4μl of 5x first strand buffer, 1μl of 0.1M DTT, 1μl of 
RNaseOUT (40units/μl) and 1μl of SuperScriptIII reverse transcriptase (200units/μl). 
The reaction mixture was incubated at 50
o
C for one hour, followed by incubation at 
70
o
C for 15 minutes to inactivate the reaction. The First strand cDNA was used as a 
template for amplification. 
 
2.8.1.2 Polymerase chain reaction 
Polymerase chain reaction (PCR) was performed to amplify a specific region of the 
DNA template. The forward and reverse primers for C-FABP are listed as below: 
Forward primers sequence: 5’- ACCATGGCCACAGTTCAGCA -3’ 
Reverse primers sequence: 5’- CCTGTCCAAAGTGATGATGGAA -3’ 
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The DNA template was amplified in a total volume of 50μl reaction mixture as 
shown in Table 2.8.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.8: PCR mixture 
 
The reaction was incubated in a thermal cycler at 95
o
C for 5 minutes, followed by 35 
cycles of PCR amplification, each cycle consisting of denaturing: 95
o
C for 30 
seconds; annealing: 55
o
C for 45 seconds; extension: 72
o
C for 1 minute, followed by 
one cycle incubation at 72
o
C for 5 minutes and then maintained the reaction at 4
o
C. 
PCR amplification products were analysed by agarose gel electrophoresis and 
purified as previously described in section 2.2.3 and 2.2.4. 
 
DNA template 50-200ng 
10x PCR buffer 5µl 
MgCl2 (25mM) 3µl 
Forward primer (10µM) 1µl 
Reverse primer (10µM) 1µl 
dNTPs mixture 
 (10mM each) 
1µl 
Taq polymerase 
( 5U /µl) 
1µl 
Nuclease-free water Up to 50µl 
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2.8.1.3 Real-time PCR 
The real-time PCR, also known as quantitative real time polymerase chain reaction 
(qPCR), was applied in order to quantify the level of C-FABP mRNA in the 
transfected LNCaP cells. Traditional PCR or RT-PCR uses agarose gel 
electrophoresis for detection of amplified DNA fragments at the end of the reaction. 
However, real-time PCR is designed to collect data in the exponential growth phase 
when the reaction is in progress, which significantly increased the accuracy for DNA 
and RNA quantitation compare to the traditional PCR or RT-PCR.  
 
Several methods exist for real-time quantitation of amplification products, including 
fluorescence resonance energy transfer techniques using fluorescently labelled 
molecular beacons, SYBR Green I. During the PCR amplification, the fluorescence 
of SYBR Green I increases 100- to 200-fold when bound to double stranded DNA as 
presented in Figure 2.8. The number of amplicons generated is directly proportional 
to the increase in reporter fluorescent signal which was detected at the end of the 
elongation step of the PCR reaction by Chromo4 fluorescence detector. 
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Figure 2.8: SYBR Green Dye binds to the double stranded DNA and fluoresces 
 
2.8.1.3.1 Real-time PCR primer design 
The real-time PCR primers were designed spanning exon-exon junctions of C-FABP 
gene in order to avoid amplifying any genomic DNA contamination. The size of 
PCR amplicon was limited to between 50bp to 200bp and the primers self 
complimentarity and hair pins was also checked as SYBR Green Dye bound to all 
double stranded PCR products, including non-specific PCR products. Similarly, the 
house-keeping gene, β actin primers were designed as listed below: 
 
Real-time PCR primers for C-FABP 
Forward primers sequence: 5’- CATTGGTTCAGCATCAGGAG -3’ 
Reverse primers sequence: 5’- TTCATGACACACTCCACCACT -3’ 
Real-time PCR primers for β actin 
Forward primers sequence: 5’- CTGGTGCCTGGGGCG -3’ 
Reverse primers sequence: 5’- AGCCTCGCCTTTGCCGA – 3’ 
Chapter 2: Methodology          P a g e  | 142 
 
 
 
 
2.8.2 Relative real-time PCR 
The total RNAs were extracted from each cell line using RNAeasy Mini Kit as 
described in section 2.8 and reverse transcribe 1µg of total RNA to cDNA using 
SuperScriptIII reverse transcriptase as mentioned in section 2.8.1.1. The real-time 
PCR mixture for both C-FABP and β actin was prepared with 5µl of 2× Brilliant 
SYBR Green qPCR master mix (containing SureStart Taq DNA polymerase, dNTPs 
mixture, MgCl2 and optimized buffer), 1µl of forward primer, 1µl of reverse primer, 
1µl of cDNA generated by reverse transcription and  2µl of nuclease-free water. 
After gentle mix, the reactions were centrifuged briefly and placed to a real-time 
PCR thermocycler. The real-time PCR program is listed in Table 2.9.  
 
 
 
 
 
 
 
 
 
Table 2.9: Real-time PCR program for amplification of short target DNAs (50-400bp) 
 Temperature Time 
Step1 Denaturation 95
o
C 15mins 
Step2 Denaturation 94
o
C 15 seconds 
Step3 Annealing 60
o
C 30 seconds 
Step4 Extension 72
o
C 30 seconds 
Step5 Plate reading 57
o
C 15 seconds 
Step6 Go back to step 2 and repeat 38 cycles 
Step7 Final extension 72
o
C 10mins 
Step8 Melting curve 65-95
o
C 
1
o
C increment for 
10mins 
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2.8.2.1 Relative quantitation analysis 
Melting curve analysis was performed to detect the presence of nonspecific products 
and the primer dimers. The relative fold differences of C-FABP mRNA between 
transfected cell lines and parental cell line LNCaP were obtained using the formula 
listed below (Pfaffl, 2001) : 
Relative fold difference=2 
-ΔΔCt
 
ΔCt was calculated as the average Ct for the gene of interest minus the average Ct for 
the house keeping gene, β actin.  
ΔΔCt was calculated as the ΔCt of the test sample minus the ΔCt of the calibrator 
sample 
 
2.9 Fatty Acid Binding Assay 
In order to monitor the fatty acid–binding activity, the fatty acid dissociation constant 
of three recombinant C-FABP proteins was determined by following the changes in 
fluorescence by increasing the concentration of fluorescent fatty acid analogue 11-
(dansylamino) undecanoic acid (DAUDA) (Hagan et al, 2008). The excitation 
wavelength used for DAUDA was 345 nm. A stock solution of 10mM DAUDA in 
ethanol, kept in the dark at – 20°C, was freshly diluted in PBS to 1mM or 0.1mM 
before use in fluorescence experiments. The protein concentration was 2µM in 1ml 
of PBS at 20°C. Fluorescence data were subtracted for the blank values (sample 
without proteins) and fitted by standard non-linear regression techniques (ORIGIN 
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software version 6.1, Origin Lab Corporation, MA) to a single non-compatible 
binding model to estimate the apparent dissociation constant (Kd) and maximal 
fluorescence intensity (Fmax). Competitive experiments were designed to reveal a 
possible difference in affinity of the three C-FABP proteins for the various natural 
fatty acids. The myristic, palmitic, oleic and linoleic acids were stored and diluted as 
described above for DAUDA. In these experiments, the binding of 2µM DAUDA to 
2µM proteins was performed in the presence or absence of 2µM of each fatty acid. 
 
2.10 Fatty acid uptake assay  
Fatty acid uptake assay was designed in order to test long chain fatty acid (LCFA) 
uptake kinetics in different LNCaP cells containing fatty acid transporters. 
Conventional protocols utilizing radioactivity often require cell lysis and processing 
at very low temperature. Whereas, uptake of fluorescently-labelled fatty acids 
requires neither radioisotope usage nor cell lysis and also the fluorescence intensity 
in each individual cell can be measured by flow cytometry precisely. The red 
fluorescence-labelled LCFA, BODIPY 558/568C12 (4, 4-difluoro-5-(2-thienyl)-4-
bora-3a, 4a-diaza-s-indacene-3-dodecanoic acid), was used as the analogue of natural 
LCFA in the fatty acid uptake assay. BODIPY analogue behaves much like natural 
fatty acids: it becomes activated by acyl-CoA attachment; is incorporated into 
triglycerides; and accumulates in intracellular lipid droplets. In addition, the 
BODIPY analogue is also known as the substrate for fatty acid transporters since its 
uptake by adipocytes and can be competed by natural LCFA. 
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Cultured cells (1x10
5
 cells, already treated by 15μM recombinant C-FABPs) in 2ml 
routine culture medium were seeded into 6-well plates and incubated at 37
o
C, 5% 
CO2 overnight. After replacing the medium with 2ml of solution containing 25μg 
BODIPY 558/568C12 in 200μm BSA/PBS, the cells were incubated for 30 minutes at 
37
o
C, 5% CO2. The fatty acid uptake was stopped by removal of BODIPY fatty acid 
solution followed by addition of 3ml of an ice-cold stop solution (PBS containing 
0.5% BSA). The stop solution was discharged after 2 minutes and the culture plates 
were washed another two times by fresh ice-cold stop solution. Then, cells were 
detached using 2.5% (V/V) trypsin/versene at 4
o
C and the fluorescence intensity of 
each cell line was measured with an EPICS XL Cytometer at the wave length of 570 
nm to assess the fatty acid uptakes. 
 
2.11 Cell proliferation assay 
Proliferation is an important biological process for maintaining cell growth and tissue 
homeostasis. Cell growth is defined as the increase in cell number that occurs as the 
net number of cells gained by proliferative activity and offset by the net cell loss by 
apoptosis and necrosis. Cell proliferation results from the action of the cell cycle. 
Includes interphase (G1, S and G2 phases) and mitosis phases (M). Proliferative 
activity (Pich et al, 2004) defines the rate of the cell cycle, and represents the relation 
between cell generations time (T) and the cells committed to the cycle such as the 
growth fraction time (G). High proliferative activity can be the result of either a high 
growth fraction or a short generation time.    
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2.11.1 Preparation of growth curve 
LNCaP, LNCaP-C42 and 22RV-1 cells were grown to 70-80% confluence in 175cm
2
 
flasks and harvested as previously outlined and resuspended in 10ml of complete 
culture medium. Each cell line was counted using a hemocytometer as previously 
mentioned in section 2.3.1.3 and was made up in 5x10
5
/ml in 4mls of complete 
culture medium. A standard growth curves was prepared in serial dilution at: 
6.25x10
3
/ml, 1.25x10
4
/ml, 2.5x10
4
/ml, 5x10
4
/ml, 1x10
5
/ml, 2.5x10
5
/ml and 
5x10
5
/ml. Then, 200µl of cell suspension from each dilution was plated into a 96-
well plate in triplicate. Each cell line requires its own standard curve. 
In the mean time, two sets of cells for proliferation assay were also prepared at the 
concentration of 5x10
4
/ml. Similar as preparation of standard curve;  
Cell suspensions were treated with 15μM recombinant C-FABP wild type and 
mutants only. 
Cell suspensions were treated with 15μM recombinant C-FABP wild type and 
mutants and further stimulated with 10μM of Myristic acid (natural fatty acid). 
All suspensions were plated into six separate 96 well plates in triplicate. After 
overnight incubation with 5% CO2 at 37
o
C, the cell growth of the standard curve and 
first experimental day analysed by the MTT assay as described in section 2.11.2. The 
cell proliferation assay was set to run for six days at each plate per day.  
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2.11.2 Assessing cell numbers using MTT assay 
MTT is a yellow coloured chemical and it entered into the mitochondria of the cells. 
In mitochondria, MTT is oxidised into an insoluble blue dye known as formazan 
which forms blue crystals in the cytoplasm. The crystals are dissolved by adding 
DMSO and leave a coloured liquid, which is directly proportional to the number of 
cells present. The optical density (OD) of the cell population colour is measured 
accurately with a Multiscan plate reader at 570nm. For each cell line, a standard 
curve was constructed by plotting OD (570nm) against the number of cells. The cell 
number of the test samples was determined from the standard curve. 
 
MTT stock solution is prepared at a concentration of 5mg/ml (100mg MTT in 20ml 
PBS) and stored at 4
o
C. At each time point (every 24 hours), 50 l of MTT stock 
solution was added to each well in a 96-well plate and the cells were incubated at 
37
o
C, 5% CO2 for 4 hours. The cell culture medium and MTT is removed gently to 
avoid disturbing cells followed by adding 200 l of DMSO to each well including 
blank control wells mixed by pipetting up and down. The plate was incubated for a 
further 10 minutes at 37
o
C, 5% CO2 and read at 570nm in the optical density plate 
reader. The growth rate for each cell line is quantified against the standard curve to 
obtain the number of cells/well in each day for six days. Graphs of cell number/time 
were plotted. 
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2.12 Cell migration assay in Boyden chamber system 
The Boyden chamber system was used to examine the difference in invasive ability 
in cell lines stimulating by wild-type and mutant C-FABPs. The results are often 
variable, as many factors are involved in the assay, including the number of cells 
added to the upper chamber, the duration of the assay and the way to measure the 
number of the cells (Kassis et al, 1999). Therefore, it is important for the system 
gives reproducible results by setting up an optimized procedure considering the 
variables mentioned above. All materials used in this section can be found in 
Appendix 1 and 2.  
 
Cells to be used in invasion assay were cultured in flasks until 70-80% confluent. 
Cell invasion assays performed out using a modified Boyden chamber system. Wells 
of the 24-wells plate were divided into upper and lower compartment by 6.5mm 
diameter polycarbonate membrane containing 8µm pores. The polycarbonate filters 
were wetted with 200μl XGI medium for 30 minutes and the medium was removed 
followed by adding further 100μl XGI medium containing 30μg of matrigel to the 
upper side of the filters. The plates were incubated at 37
o
C, 5% CO2 for 2 hours to 
allow the matrigel solidification. The assays were set up with 1x10
5 
cells in the upper 
compartment in 200μl of 2% (v/v) FCS growth medium, 500μl of 10% (v/v) FCS 
growth medium and 10μM natural fatty acid (Myristic acid) was placed to the lower 
chamber. After 24 hours incubation at 37
o
C, 5% CO2, the cells remaining in the 
upper side of the filters were removed gently by cotton swabs and the cells attached 
to the lower side of the filter were fixed and stained by crystal violet reagent. None 
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of cell was found in lower compartment indicated that all cells invaded through the 
matrigel coated filter were attached to the lower side of the filter. The numbers of the 
invaded cells were counted under microscope. The results were finally normalized by 
the cell number in the 24-well plate after 20 hours incubation because the cells after 
typsinisation may vary in viability. In this way, the cell motilities measured from 
different cell lines were more comparable. The results are the mean ± SD of three 
separate experiments. 
 
2.13 Soft agar assay 
Soft agar assay was designed in order to examine the tumorigenicity of each cell 
lines in anchorage-independent environment. To perform the assays, 2g of low-
melting agarose was added to 100ml of distilled water to make-up final concentration 
2% (
W
/V). The low melting agarose was sterilized by autoclaving and placed in a 
water bath at 45
o
C to prevent agarose from solidifying until required. The assay was 
carried out in 6-well plates which were pre-coated with 2ml of 2% (w/v) low melting 
point agarose in routine culture medium with 10% (v/v) FCS and the mixture 
solidified in refrigerator at 4
o
C for 10mins. LNCaP, LNCaP-C42 and 22RV-1cells 
were routinely grown to 70-80% confluent in flasks, detached and counted as 
previously described in section 2.4.1.2 and 2.4.1.3. Cells were washed once by 
centrifugation and resuspended in routine culture medium with 10% (v/v) FCS at the 
concentration of 2x10
4
/ml. Two sets of cell suspensions were prepared: 
Cell suspensions were treated with 15μM recombinant C-FABP wild type and 
mutants only. 
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Cell suspensions were treated with 15μM recombinant C-FABP wild type and 
mutants and further stimulated with 10μM of Myristic acid (natural fatty acid). 
 
The cell suspensions were mixed with 2% low melting point agarose in a ratio of 1:1 
and 2ml of mixtures were seeded to the pre-coaded wells to make the final cell 
concentration at 1x10
4
 per well. The plates were placed at 4
o
C until solidified. Once 
the top layer was set, the 6-well plates were placed in the incubator at 37
o
C, 5% CO2 
for 4-6 weeks. During this period, 2 drops of routine culture medium were added to 
each well twice a week to keep the soft agar moist. At the end of the soft agar assay, 
colonies were dyed by adding 2ml of MTT (5mg/ml) followed by incubation at 37
o
C, 
5% CO2 for 2 hours. Colonies larger than 150μm in diameters were counted by the 
GelCount. 
 
2.14 Statistic methods 
The Student’s t-test is the most commonly used method to evaluate the differences in 
averages between two groups. In this thesis, the Student’s t-test was used to compare 
any differences observed between each experimental group and the control group.  
The results from most of assays were statistically assessed using the Student’s t-test. 
For all Students’s t-test calculated by online calculator 
(http://www.graphpad.com/quickcalcs/ttest1.cfm), the P-value less than 0.05 was 
regarded as statistical significance.  
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The fatty acid binding assay, fluorescence data were subtracted for the blank values 
(samples without proteins) and fitted by standard non-linear regression techniques 
(ORIGIN software version 6.1, Origin Lab Corporation, MA) to a single non-
competitive binding model to estimate the apparent dissociation constant (Kd) and 
maximal fluorescence intensity (Fmax).  
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3 Generation of mutation in C-FABP cDNAs and 
Transfected them into LNCaP prostate cancer 
cells   
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3.1 Introduction 
Cutaneous fatty acid binding protein (C-FABP) is a FABP family member binding to 
long chain fatty acids with high affinity. C-FABP was identified by our research 
group as a gene involved in malignant progression of prostate cancer and able to 
promote the growth of primary tumours and induce metastasis when transfected into 
rat benign Rama 37 model cells (Jing et al, 2000). Further, it was demonstrated that 
C-FABP was a prognostic marker for patient outcome and a target of tumour-
suppression for prostate cancer (Adamson et al, 2003).  
Several studies indicated that C-FABP might promote the malignant progression of 
prostate cancer by up-regulating the expression of the gene for vascular endothelial 
growth factor (VEGF), a potent factor for angiogenesis which is essential for growth 
and expansion of solid tumours (Adamson et al, 2003; Chen et al, 2000; Jing et al, 
2001). However, the mechanism by which C-FABP up-regulates the expression of 
VEGF remains unclear. Since the common biological function of FABPs, including 
C-FABP, is to transport the intracellular fatty acids into cells, therefore it is 
interesting to know whether the tumorigenicity-promoting function of C-FABP is 
related to its activity of transporting fatty acids. It has been confirmed that there are 
three key amino acids (Arg
109
, Arg
129
, and Tyr
131
) of  C-FABP, which are highly 
conserved amongst the FABP protein family, and which are responsible for binding 
to the carboxylate group in the fatty acids (Vorum et al, 1998). Mutation of one or 
two of the three key amino acids would either partially or completely deprive of C-
FABP fatty acid-binding ability.  
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In order to investigate whether binding to fatty acids is essential for C-FABP to 
promote cancer malignant progression, one and two site-directed point mutations 
were introduced to the C-FABP cDNA region which contains the fatty acid-binding 
motif. The mammalian expression vector pIRES2-EGFP containing wild type and 
mutated C-FABP cDNAs were transfected respectively into the LNCaP prostate 
cancer cells, which did not express C-FABP prior to the transfection, to establish cell 
lines expressing wild type C-FABP and mutated C-FABPs 
 
3.2 Results 
3.2.1 Generation of mutations in C-FABP cDNA 
Point mutations were introduced into fatty acid binding domain of the C-FABP 
cDNA using Transformer
tm 
Site-Directed Mutagenesis Kit (Chapter 2). The 
pBluescript II SK vectors containing wild type, single-mutation and   double-mutated 
C-FABP cDNA were transformed into DH5α E.coli competent cells respectively for 
amplification. After overnight incubation at 37
o
C, 225xg, the plasmid vectors were 
isolated from DH5α cells using midiprep and the presence of mutations were 
confirmed by nucleotide sequence analysis using specific C-FABP cDNA forward 
and reverse primers (Chapter 2). The construct harboring wild type of C-FABP 
cDNA was designated as C-FABP-WT. Those containing the single and double-
mutated C-FABP cDNAs were denoted as C-FABP-109A and C-FABP-109/129A, 
respectively. 
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As showing in Figure 3.1, sequencing analysis results demonstrated that the sequence 
of the C-FABP cDNA region containing the first mutation site was successfully 
altered by converting Arginine 109 to Alanine 109. Thus the triplet AGA was 
changed into GCA. In the second mutation site the triplet CGG was changed into 
GCG by replacing Arginine 129 with Alanine 129. In the construct of C-FABP-
109A, only one amino acid was changed in first mutation site and no change was 
made in second mutation site. In the construct of C-FABP-109/129A, amino acids in 
both mutation sites were changed. 
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Figure 3.1: Detection of mutations in C-FABP cDNA by sequencing analysis 
(A) Point mutantion in first site is shown in panel A. The Alanine (GCA), mutated 
from Arginine (AGA), is presented both in C-FABP-109A and C-FABP-109/129A 
constructs. (B) Point mutation in second site is shown in panel B. The Alanine 
(GCG), converted from Arginine (CGG), is presented in C-FABP-109/129A but not 
in single-mutated C-FABP, C-FABP-109A and C-FABP-WT constructs. 
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3.2.2 Insertion of wild type C-FABP and mutant C-FABPs into a 
mammalian expression vector - pIRES2-EGFP 
The C-FABP-WT, C-FABP-109A and C-FABP-109/129A cDNAs were removed 
from pBluescript II SK vector by restriction enzyme digestion using XhoI/PstI 
restriction enzymes. The products of restriction enzyme digestion were separated by 
agarose gel electrophoresis (1%) as presented in Figure 3.2A. The DNA fragments of 
C-FABP-WT, C-FABP-109A and C-FABP-109/129A were recovered from agarose 
gel respectively as described in Chapter 2 section 2.2.1.4. The mammalian 
expression vector pIRES2-EGFP was linearized using XhoI/PstI restriction enzymes 
as shown in Figure 3.3A and purified from agarose gel. The purified DNA fragment 
of wild type and mutant C-FABPs were inserted into pIRES2-EGFP vector 
respectively using T4 DNA ligase. The recombinant DNAs were transformed into 
DH5α bacterial cells and plated onto LB plates in the presence of antibiotics 
(50µg/ml ampicillin). Single colonies of transformed DH5  bacteria were transferred 
into flasks containing 10ml of LB medium with 50µg/ml ampicillin and left to grow 
overnight at 37 C, 225xg. The overnight cultured bacterial cells (5ml) were 
harvested and the pIRES2-EGFP vectors containing C-FABP-WT, C-FABP-109A 
and C-FABP-109/129A were isolated from bacterial cells respectively using 
miniprep as described in Chapter 2 section 2.2.3.1. The ligation was examined using 
restriction enzyme digestion as shown in Figure 3.3B. The sequencing analysis also 
confirmed the presence of the insertions in pIRES2-EGFP vector. 
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Figure 3.2: The products of restriction enzyme digestion for the ligation 
reaction 
(A) After DNA sequencing analysis, the pBluescript II SK vector containing C-
FABP-WT (Lane 2), C-FABP-109A (Lane 3) and C-FABP-109/129A (Lane 4) was 
digested by XhoI/PstI for the ligation reaction. The control vector digested by 
XhoI/PstI is presented in lane1. For lanes 2, 3 and 4, the bottom band represents 
DNA fragment of C-FABP-WT, C-FABP-109A and C-FABP-109/129A respectively. 
The top band in lanes 1, 2, 3, and 4 represents digested pBluescript II SK vector (3.0 
kb). (B) The DNA standard marker is denoted in number of base pairs. 
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Figure 3.3: Identification of the recombinant DNAs by restriction enzyme digestion 
(A) Two restriction enzyme digestions (Lanes 1 and 2) of mammalian expression 
vector pIRES2-EGFP (5.3 kb) using XhoI/PstI restriction enzymes to linearize the 
plasmid for the ligation reaction. (B) After ligation reaction, the recombinant DNAs 
were digested using XhoI /BamHI to assure that the DNA fragment of C-FABP-WT, 
C-FABP-109A and C-FABP-109/129A was inserted into the vector. The empty 
pIRES2-EGFP vector was used as control in lane 1. The vector containing C-FABP-
WT digested with BamHI was shown in lane 5 for comparison with the recombinant 
DNAs digested with XhoI/PstI restriction enzymes. For lanes 2, 3 and 4, the bottom 
band represents DNA fragment of C-FABP-WT, C-FABP-109A and C-FABP-
109/129A respectively. The top band in lanes 1, 2, 3, 4, and 5 represents digested 
pIRES2-EGFP vector. In panel A and B, the DNA standard marker in lane M is 
denoted in number of base pairs. 
Chapter 3: Results 1      P a g e  | 160 
 
 
 
 
3.2.3 Detection of wild type and mutated C-FABP mRNAs in transfected 
LNCaP cells by RT-PCR 
LNCaP cells were stably transfected with the empty pIRES2-EGFP vector containing 
C-FABP-WT or one of the two mutated C-FABP: C-FABP-109A and C-FABP-
109/129A using a polyamine based transfection reagent. The cell line transfected 
with C-FABP-WT, C-FABP-109A, C-FABP-109/129A and the empty pIRES2-
EGFP vector were designated LNCaP-WT, LNCaP-R109A, LNCaP-R109/129A and 
LNCaP-V.  
It was difficult to establish transfected clones as LNCaP cells had an extremely low 
survival rate when plated at very low concentrations in tissue culture flask (Bennett 
et al, 1997). Furthermore, the Geneticin also significantly slowed the growth rate of 
the transfected cells in selection step which makes the formation of transfected 
clones more difficult. In order to overcome the difficulties in generating LNCaP 
clones, the modified transfection method was developed using GeneJammer 
transfection reagent which is a proprietary formulation of polyamine offering high 
efficiency with low cytotoxity. After selection step, the surviving clones were 
analyzed by fluorescence microscopy as described in Chapter 2 section 2.2.6.2.  
The successful transfected clones for LNCaP-WT, LNCaP-R109A, LNCaP-
R109/129A and LNCaP-V were isolated using ring clone and cultured in selective 
medium separately. The pool of wild type C-FABP and mutant C-FABP transfected 
clones was also established by random selection of five single clones. The abundant 
green fluorescence images for pooled transfected cell lines were presented Figure 3.4 
confirmed the expression of recombinant pIRES2-EGFP vectors. For LNCaP-WT, 
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LNCaP-R109/129A and LNCaP-V transfected cell lines, the fluorescence-positive 
cells represented a subset of approximately 90% of the whole population. For 
LNCaP-R109A, approximately 80% of cells displayed strong green fluorescent 
emission and about 10% of LNCaP-R109A transfectant expressed less green 
fluorescence. The rest 10% populations of all four pooled transfected cell lines were 
fluorescence-negative. The fluorescence-positive cell population stayed at same level 
when increased the concentration of Geneticin or removed the antibiotic for a period 
of time (4 weeks). Similar observations were found in single cloned transfectants. 
 
Figure 3.4: Green fluorescent emission images of successful transfected cells 
The green fluorescence images of pooled LNCaP-WT, LNCaP-R109A, LNCaP-
R109/129A and LNCaP-V are shown in panel A1, A2, A3 and A4 respectively. All 
four cell lines appeared strong green fluorescence confirmed the expression of 
recombinant pIRES2-EGFP vectors.  
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To confirm the presence of the wild type and mutated C-FABP mRNAs existence in 
the transfected cell lines, total RNA was isolated from each pooled clones of 
transfectants. The total RNAs were amplified by PCR using a specific C-FABP 
forward primer which was listed in Chapter 2 section 2.2.9.2 and a specific pIRES2-
EGFP plasmid reverse primer to ensure the amplification products were from the 
transgenes instead of the endogenous gene for C-FABP. The products of PCR 
amplification were analysed by agarose gel electrophoresis as shown in Figure 3.5. 
No band was detected in PCR amplification without reverse transcriptase indicating 
that the amplified bands were not arising from total RNA isolation. The RT-PCR 
products on the agarose gel were excised and purified as mentioned in Chapter 2 and 
send for sequencing analysis (Liverpool University, School of tropical Medicine, 
Sequencing Unit). 
The RT-PCR products of LNCaP-R109A and LNCaP-R109/129A were the same 
size as LNCaP-WT (623kb). In contrast, no band was detected in LNCaP-V and 
negative control amplifications. Subsequent nucleotide sequencing also confirmed 
the presence of C-FABP-WT, C-FABP-109A, and C-FABP-109/129A. 
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Figure 3.5: Detection of mRNAs from transfected cell lines by RT-PCR 
Reverse transcriptase PCR was carried out using the Taq polymerase with specific 
primers to amplify the wild type and mutated C-FABP gene. Total RNAs were 
isolated from LNCaP cell line (Lane 1) and transfected cell lines LNCaP-V (Lane 2), 
LNCaP-WT (Lanes 3 and 4), LNCaP-R109A (Lanes 5 and 6) and LNCaP-R109/129A 
(Lane 7 and 8). Negative controls are presented in lanes 4, 6 and 8 in which the 
reverse transcriptase was omitted. The PCR products were analyzed on a 2% 
agarose/EtBr gel in 1xTBE buffer alongside 100 base pair ladder DNA marker (Lane 
M). 
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3.2.4 Expression of wild type and mutant C-FABP proteins in LNCaP 
cell line  
Levels of wild type and mutant C-FABP proteins expressed in transfected LNCaP 
cells were examined by Western Blot as described in Chapter 2. The LNCaP-V cells 
and highly malignant prostate cancer cells, PC-3M were used as negative and 
positive control respectively. The C-FABP specific primary antibody used in 
Western Blot analysis was provided by Dr. Hiroshi Fujii, Niigata University, Japan. 
The level of β-actin expression in each cell line was also examined and used as 
loading control. The C-FABP expression in transfectant cells was quantified by 
relating to that in positive control cells using scanning densitometry.  
The expression of wild type C-FABP (15 KDa) in LNCaP-WT and PC-3M cells are 
shown in Figure 3.6A and B. When the level of C-FABP expression in positive 
control PC-3M cells was set as 1, the level of C-FABP in LNCaP-WT was 
significantly increased (Students t-test P<0.05) to approximately 70% of that in the 
PC-3M cells. No band was observed in LNCaP-R109A, LNCaP-R109/129A and 
LNCaP-V. In addition, no significant difference was detacted in wild type C-FABP 
levels between single cloned and pooled LNCaP-WT cells (Students t-test P>0.05). 
The expression of β-actin, served as a loading control, is also examined as shown in 
Figure 3.6A at the size of 42 KDa. 
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Figure 3.6: Detection of protein expression levels of wild type C-FABP in single 
cloned and pooled transfectant LNCaP cell lines 
(A) Cellular lysates from three individual cloned (Lanes 3, 5 and 7) and three pooled 
(Lane 4, 6 and 8) of transfectant lines: LNCaP-WT (Lanes 3 and 4), LNCaP-R109A 
(Lanes 5 and 6) and LNCaP-109/129A (Lanes 7 and 8), were subjected to Western 
blot analysis. C-FABP protein band was recognized by a monoclonal anti-human C-
FABP antibody and visualized as described in Chapter 2 section 2.2.7. The β-actin 
antibody was used to correct the possible loading artifacts. (B) The relative levels of 
C-FABP expression in different transfectants. The results (mean S.D. of three 
experiments) were obtained by densitometry analysis of the band intensities. 
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Both wild type and mutant C-FABPs were picked up using a rabbit polyclonal anti-
human C-FABP antibody. It was observed that intensities of the bands in LNCaP-
WT, LNCaP-109A and LNCaP-109/129A were very similar, whereas the expression 
of C-FABP in control cell line LNCaP-V and parental cell line LNCaP is barely 
detectable as shown in Figure 3.7. The β-actin protein expression level in each cell 
lines, served as a loading control, was also presented. Further relative quantifications 
by scanning densitometry were shown in Figure 3.7. When wild type C-FABP 
expression in LNCaP-WT was set as 1, the level of mutant C-FABPs were 1.09 and 
0.946 in LNCaP-R109A and LNCaP-109/129A cells respectively. No significant 
expression differences have been found between the level of wild type C-FABP and 
level of mutant C-FABPs (Students t-test P>0.05) in the transfectants. LNCaP-V 
with empty pIRES2-EGFP vector and parental LNCaP cells exhibited undetectable 
level of C-FABP.  
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Figure 3.7: Detection of protein expression levels of wild type and mutant C-
FABPs in pooled transfected LNCaP cell lines 
(A) The mutant C-FABP proteins in LNCaP-R109A cells (Lane 2) and LNCaP-
109/129A cells (Lane 3) were recognized using a polyclonal anti-human C-FABP 
antibody. The wild type C-FABP in LNCaP-WT cells (Lane 1) was also detected by 
the antibody. LNCaP-V and LNCaP cells were used as negative control in Lane 4 
and 5 respectively.  
(B) The mean and S.D. of the relative band intensities of each cloned and pooled cell 
lines from three individual experiments. 
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3.2.5 Measurement of levels of wild type and mutant C-FABP mRNAs in 
different transfectants by Real-time PCR 
To confirm that the transfected wild type and different mutant cDNAs were 
expressed, the relative C-FABP mRNA levels in each transfectant cell line was 
measured by real-time PCR. The parental cells, LNCaP were used as the calibrator. 
Total RNAs from each cell lines were isolated routinely and purified by RNAeasy 
Mini column. 
As poor quality RNA samples can lead to spurious Real-time PCR results, the 
integrity and quality of the total RNAs were determined by Agilent 2100 bioanalyzer 
using RNA 6000 Nano Kit. The results (as shown in Figure 3.8A) were analyzed by 
the 2100 Expert Software and visual output were confirmed that the isolated total 
RNAs were in high quality with both rRNA bands (18S/28S) distinguishable as 
shown in Figure 3.8B. The RNA integrity numbers (RIN) for each isolated RNA 
were between 9.0 to 9.6 out of 10 and no degradation was observed. The RNA 
concentration of each sample was also calculated by the 2100 Expert Software. 
 
After RNA purification, relative quantification real-time PCR was preformed to 
measure the mRNA levels of wild type and mutant C-FABPs using exon-exon 
junction primers as described in Chapter 2 section 2.2.10. Figure 3.9 summarizes the 
relative level of C-FABP mRNA in total RNA isolated from each pooled cell line. 
The   LNCaP-WT, LNCaP-R109A and LNCaP-R109/129A cell line showed a 
significant increase in the relative C-FABP mRNA level when compared to parental 
cell line LNCaP. When the C-FABP mRNA level in the parental cell line LNCaP 
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was set at 1, the levels of expression was 137.5±18.1, 114.1±15.6, and 115±25.2 in 
LNCaP-WT, LNCaP-R109A and LNCaP-R109/129A, respectively. On the other 
hand, the C-FABP mRNA level in LNCaP-V cells was only slightly increased. The 
C-FABP mRNA level between LNCaP-R109A and LNCaP-R109/129A did not show 
significant difference (Students t-test P>0.05). Similarly, no difference was found 
when they compared to LNCaP-WT (Students t-test P>0.05). However, the relative 
levels of C-FABP mRNA expressed in all three transfectant lines (LNCaP-WT, 
LNCaP-R109A and LNCaP-R109/129A) were significantly increased when 
compared to the control LNCaP-V cells (Students t-test P<0.05). 
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Figure 3.8: Quality checks of total RNA samples by Agilent 2100 bioanalyzer 
The quality and quantification of total RNA were assessed using the RNA 6000 Nano 
LabChip on Agilent 2100 bioanalyzer. The gel electropherogram images for LNCaP-
WT (Lane 1), LNCaP-R109A (Lane 2), LNCaP-R109/129A (Lane 3), LNCaP-V 
(Lane 4) and LNCaP (Lane 5) were shown in panel A. The fluorescence plots with 
two peaks of 18S and 28S ribosomal RNAs of each sample were shown in panel B. 
The qualities of RNAs were presented by RINs which were calculated from the plots. 
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Figure 3.9: Relative level of C-FABP mRNA in transfectant and LNCaP cell lines 
The Real-time PCR products of LNCaP-WT (A), LNCaP-R109A (B), LNCaP-
R109/129A (C), LNCaP-V (D) and LNCaP (LNCaP) were analyzed by Chromo4 
fluorescence detector. The mean and S.D. of relative C-FABP mRNA level for each 
cell line from three individual experiment were shown in the bar chart. LNCaP cells 
were used as calibrator. 
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3.3 Discussion 
C-FABP is a member of FABP family which binds with high affinity to long chain 
fatty acid. It has been revealed that over-expression of C-FABP may promote VEGF 
to facilitate angiogenesis which contributed to tumour progression such as tumour 
formation and metastasis (Adamson et al, 2003; Jing et al, 2001). However, the exact 
mechanism remains unclear. In order to establish transfectants expressing mutant 
forms of C-FABP which are not able to bind to fatty acids, point mutations were 
introduced to two key amino acids (Arg
109
 and Arg
129
) which are responsible for fatty 
acid-binding in C-FABP gene. As a result, the relationship between the fatty acid 
binding capacity and the tumour promoting function can be assessed by investigating 
whether the transfectants expressing mutant C-FABP can still promote tumour 
growth.  
 
Two mutated gene have been successfully generated from the wild type C-FABP 
gene using Transformer
tm
 Site-Directed Mutagenesis Kit: (1) C-FABP-109A where 
Arginine 109 was converted to Alanine 109; (2) C-FABP-109/129A where Arginine 
109 and Arginine 129 were converted to Alanine 109 and Alanine 129. The point 
mutations in both mutated genes were confirmed by sequencing analysis. Then, the 
wild type and mutant C-FABPs were transferred into a mammalian expression vector 
pIRES2-EGFP with enhanced green fluorescent protein coding region using XhoI 
and PstI restriction digestion enzymes. The pIRES2-EGFP empty vector and vectors 
containing C-FABP-WT, C-FABP-109A, and C-FABP-109/129A were transfected 
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into LNCaP cells to create transfected cell lines LNCaP-V, LNCaP-WT, LNCaP-
R109A and LNCaP-R109/129A respectively. 
 
LNCaP cell line, established from a needle aspiration biopsy of the lymph node of 
male patient with diagnosed metastatic prostate carcinoma, is a widely used 
androgen sensitive human prostate cancer model cell line (Horoszewicz et al, 1983a). 
Two properties of LNCaP cells make them a particularly difficult cell line to 
generate transfectants compared to other cell lines firstly; LNCaP cells have a low 
growth rate and a tendency to form aggregates. Secondly; LNCaP cells have a poor 
survival rate when seeded at low concentration in tissue culture plate (Bennett et al, 
1997), which can significantly affect the efficiency of transfection as the cell 
colonies were developed from a single transfected cell. To overcome the difficulties 
in cloning LNCaP cells, the modified transfection method was carried out using a 
polyamine based transfection reagent, GeneJammer which provided a higher 
transfection efficiency and lower cytotoxity to LNCaP cells compared to calcium 
phosphate method (Orth et al, 2008). The transfected cell lines were selected by 
0.5mg/ml antibiotic G418 for 10 days in a 75cm
2
 tissue culture flask. Then, the G418 
was removed and 500µl of untransfected LNCaP cells at a concentration of 
2x10
4
cells/ml were seeded into the flask as a feeder layer. The cells were allowed to 
grow in routine culture medium until cellular confluence reached at 80%. Then, the 
cells were re-select followed the same procedure as for the first selection. After 5 
round selections, the cells were maintained in selective culture medium and 
successfully transfected colonies were determined by green fluorescence imaging 
and recovered by ring cloning. 
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Transfectant lines: LNCaP-WT transfected with wild type C-FABP, LNCaP-R109A 
transfected with single site mutated C-FABP, LNCaP-R109/129A transfected with 
double site mutated C-FABP and LNCaP-V (control) transfected with pIRES2-EGFP 
vector only were successfully generated. The wild type or mutant C-FABP cDNAs in 
each transfected cell line were examined by RT-PCR. The Western Blot assays were 
applied to determine the protein level of C-FABP-WT, C-FABP-R109A and C-
FABP-R109/129A in each transfected cell line. The results demonstrated that 
expression level of C-FABP-WT in pooled LNCaP-WT cells and mutant C-FABPs 
in pooled LNCaP-R109A and LNCaP-109/129A cells were at similar level, which 
indicated that these transfectants were suitable for comparison. However, there is no   
C-FABP cDNA or protein has been detected in LNCaP cells transfected with empty 
vector and paraental cells indicating that transfected with pIRES2-EGFP vector did 
not change the expression level of C-FABP. The same pattern of relative C-FABP 
mRNA level obtained by Real-time PCR analysis also confirmed the Western Blot 
results. 
 
The results in this chapter demonstrated the successful establishment of transfected 
cell lines with expression of wild type or mutant C-FABPs. However, the effect of 
wild type or mutant C-FABP expression prostate cells is unknown. These aspects 
such as recombinant protein of mutant and wild-type C-FABP will be produced in 
E.coli cells and purified as described in Chapter 2 and fatty acid-binding assay will 
be conducted in order to monitor the fatty acid-binding activity, both will be 
examined and presented in the Chapter 4.  
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4 Production of recombinant C-FABPs and testing 
their fatty acid binding ability   
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4.1 Introduction 
In Chapter 3, four transfected LNCaP cell lines with expression of wild type and 
mutant C-FABPs were successfully established to generate transfectants with 
different fatty acids uptake capacities. To reveal whether the fatty acid binding 
ability is essential for C-FABP to promote cancer development and progression, fatty 
acid binding ability of recombinant wild type and mutant types of C-FABPs 
produced by cancer cells were measured and compared. In this Chapter, recombinant 
proteins of mutant and wild type C-FABPs were produced in E. coli cells and 
purified according to the procedure described in Chapter 2 so that the fatty acid 
binding activity of these proteins can be clearly monitored. 
Long chain fatty acids are not only served as metabolic fuel but also act as 
endogenous ligands for nuclear receptors such as PPAR (Furuhashi & Hotamisligil, 
2008). Within the cells, it is possible that excessive amount of intracellular fatty 
acids may contribute to both breast and prostate cancer risk and disease progression 
(Collett et al, 2000; Hughes-Fulford et al, 2001). Although the three key amino acids 
conserved in FABPs were suggested to be the fatty acid binding site, direct evidence 
on the effect of changing this site on fatty acid binding ability of C-FABP is lacking. 
Thus, it is important to examine the fatty acids binding-capacities of recombinant 
wild type and mutant C-FABP proteins.  
In order to establish a construct to express a wild type and mutant type of C-FABPs, 
the cDNAs were cloned into expression vector pQEs then since there is no restriction 
site from pQEs can be directly used. The C-FABP cDNAs excised out from a 
pIRES2-EGFP construct by XhoI/KpnI restriction enzymes and first inserted into 
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pBluescript II SK vector so that desired restrict sites can be generated then existed 
out with KpnI and PstI which are located in multiple cloning sites of the expression 
vector pQEs. Thus C-FABP cDNAs from pBluescript II SK can be directly inserted 
into the pQEs to form 3 constructs capable of expressing C-FABP-WT, C-FABP-
R109 and C-FABP-R109/129A respectively. The recombinant His6-tagged protein of 
wild type and mutant C-FABPs were expressed and purified using QIAexpress Ni-
NTA Fast Start kits (for purification and detection of recombinant 6xHis-tagged 
proteins). Single protein bands with molecular masses of ~ 14 KDa were observed 
for recombinant C-FABPs when subjected to SDS-PAGE analysis. The fatty acid 
binding capability of three C-FABP proteins was examined by using the 
environment-sensitive fluorescent fatty acid analogue DAUDA that alters its 
fluorescence emission spectra and intensities on entry into binding proteins. 
Since the biological activity of C-FABP in normal condition is to bind to fatty acids 
and to transport them into cells, it is important to understand whether the ability of 
binding to fatty acids is related to the tumorigenicity promoting function of C-FABP 
in experiments of this Chapter. Firstly, generation of construct expressing wild type 
and mutant C-FABPs cDNA and cloning the expression construct into E.coli cells. 
Then expressed and purified the His6-tagged protein of wild type and mutant C-
FABPs and analysed the C-FABP proteins by sequencing analysis and SDS-PAGE. 
Thirdly, monitor the fatty acid binding capability of three C-FABP proteins by fatty 
acid binding assay.  
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4.2 Results  
4.2.1 Generation of complementary restriction sites  
The cDNAs for C-FABP-WT, C-FABP-R109A and C-FABPR109/129A were cut 
out from three pIRES2-EGFP by restriction enzyme digestion using XhoI and PstI. 
The products of restriction enzyme digestion were separated by agarose gel 
electrophoresis (1%) as presented in Figure 4.1. The DNA fragments of C-FABP-
WT, C-FABP-109A and C-FABP-109/129A were recovered from agarose gel 
respectively as described in Chapter 2. The expression vector pBluescript II SK was 
linearized using XhoI/PstI restriction enzymes as shown in Figure 4.2 and purified 
from agarose gel. The purified DNA fragment of wild type and mutant C-FABPs 
were inserted into pBluescript II SK vector respectively using T4 DNA ligase. The 
recombinant DNAs were transformed into DH5α bacterial cells and plated onto LB 
plates in the presence of antibiotics (50µg/ml ampicillin). Single colonies of 
transformed DH5  bacteria were transferred into flasks containing 10ml of LB 
medium with 50µg/ml ampicillin and incubated overnight at 37 C, 225xg. The 
overnight cultured bacterial cells (5ml) were harvested and the pBluescript II SK 
vectors containing C-FABP-WT, C-FABP-109A and C-FABP-109/129A were 
isolated from bacterial cells respectively using miniprep as described in Chapter 2. 
The ligation was examined using restriction enzyme digestion as shown in Figure 
4.3. The sequencing analysis confirmed the presence of the insertions in pBluescript 
II SK vector as shown in Figure 4.4 - Figure 4.6.  
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Figure 4.1: the product of restriction enzyme digestion for the ligation reaction  
After DNA sequencing analysis, the pBluescript II SK vector containing C-FABP-WT 
(A), C-FABP-109A (B) and C-FABP-109/129A (C) was digested by XhoI/PstI for the 
ligation reaction. The control vector digested by XhoI/PstI is presented in control 
lanes. The bottom bands represent DNA fragment of C-FABP-WT, C-FABP-109A 
and C-FABP-109/129A respectively. The top bands represent digested pBluescript II 
SK vector (3.0 kb). *M: marker; C: Control; pblue+WT,R and RR: Ligated 
pBluescript and C-FABP-WT, C-FABP-109A and C-FABP-109/129A respectively. 
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Figure 4.2: Linearization of the protein expressing vector   
Two restriction enzyme digestions (Lanes 1 and 2) of mammalian expression vector 
pBluescript II SK (5.3 kb) using XhoI/PstI restriction enzymes to linearize the 
plasmid for the ligation reaction. 
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Figure 4.3: Digestion of vector DNAs  
To generate a cohesive end with the insert, the DNAs were digested using XhoI /PstI 
which is complimentary to the sequence on both ends of the C-FABP CDNAs.    After 
ligation reaction, the recombinant DNAs were double digested using XhoI /PstI to 
confirm that the DNA fragment of C-FABP-WT (B), C-FABP-109A and C-FABP-
109/129A (A) was inserted into the vector. The undigested pBluescript II SK vector 
was used as control as shown in control lanes. (A) The bottom bands represent DNA 
fragment of C-FABP-109A and C-FABP-109/129A respectively. The top bands 
represent digested pBluescript II SK vector. (B) The bottom band represents DNA 
fragment of C-FABP-WT. The top band represents digested pBluescript II SK vector.  
In panel A and B, the DNA standard marker in lane M is denoted in number of base 
pairs. 
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4.2.2 Confirmation of successful insertion of wild type and mutant 
cDNAs into pBluescript cloning vector  
4.2.2.1 Sequence analysis of plasmid DNAs   
The ligation reaction was transfected into E.coli cells and the colonies have the 
cloning vector was selected and the total DNA from E.coli cell purified and 
subjected to sequencing analysis. The sequence obtained from the cloning vector was 
shown in Figure 4.4 - Figure 4.6. Total DNAs were sent for sequencing at the 
Cogenics Technolgies
TM
 (Essex, UK), 100ng/µl (10µl) of each purified DNA was 
analysed. M13F and M13R primers were used according to Cogenics Technologies. 
Sequence alignment was determined by using BioEdit for searching Genbank 
(BLAST). 
 
Forward sequence (M13F) 
5'- GTTTTCCCAGTCACGACGTTGTA-3' 
Reverse sequence (M13R) 
5'- CAGGAAACAGCTATGACC -3' 
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Figure 4.4: Insertion of C-FABP-WT cDNA into pBluescript cloning vector  
Sequence alignment was determined by using BioEdit for searching Genbank 
(BLAST) (appendix 3). The sequences marked in red colour are C-FABP-WT (insert) 
while the sequences marked in black colour are pBluescript (vector). The sequences 
marked in blue colour are multiple restriction sites as GGTACC represents KpnI, 
CTCGAG represents XhoI and CTGCAG represents PstI.  
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Figure 4.5: Insertion of C-FABP-R109A cDNA into pBluescript II SK  cloning 
vector  
Sequence alignment was determined by using BioEdit for searching Genbank 
(BLAST) (appendix 3). The sequences marked in red colour are C-FABP-R109A 
(insert) while the sequences marked in black colour are pBluescript (vector). The 
sequences marked in blue colour are multiple restriction sites as GGTACC 
represents KpnI, CTCGAG represents XhoI and CTGCAG represents PstI. GC 
represents single mutation (The Alanine GCA, mutated from Arginine AGA). 
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Figure 4.6: Insertion of C-FABP-R109/129A cDNA into pBluescript II SK 
cloning vector  
Sequence alignment was determined by using BioEdit for searching Genbank 
(BLAST) (appendix 3). The sequences marked in red colour are C-FABP-R109/129A 
(insert) while the sequences marked in black colour are pBluescript (vector). The 
sequences marked in blue colour are multiple restriction sites as GGTACC 
represents KpnI, CTCGAG represents XhoI and CTGCAG represents PstI. GC and 
GC represent double mutation (The Alanine GCA, mutated from Arginine AGA and 
the Alanine GCG, converted from Arginine CGG). 
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4.2.3 Cloning of wild type and mutant C-FABPs into an expression 
vector pQEs 
The cDNAs for C-FABP-WT, C-FABP-109A and C-FABP-109/129A were excised 
from pBluescript II SK vector by restriction enzyme digestion using KpnI and PstI. 
The products of restriction enzyme digestion were separated by agarose gel 
electrophoresis (1%) as presented in Figure 4.7. The DNA fragments of C-FABP-
WT, C-FABP-109A and C-FABP-109/129A were recovered from agarose gel 
respectively as described in Chapter 2. The expression vector pQE 30, 31 and 32 was 
linearized using KpnI/PstI restriction enzymes and purified from agarose gel. The 
purified DNA fragment of wild type and mutant C-FABPs were inserted into pQE 
vector respectively using T4 DNA ligase. The recombinant DNAs were transformed 
into BL21 bacterial cells and plated onto LB plates in the presence of antibiotics 
(50µg/ml ampicillin). Single colonies of transformed BL21 bacteria were transferred 
into flasks containing 10ml of LB medium with 50µg/ml ampicillin and left to grow 
overnight at 37 C, 225xg. The overnight cultured bacterial cells (5ml) were 
harvested and the pQE vectors containing C-FABP-WT, C-FABP-109A and C-
FABP-109/129A were isolated from bacterial cells respectively using miniprep as 
described in Chapter 2. The ligation was examined using restriction enzyme 
digestion as shown in Figure 4.8. The expression and purification of C-FABP 
recombinant proteins conducted using QIAexpress Ni-NTA Fast Start kits (for 
purification and detection of recombinant 6xHis-tagged proteins. Protein were 
analysed by SDS-PAGE to confirm the presence of insertion in pQE vector.  The 
sequencing analysis also confirmed the presence of the insertions in pQE vector as 
shown in Figure 4.11 - Figure 4.13.  
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Figure 4.7: the product of restriction enzyme digestion for the ligation reaction 
After DNA sequencing analysis, the pBluescript II SK vector containing C-FABP-WT 
(A), C-FABP-109A (B) and C-FABP-109/129A (C) was digested by KpnI/PstI for the 
ligation reaction. The control vector digested by KpnI/PstI is presented in control 
lanes. (A) The bottom band represents DNA fragment of C-FABP-WT. The top bands 
represent digested pQE vectors (3.4 kb). (B) The bottom bands represent DNA 
fragment of C-FABP-109A and C-FABP-109/129A, respectively. The top bands 
represent digested pQE vectors. 
*M: marker, C: Control, C-FABP-WT: Ligated pQE32 and C-FABP-WT, R & RR: 
Ligated pQE32 and C-FABP-R109 and C-FABP-R109/129A, respectively.  
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Figure 4.8: Digestion of vector DNAs 
To generate a cohesive end with the insert, the DNAs were digested using KpnI /PstI 
which is complimentary to the sequence on both ends of the C-FABP CDNAs.    After 
ligation reaction, the recombinant DNAs were double digested using KpnI /PstI to 
confirm that the DNA fragment of C-FABP-WT (A), C-FABP-109A and C-FABP-
109/129A (B) was inserted into the vector. The undigested pQE vector was used as 
control as shown in control lanes. (A) The bottom band represents DNA fragment of 
C-FABP-WT. The top band represents digested PQE 30, 31 and 32 vectors. (B) The 
bottom bands represent DNA fragment of C-FABP-109A and C-FABP-109/129A, 
respectively. The top bands represent digested pQE 32 vector.  In panel A and B, the 
DNA standard marker in lane M is denoted in number of base pairs. 
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4.2.4 Confirmation of successful insertion of wild type and mutant C-
FABP cDNAs into pQEs expression vector  
4.2.4.1 Sequences analysis of plasmid DNAs 
The ligation reaction was transfected into E.coli cells and the colonies have the 
cloning vector was selected and the total DNA from E.coli cell purified and 
subjected to sequencing analysis. The sequence obtained from the cloning vector was 
shown in Figure 4.11, Figure 4.12 and Figure 4.13. The total DNAs were sent for 
sequencing at the Cogenics Technolgies
TM
 (Essex, UK), 100ng/µl (10µl) of each 
purified DNA was analysed. pQE Forward and pQE Reverse primers were used 
according to Cogenics Technologies. Sequence alignment was determined by using 
BioEdit for searching Genbank (BLAST). 
Forward primer (pQEF) 
5'-CCCGAAAAGTGCCACCTG-3' 
Reverse primer (pQER) 
5'-GTTCTGAGGTCATTACTGG-3' 
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Figure 4.9: Sequencing primers for pQE vectors  
 
4.2.4.2 Confirmation of Correct reading frame for recombinant proteins 
production   
Expression vectors pQE30, 31 and 32 plasmid DNA containing wild type and mutant 
types of C-FABP were sequenced in order to determine which plasmid ought to be 
used for recombinant protein production. It is important that the start codon (ATG) 
for the C-FABPs is in the same reading frame as the start codon (ATG) for the 
6xhistage of the expression vector pQEs.  
Sequencing results showed that pQE32 was the clone that achieved the correct 
reading frame for the C-FABP (wild type and mutants) as shown in Figure 4.10. 
Therefore, pQE32 was identified and chosen for protein induction.   
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Figure 4.10: confirmation of correct reading farm for recombinant C-FABP 
proteins production  
(A) Insertion of C-FABP-WT into expression vector pQE30. (B) Insertion of C-
FABP-WT into pQE31. (C) Insertion of C-FABP-WT into pQE32. According to the 
sequencing analysis and the alignment of the codon, pQE32 has the correct reading 
frame that was identified and used for protein production.       
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Figure 4.11: Insertion of C-FABP-WT cDNA into pQE32 expression vector  
Sequence alignment was determined by using BioEdit for searching Genbank 
(BLAST) (appendix 3). The sequences marked in red colour are C-FABP-WT (insert) 
while the sequences marked in black colour are pQE32 (vector). The sequences 
marked in blue colour are multiple restriction sites as GGTACC represents KpnI and 
CTGCAG represents PstI.  
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Figure 4.12: Insertion of C-FABP-R109A cDNA into pQE32 expression vector  
Sequence alignment was determined by using BioEdit for searching Genbank 
(BLAST) (appendix 3). The sequences marked in red colour are C-FABP-R109A 
(insert) while the sequences marked in black colour are pQE32 (vector). The 
sequences marked in blue colour are multiple restriction sites as GGTACC 
represents KpnI and CTGCAG represents PstI. GC represents single mutation (The 
Alanine GCA, mutated from Arginine AGA). 
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Figure 4.13: Insertion of C-FABP-R109/129A cDNA into pQE32 expression 
vector  
Sequence alignment was determined by using BioEdit for searching Genbank 
(BLAST) (appendix 3). The sequences marked in red colour are C-FABP-R109/129A 
(insert) while the sequences marked in black colour are pQE32 (vector). The 
sequences marked in blue colour are multiple restriction sites as GGTACC 
represents KpnI and CTGCAG represents PstI. GC and GC represent double 
mutation (The Alanine GCA, mutated from Arginine AGA and the Alanine GCG, 
converted from Arginine CGG). 
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4.2.5 Expression and purification of recombinant C-FABP proteins  
4.2.5.1 Time course analysis of protein expression  
To optimize the expression of a given protein construct, a time-course analysis of the 
level of protein expression is recommended (Figure 4.14). Intracellular protein 
content is often a balance between the amount of soluble protein in the cells, the 
formation of inclusion bodies, and protein degradation. By checking the 6xHis-
tagged protein present at various times after induction in the soluble fractions, the 
optimal induction period can be established. The maximum amount of protein was 
achieved at 5 hours of IPTG induction as shown in Figure 4.14. However, continuo 
in incubation after this time protein started to degrade.    
A single colony was picked from selective antibiotic LB agar plate and inoculated 
into a 10ml LB medium containing 50µg/ml ampicillin in a 50ml flask and incubated 
at 37 C overnight. 250ml of pre-warmed media with ampicillin was inoculated with 
10ml of the overnight culture and grow at 37°C with vigorous shaking until an OD600 
of 0.6 was reached (30-60 min). 0.5ml sample was taken immediately before 
induction (this sample is the non-induced control). Expression of wild type and 
mutant C-FABP proteins were induced by adding 1mM of IPTG. A second 0.5ml 
was collected (this sample is the induced control). Culture was incubated for an 
additional 4-5 hours with 0.5ml samples were taken each an hour. Cells were 
harvested by centrifugation at 4000xg for 20 min. Cell pellets were stored overnight 
at -20°C until further use.   
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Figure 4.14: protein expression and time course for C-FABP-WT 
Expression of 6xHis-tagged was induced with 1mM IPTG. Aliquots were removed at 
the times indicated purified on Ni-NTA agarose under denaturing conditions. 
Proteins were visualised by SDS-PAGE analysis. Yields per litre cultures were 2.9, 
5.7, 12.6, 34 and 60.2 mg respectively. (A) Crude cell lysate. M: Marker, T0: non 
induced control, T1-6: IPTG induced after an hour to 6 hours, 6His-tagged pounded 
protein bands were recognised by Penta-His antibody (31 KDa). (B) Purification 
with Ni-NTA, C-FABP protein bands were recognized by a monoclonal anti-human 
C-FABP antibody and visualized as described in Chapter 2 (14 KDa). 1: flow 
through fraction, 2 & 3: first and second elutes.  
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4.2.5.2 Purification of 6xHis-tagged C-FABP proteins 
Cell pellets were resuspended in 10ml denaturing lysis buffer (pH 8.0). Cell 
suspensions were incubated at RT (15-25°C) for 60 min. After an hour cell 
suspensions were mixed 2-3 times by gently swirling the suspensions (lysis is 
completed when the suspension is translucent). Lysates were centrifuged at 14000xg 
for 30 min at RT to pellet the cellular debris (the supernatants contain the 
recombinant protein). 5µl 2x SDS-PAGE sample buffer was added to a 5µl aliquot of 
the supernatant and stored at -20°C for SDS-PAGE analysis. The resin in a fast star 
column was gently resuspended by inverting it several times. The seal at the outlet of 
the column was broken, screw cap was opened, and the storage buffer allowed 
draining out. The cell lysate supernatants were applied to the column. The flow-
through fractions were collected and 5µl 2x SDS-PAGE sample buffer was added to 
a 5µl aliquot of the flow-through fractions and stored at -20°C for SDS-PAGE 
analysis. Columns were washed 2 times with 4ml of denaturing wash buffer (pH 6.3) 
and both wash fractions were collected. 5µl 2x SDS-PAGE sample buffer was added 
to a 5µl aliquot of each wash fraction and stored at -20°C for SDS-PAGE analysis. 
Bound 6xHis-tagged proteins were eluted with 1ml aliquots of denaturing elution 
buffer (pH 4.5) and each elution fraction was collected in a separate tube. 5µl 2x 
SDS-PAGE sample buffer was added to a 5µl aliquot of each elution fractions and 
stored at -20°C for SDS-PAGE analysis. All fractions were analysed by SDS-PAGE 
as shown in Figure 4.15. 
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Figure 4.15: Western blot analysis of the 6xHis-tagged wild type and mutant C-
FABP proteins 
After elution, un-bound 6xHis-tagged proteins were subjected to western blot 
analysis. C-FABP protein bands were recognized by a monoclonal anti-human C-
FABP antibody and visualized as described in Chapter 2. (A) C-FABP-WT. (B) C-
FABP-R109A. (C) C-FABP-R109/129A. CL: Cell lysate, FT: Flow-through fraction, 
E1 & E2: first and second elutes. 
 
 
4.2.6 Fatty acid binding assay for recombinant C-FABP proteins  
Fatty acid binding capability of the three FABPs was examined by using the 
environment-sensitive fluorescent fatty acid analogue DAUDA (11-
(Dansylamino)undecanoic acid) that alters its florescence emission spectra and 
intensities on entry in to binding proteins. The blue shift of DAUDA fluorescence 
maximum from 542 to 537, 529 and 527 nm for C-FABP-WT, C-FABP-R109A and 
C-FABP-R109/129A, respectively, and the associated increase of its fluorescence 
emission (both indicative of the entry of DAUDA into a polar environment (Hagan et 
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al, 2008)) confirmed the binding of the fluorescent fatty acid to the three C-FABP 
variants. These shifts are comparable with the result obtained from structurally 
related FABPs such as the heart FABP, brain FABP and adipocyte FABP where the 
fluorescence emission moves to 536, 531 and 530nm, respectively (Zimmerman et 
al, 2001), value closer to what was observed for C-FABP. Interestingly, the 
dissociation constants (Kd) for DAUDA binding to the three C-FABP variants were 
similar (0.65, 0.75 and 0.67 for C-FABP-WT, C-FABP-R109A and C-FABP-
R109/129A, respectively) and the maximum fluorescence (Fmax) were also similar 
(125, 123 and 132 for C-FABP-WT, C-FABP-R109A and C-FABP-R109/129A, 
respectively) as shown in Figure 4.16. To highlight the possible differences in the 
binding affinities of the three C-FABP proteins for other fatty acids, we performed 
competitive experiments using DAUDA as a tracer and some natural fatty acids as 
competitor. The addition of myristic (C14), palmitic (C16), oleic (C18) and linoleic 
acids (C20) indeed revealed a diverse affinity of the three wild type and mutants C-
FABP. The efficiency of each fatty acid to displace DAUDA from the C-FABP 
proteins binding pocket is shown in Figure 4.17. A value of 100% indicates the 
complete displacement of DAUDA.  The data showed that C-FABP-WT has the 
higher affinity of DAUDA displacement and binding to natural fatty acids (80, 81, 84 
and 92% for myristic, palmitic, oleic and linoleic acids, respectively). In contrast, 
when fatty acid binding ability of the C-FABP-WT is set at 1, the fatty acid binding 
ability of the C-FABP-R109A was significantly reduced to 0.35, 0.37, 0.39 and 0.43, 
respectively, when bound to natural fatty acids. The fatty acid binding ability of the 
C-FABP-R109/129A was further significantly reduced to 00, 0.08, 0.15 and 0.17, 
respectively (Student t-test, P<0.001). 
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Figure 4.16: Titration curves of DAUDA binding to C-FABP proteins. 
Increasing amounts of DAUDA were added to a 2 µM solution of the protein in PBS. 
The enhancement of DAUDA fluorescence upon binding to the C-FABP variants was 
obtained by subtracting the florescence of the same concentration of DAUDA in the 
absence of the protein. All of the data were analyzed by a non-linear regression 
model according to Hill’s function using the origin programme. (A) C-FABP-WT. 
(B) C-FABP-R109A. (C) C-FABP-R109/129A.      
 
 
 
Fmax  = 125 
Kd     = 0.65 +/- 0.09 µM 
Fmax  = 123 
Kd     = 0.75 +/- 0.07 µM 
Fmax  = 132 
Kd     = 0.67 +/- 0.12 µM 
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Figure 4.17: Displacement of DAUDA binding to three C-FABP proteins by 
natural fatty acids. 
The percentage of displacement is indicated above each bar. Competitive binding 
experiments were carried out using 2 µM DAUDA in the presence of 2 µM of each 
natural fatty acid and 2 µM of each C-FABP proteins. Data expressed as means±SD 
of three independent experiments. 
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4.3 Discussion  
In previous chapter, one or two site-directed point mutations into the C-FABP cDNA 
region containing the fatty acid-binding motif were successfully generated. The wild 
type and mutant C-FABP cDNAs were contained in the pIRES2-EGFP vector. When 
the wild type and mutant C-FABP cNDAs were cloned into an expression vector to 
produce recombinant C-FABPs, it was found that in the multiple cloning sites of this 
construct, there was no complimentary restriction site for the expression vector pQE. 
Therefore, before the C-FABP cDNAs were inserted into to the expression vector 
pQEs, it was necessary to generate complimentary restriction sites at both ends of the 
cDNAs. Thus, the C-FABP-cDNAs were excised from pIRES2-EGFP with 
restriction enzymes XhoI and PstI and inserted into cloning vector pBluescript which 
contains the multiple restriction sites (KpnI and PstI). The C-FABP cDNAs were 
then excised out from the pBluescript vector with KpnI and PstI and then inserted 
into the expression vector pQEs to form three constructions which will express the 
C-FABP-WT, C-FABP-R109, and C-FABP-R109/129A, respectively.  
 
The insertion of C-FABP cDNAs into pQEs expression vector (Figure 4.11) were 
successful and confirmed by sequences analysis. Further analysis confirmed that 
pQE32 (Figure 4.10) is only vector that remain the ATG codon unchanged. 
Therefore, PQE32 was identifies and chosen as the construct to produce recombinant 
proteins. 
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When the recombinant protein is synthesised in E.coli cells, different expression 
systems have different efficiencies. Thus, it is necessary to found out the time point 
at which the maximum yield of protein is synthesised in E.coli cells.  In this work, it 
was found that the amount of protein synthesis is increased as the increasing 
incubation time, and reached the maximum at five hours after IPTG induction. Once 
reached the maximum, any further induction and incubation was not accompanied 
with any further increment in protein synthesis. Instead, the yield of recombinant 
protein was reduced (Figure 4.14). This could due to either the cessation of 
production inside the E. coli cells or the degradation of the completed synthesised 
proteins. Therefore, the optimal time at which the maximum yield of protein 
production was achieved is 5 hours after IPTG induction.   
 
C-FABP is a small molecule (14 KDa) and the protein produced in E.coli was 
soluble with the 6xHis-tagged system. The 6xHis affinity tag facilitates binding to 
Ni-NTA. Using pQE vectors it can be placed at the C- or N-terminus of the protein. 
It is poorly immunogenic, and at pH 8.0 the tag is small, uncharged, and therefore 
does not generally affect secretion, compartmentalization, or folding of the fusion 
protein within the cell. As well as, the 6xHis tag does not affect the structure or 
function of the purified protein as demonstrated for a wide variety of proteins, 
including C-FABP proteins. 
 
 After C-FABP was separate from the 6xhis-tagged using Ni-NTA Fast Start column 
and subjected to Western blot analysis (Figure 4.15), a single band at the correct site 
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of the blot was visualised.  This result indicated that the separation of the 
recombinant C-FABP proteins from the E. coli bacterial proteins was very successful 
and the recombinant proteins obtained from purification procedures were very pure.  
To test whether the recombinant proteins produced were biological active, we have 
tested the fatty acid binding ability of wild type and mutant C-FABPs. The fatty acid 
binding ability of the C-FABP-WT was 80%, 81%, 84% and 92%, respectively, 
when bind to natural fatty acids (myristic, palmitic, oleic and linoleic acids). When 
fatty acid binding ability of the wild type C-FABP is set at 1, the fatty acid binding 
ability of the C-FABP-R109A was reduced to 0.35, 0.37, 0.39 and 0.43, respectively, 
when bind to natural fatty acids. The fatty acid binding ability of the C-FABP-
R109/129A was further reduced to 00, 0.08, 0.15 and 0.17, respectively, when bound 
to natural fatty acids (Figure 4.17). These result suggested that fatty acid binding 
ability of C-FABP depends on its structure integrity of the binding motif. Therefore, 
changing one amino acid in motif by site-directed point mutation significantly 
reduced the fatty acid binding ability and changing two amino acids by sites-directed 
mutations almost completely deprived the fatty acid binding ability of C-FABP. 
In the experiments described in this chapter, the wild type and mutated C-FABP 
cDNAs have been successfully cloned into the expression vector and different 
recombinant protein expression constructs were successfully established. Using the 
pQE E. coli expression system, it is possible that 60.2mg of recombinant proteins can 
be produced and purified from 1 litre of bacterial cells. The availability of large 
amount of pure wild type and mutant C-FABPs provided an excellent opportunity to 
further study and compare their biological activities.   
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5 Effect of overexpression of recombinant wild type 
and mutant C-FABPs on tumorigenicity of 
prostate cancer cells 
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5.1 Introduction  
In Chapter 4, recombinant protein of mutant and wild type C-FABPs were produced 
in E. coli cells and successfully expressed and purified. To reveal whether the fatty 
acid binding ability is essential for C-FABP to promote cancer development 
progression, fatty acid binding ability of recombinant wild type and mutant C-FABPs 
were monitored. In this Chapter, to study further the effect of the structure changing 
of fatty acid binding motif of C-FABP on its ability of cancer promoting activity, we 
have further conducted experiments to study the relationship between fatty acid 
binding motif and tumorigenicity. 
Cell proliferation and invasion ability are significant factors which contribute to 
tumorigenicity and metastasis. Morgan et. al found that cell proliferation rate was 
significantly reduced by 2.5-fold in siRNA transfected prostate cancer cell line PC-
3M, in which the expression level of C-FABP was suppressed, compared to the 
parental cell line (Morgan et al, 2008). Moreover, it has been showed that 
suppression of C-FABP expression resulted in a significant reduction of the cell 
invasiveness and inhibition of metastasis (Adamson et al, 2003; Morgan et al, 2008). 
In contrast, Fang et.al reported that overexpression of C-FABP in transfected human 
oral squamous carcinoma cells was associated with promoting the cancer cells 
growth rate and invasion ability (Fang et al, 2009) suggesting that increase 
expression of C-FABP may be related to malignant progression. 
Tumour progression is complex, involving multiple mutations of tumour suppressor 
genes, and/or proto-oncogenes resulting in loss of control of cell proliferation. 
Several studies showed that androgen-dependent human prostate cancer LNCaP cells 
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hardly formed tumours with 0%-50% tumorigenicity rate when inoculated 
subcutaneous (SC) in immunodeficient nude mice (Gleave et al, 1991; Horoszewicz 
et al, 1983b) and even if the tumour was formed, the tumour growth was very slow. 
Morgan et.al showed that suppression of C-FABP expression level in PC-3M cells 
significantly reduced tumour formation ability of the cancer cells both in vitro and in 
vivo (Morgan et al, 2008). Similar results had been achieved by using antisense RNA 
to suppress C-FABP expression (Adamson et al, 2003). Nevertheless, the 
tumorigenicity of LNCaP cells with overexpression of C-FABP has not been 
reported. In contrast to PC-3M cells which express very high level of C-FABP, the 
weakly malignant LNCaP cells do not express detectable level of C-FABP. It is 
interesting to know whether the tumorigenicity of LNCaP can be increased by 
elevated C-FABP expression. 
As mentioned in Chapter 4, the biological function of C-FABP in normal condition is 
to bind to fatty acids and to transport them into cells, it is important to understand 
whether the ability of binding to fatty acids is related to the tumorigenicity promoting 
function of C-FABP in experiments of this Chapter. The recombinant C-FABPs were 
subjected to different in vitro assessments to analyze the effect of overexpression of 
wild type and mutant C-FABPs on the cell properties associated with tumour 
development and malignancy.    
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5.2 Results  
5.2.1 The effect of wild type and mutant C-FABPs on cellular fatty acid 
uptake   
The orange-red fluorescence-labelled fatty acid BODIPY 558/568 C12 [4, 4-difluoro-
5- (2-thienyl)-4-bora-3a, 4a-diaza-s-indacene-3-dodecanoic acid], which act as the 
analogue of natural LCFA, was applied to examine the level of fatty acid uptake for 
each C-FABPs. The fluorescence intensity of each single cell before and 45 minutes 
after adding labelled LCFA was measured using an EPICS XL Cytometer at the 
wave length of 570 nm to assess the fatty acid uptake capacities as described in   
Chapter 2.  
The fatty acid uptakes in LNCaP cells treated with C-FABP proteins were shown in 
Figure 5.1. The peaks in the each diagram represented the red fluorescence 
intensities which were quantified by manufacture’s software as demonstrated in X-
Mean. The number and proportion of cells in each cell line were also indicated in the 
diagram column number and %Gated respectively. Relative levels of LCFA uptake 
(Figure 5.2). When the level of fatty acid uptake in control was set at 1, levels in C-
FABP-WT, C-FABP-R109A, and C-FABP-R109/129A were 6.8±0.75, 3.5±0.5 and 
2.7±0.8 respectively. In comparison with the control, the fatty acid uptake by C-
FABP-WT was significantly higher (Student t-test, P=0.005).  However, the fatty 
acid uptake between C-FABP-R109A and the control, or that between C-FABP-
R109/129A and the control, was at similar level (Student t-test, P=0.013, P=0.063, 
respectively). Further statistical analysis showed that a significant difference was 
observed in fatty acid uptakes between C-FABP-WT and C-FABP-Rl09A or C-
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FABP-R109/129A (Student t-test, P=0.044, P=0.026, respectively). However, no 
difference was observed in fatty acid uptakes between C-FABP-R109A and C-
FABP-R109/129A (Student t-test, P=0.199). 
 
 
Figure 5.1: Fatty acid uptakes by C-FABP cDNAs at absence and presence of 
red fluorescence labelled LCFA.  
Flow cytometry analysis of LCFA uptake by LNCaP cell line.  Florescence labelled 
BODIPY 558/568C12 was added to the cultured cells and plated at 1x10
6
cells/well in 
a 6-well plate. The fluorescence intensity of each transfected cell lines was assessed 
(X-Mean) and plotted as histogram before (left panel) and after 30min (right panel) 
incubation. A: C-FABP-WT; B: C-FABP-R109A; C: C-FABP-R109/129A and D: 
Control. X-Mean values were; 74.1. 27.1, 20.2 and 14.2, respectively. 
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Figure 5.2: Relatives level of LCFA uptake by wild type and mutants C-FABP 
cDNAs. 
Relative levels of LCFA uptake C-FABP-WT (Column 1), C-FABP-R109A (Column 
2) and C-FABP-R109/129A (Column 3) and the control (Column 4) were measured 
by flow cytometer. C-FABP-WT had the highest fatty acid uptake capacity and 
significantly higher than the rest (Student t-test P<0.05). Data expressed as 
means±SD of three independent experiments. 
 
 
5.2.2 Effect of wild type and mutants C-FABPs on cell proliferation 
A proliferation assay in-vitro was performed to determine the potential tumorigenic 
capacity of the wild type and mutant C-FABPs on the weakly malignant and 
androgen-dependent LNCaP, the androgen-independent but has androgen receptor 
22RV1 and the highly malignant and androgen-independent LNCaP-C42 cell lines. 
Standard curve of each tested cell line was constructed as described in Chapter 2. 
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Diagrams in Figure 5.3, Figure 5.5 and Figure 5.7 presented standard curves for the 
three cell lines. The MTT forms crystals in cytoplasm and the crystals were dissolved 
by DMSO. The colorimetric measurement was performed at 570nm wavelength 
using a spectrophotometer. The values obtained from the plate reader were converted 
to cell numbers which were extrapolated from the standard curve.  
 
5.2.2.1 LNCaP cell line  
The detailed proliferation assay results were shown in Figure 5.4. During the first 
two days, growth rates of all tested cells were very similar. However, from the 3rd 
day on, the proliferation rate of C-FABP-WT stimulated cells started to be higher 
than those of other lines. On the 4
th
, 5
th
 the 6
th
 day, the numbers of C-FABP-WT 
stimulated LNCaP cells without adding natural fatty acid were 25941, 28733 and 
33608, respectively. At same time points, number of those cells with natural fatty 
acid stimulations were 31138, 34480 and 50412, respectively. Whereas in the same 
time points, numbers of cells from the control LNCaP cells only were 19691, 24608 
and 27191, respectively and 23630, 29530 and 40787, respectively, of those cells 
with natural fatty acid stimulations. The proliferation rate of C-FABP-WT stimulated 
cells was significantly increased by 24% (Day 4), 14% (Day 5) and 19% (Day 6) 
compared with control cells (Student t-test, P=0.0399). Similarly, number of cells 
stimulated by mutants C-FABP-R109A and C-FABP-R109/129A only were 
significantly reduced when compared to control cells during the 6 days culture 
(Student t-test, P=0.0069 and P=0.0096, respectively ). In addition, number of those 
cell with natural fatty acid stimulations were also significantly reduced when 
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compared to control cells during 6 days culture (P=0.03 and 0.0344, respectively). 
The final cell counts on day 6 and statistical comparison were summarised in Table 
5.1   
To assess the difference between cells stimulated by C-FABPs only and cells 
stimulated by C-FABPs plus natural fatty acid, statistical analysis showed that the 
proliferation rate of cells stimulated by C-FABPs plus natural fatty acids were 
significantly increased by 20% (C-FABP-WT), 17% (C-FABP-R109A) and 15% (C-
FABP-R109/129A) compared with cells stimulated by C-FABPs only (Student t-test, 
P>0.05).        
 
 
Figure 5.3: Standard curve for LNCaP cell line 
 A standard curve was established by plotting absorbance (OD at 570nm) (Axis Y) 
against the number of cells (Axis X). The cell number of samples was determined by 
comparing serially diluted standard from the standard curve. The curve equation 
and regression value of standard curve are presented in the diagrams. 
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Figure 5.4: Time course curve of proliferation rate for LNCaP cells stimulated 
by wild type and mutant C-FABP proteins  
The numbers of cells stimulated with different C-FABPs, shown mean of three 
individual experiments were obtained every day during the 6 days period. (A) 
LNCaP cells were stimulated by recombinant C-FABPs only. (B) LNCaP cells were 
stimulated by recombinant C-FABPs plus natural fatty acid (Myristic acid). Data 
expressed as means±SD of three independent experiments. 
0
5000
10000
15000
20000
25000
30000
35000
40000
1 2 3 4 5 6
N
um
be
r o
f C
el
ls
Time (Days)
Control
WT
R
RR
A
0
10000
20000
30000
40000
50000
60000
1 2 3 4 5 6
N
um
be
r o
f C
el
ls
Time (Days)
FA
FA+WT
FA+R
FA+RR
B
Chapter 5: Results 3      P a g e  | 215 
 
 
 
 
 
 
Table 5.1: Cell counts of C-FABPs at the end point of proliferation assay  
The final cell counts on day 6 and the statistic analyse were shown above. P values 
were obtained by comparing sample groups to control. (A)  LNCaP cells were 
stimulated by recombinant C-FABPs only. (B) LNCaP cells were stimulated by 
recombinant C-FABPs plus natural fatty acid (Myristic acid).   
LNCaP Mean number of cells ± SD P Value 
C-FABP-WT 21988 ± 9680 0.0165 
C-FABP-R109A 11821 ± 3941 0.0069 
C-FABP-R109/129A 9778 ± 2507 0.0096 
Control 18136 ± 7308 --- 
LNCaP Mean number of cells ± SD P Value 
C-FABP-WT 26501 ± 16501 0.0399 
C-FABP-R109A 14548 ± 6817 0.03 
C-FABP-R109/129A 11437 ± 3985 0.0344 
Control 21889 ± 12683 --- 
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5.2.2.2 22RV1 Cell line  
The detailed proliferation assay results were demonstrated in Figure 5.6. During the 
first two days, growth rates of tested cells were very similar. However, from the 3rd 
day on, the proliferation rate of C-FABP-WT stimulated cells started to be higher 
than those of other lines. On the 4
th
, 5
th
 the 6
th
 day, the numbers of C-FABP-WT 
stimulated LNCaP cells without adding natural fatty acid  were 28535, 31606 and 
36969, respectively. At same time points, number of those cells with natural fatty 
acid stimulations were 34243, 37928 and 55453, respectively. Whereas in the same 
time points, numbers of cells from the control LNCaP without adding fatty acids 
were 19691, 24608 and 33000, respectively, and number of those cells with natural 
fatty acid stimulations were 23630, 29530 and 40787, respectively. The proliferation 
rate of C-FABP-WT stimulated cells was significantly increased by 31% (Day 4), 
22% (Day 5) and 26% (Day 6) compared with control cells (Student t-test, 
P=0.0310). Similarly, cell numbers of cells stimulated by mutants C-FABP-R109A 
and C-FABP-R109/129A only were significantly reduced when compared to control 
cells during the 6 day culture (Student t-test, P=0.0017 and P=0.001). Moreover, 
number of those cells with natural fatty acid stimulations were also significantly 
reduced when compared to control cells during 6 days culture (P=0.0083 and 0.008). 
The final cell counts on day 6 and statistical comparison were summarised in Table 
5.2 
To assess the difference between cells stimulated by C-FABPs only and cells 
stimulated by C-FABPs plus natural fatty acid, statistical analysis showed that the 
proliferation rate of cells stimulated by C-FABPs plus natural fatty acids were 
significantly increased by 23% (C-FABP-WT), 20% (C-FABP-R109A) and 16% (C-
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FABP-R109/129A) compared with cells stimulated by C-FABPs only (Student t-test, 
P>0.015). 
 
 
Figure 5.5: Standard curve for 22RV1 cell line 
A standard growth curve was established by plotting absorbance (OD at 570nm) 
(Axis Y) against the number of cells (Axis X). The cell number of samples was 
determined by comparing serially diluted standard from the standard curve. The 
curve equation and regression value of standard curve are presented in the 
diagrams.  
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Figure 5.6: Time course curve of proliferation rate for 22RV1 cells stimulated 
by wild type and mutant C-FABP proteins  
The numbers of cells stimulated with different C-FABPs, shown mean of three 
individual experiments were obtained every day during the 6 days period. (A) 22RV1 
cells were stimulated by recombinant C-FABPs only. (B) 22RV1 cells were 
stimulated by recombinant C-FABPs plus natural fatty acid (Myristic acid). Data 
expressed as means±SD of three independent experiments. 
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Table 5.2: Cell counts of C-FABPs at the end point of proliferation assay  
The final cell counts on day 6 and the statistic analyse were shown above. P values 
were obtained by comparing sample groups to control. (A)  22RV1 cells were 
stimulated by recombinant C-FABPs only. (B) 22RV1 cells were stimulated by 
recombinant C-FABPs plus natural fatty acid (Myristic acid).  
 
22RV1 Mean number of cells ± SD P Value 
C-FABP-WT 24009 ± 10925 0.0139 
C-FABP-R109A 15113 ± 6090 0.0017 
C-FABP-R109/129A 13950 ± 5621 0.001 
Control 18136 ± 7308 --- 
22RV1 Mean number of cells ± SD P Value 
C-FABP-WT 29027 ± 18334 0.0310 
C-FABP-R109A 18241 ± 10569 0.0083 
C-FABP-R109/129A 16837 ± 9756 0.008 
Control 21889 ± 12683 --- 
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5.2.2.3 LNCaP-C42 cell line   
The detailed proliferation assay results were demonstrated in Figure 5.8. During the 
first two days, growth rates of all tested cells were very similar. However, from the 
3rd day on, the proliferation rate of C-FABP-WT stimulated cells started to be higher 
than those of other lines. On the 4th, 5th the 6th day, the numbers of C-FABP-WT 
stimulated LNCaP-C42 cells without adding natural fatty acids were 51883, 57466 
and 67216, respectively. At same time points, number of those cells with natural 
fatty acid stimulations were 62260, 68960 and 100825, respectively. Whereas in the 
same time points, numbers of cells from the control LNCaP-C42 cells only were 
39383, 49216 and 54383, respectively, and 47260, 59060 and 81575, respectively, of 
those cells with natural fatty acid stimulations. The proliferation rate of C-FABP-WT 
stimulated cells was significantly increased by 24% (Day 4), 15% (Day 5) and 20% 
(Day 6) compared with control cells (Student t-test, P=0.0399). Similarly, number of 
cells stimulated by mutants C-FABP-R109A and C-FABP-R109/129A only were 
significantly reduced when compared to control cells during the 6 day culture 
(Student t-test, P=0.006 and P=0.0096, respectively). Moreover, number of those 
cells with natural fatty acid stimulations were also significantly reduced when 
compared to control cells during 6 days culture (P=0.03 and 0.0344, respectively). 
The final cell counts on day 6 and statistical comparison were summarised in Table 
5.3.  
To assess the difference between cells stimulated by C-FABPs only and cells 
stimulated by C-FABPs plus natural fatty acid, statistical analysis showed that the 
proliferation rate of cells stimulated by C-FABPs plus natural fatty acids were 
significantly increased by 27% (C-FABP-WT), 19% (C-FABP-R109A) and 17% (C-
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FABP-R109/129A) compared with cells stimulated by C-FABPs only (Student t-test, 
P>0.05). 
 
 
Figure 5.7: Standard curve for LNCaP-C42 cell line 
A standard curve was established by plotting absorbance (OD at 570nm) (Axis Y) 
against the number of cells (Axis X). The cell number of samples was determined by 
comparing serially diluted standard from the standard curve. The curve equation 
and regression value of standard curve are presented in the diagrams.  
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Figure 5.8: Time course curve of proliferation rate for LNCaP-C42 cells 
stimulated by wild type and mutant C-FABP proteins  
The numbers of cells for each C-FABP proteins, shown mean of three individual 
experiments were obtained every day during the 6 days period. (A) LNCaP-C42 cells 
were stimulated by recombinant C-FABPs only. (B) LNCaP-C42 cells were 
stimulated by recombinant C-FABPs plus natural fatty acid (Myristic acid). Data 
expressed as means±SD of three independent experiments. 
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Table 5.3: Cell counts of C-FABPs at the end point of proliferation assay  
The final cell counts on day 6 and the statistic analyse were shown above. P values 
were obtained by comparing sample groups to control. (A) LNCaP-C42 cells were 
stimulated by recombinant C-FABPs only. (B) LNCaP-C42 cells were stimulated by 
recombinant C-FABPs plus natural fatty acid (Myristic acid).  
LNCaP-C42 Mean number of cells ± SD P Value 
C-FABP-WT 43977 ± 19361 0.0165 
C-FABP-R109A 23642 ± 7882 0.006 
C-FABP-R109/129A 13950 ± 5621 0.0096 
Control 36272 ± 14616 --- 
LNCaP-C42 Mean number of cells ± SD P Value 
C-FABP-WT 53003 ± 33019 0.0399 
C-FABP-R109A 29097 ± 13635 0.03 
C-FABP-R109/129A 22875 ± 7971 0.0344 
Control 43778 ± 25367 --- 
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5.2.3 The effect of wild type and mutants C-FABPs on the invasiveness 
of the cells 
The proliferation assay showed no significant differences of the effect of C-FABPs 
on LNCaP, 22RV1 and LNCaP-C42 cell line. Therefore, the invasion assay was 
conducted only on LNCaP cells.  
A modified Boyden Chamber assay was applied to evaluate the invasiveness of 
LNCaP cell stimulated by different recombinant C-FABP proteins. This chemotactic 
directional migration assay was used widely to reveal the cell invasion ability which 
correlates well with the metastasis potential (Tuszynski et al, 1987). The cells were 
examined in a Boyden Chamber with 6.5mm diameter polycarbonate membrane 
coated with 30μg of matrigel to the upper compartment before the cells were seeded. 
After 24 hours incubation, cells remaining in the upper compartment of the filters 
were removed and the cells attached to the lower side of the filter were fixed and 
stained by crystal violet reagent. The numbers of migrated and invaded cells were 
counted under a light microscope at 10/0.25 magnification. On each filter, nine 
random fields were counted and the representatives of each cell line were shown in 
Figure 5.9.  
The results were normalized by the cell number after 20 hours routine culture and 
were shown in Figure 5.10. All migrated cells remained attaching to the low surface 
of the membrane and no cells were found in the culture medium of the low chamber. 
The numbers of invading cells that pass through the membrane were shown in Table 
5.4. The number of invaded C-FABP-WT stimulated cells was the highest in all cell 
lines and more than 2.6-fold higher than the number of invaded cells from control 
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(Student t-test, P=0.03). The invasiveness of C-FABP-R109A stimulated cells was 
higher than LNCaP-R109/129A stimulated cells and control cells, but was 
significantly lower than that of C-FABP-WT stimulated cells (Student t-test, 
P=0.01). The invasiveness of C-FABP-R109/129A stimulated cells was at similar 
level to that of the control cells (Student t-test, P=0.44). Difference of invaded cells 
between C-FABP-R109A and C-FABP-R109/129A stimulated cells was considered 
to be a statistically significant (Student t-test, P=0.037). 
 
 
Table 5.4: The number of invading cells that pass through the membrane. 
Number of invaded cells (Mean±SD) produced by LNCaP stimulated by different C-
FABPs proteins in three separate experiments were shown above and P values were 
calculated by comparing sample groups to control group. 
 
 
LNCaP cells 
Mean number of invaded cells ± 
SD 
P Value 
C-FABP-WT 256 ± 40 0.03 
C-FABP-R109A 163 ± 32 0.031 
C-FABP-R109/129A 80 ± 26 0.44 
Control 96.6 ± 15.2 --- 
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Figure 5.9: The images of invaded cells stimulated by C-FABP proteins on the 
lower filter surface of the Boyden Chamber  
The appearances of invaded cells from C-FABP-WT stimulated cells, C-FABP-
R109A stimulated cells, C-FABP-R109/129A stimulated cells and the control, 
respectively.     
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Figure 5.10: Number of cells invaded per field in the invasion assay  
The columns represent the invasiveness of C-FABP-WT stimulated cells (Column A), 
C-FABP-R109A stimulated cells (Column B), C-FABP-R109/129A stimulated 
(Column C) and control (Column D). The invasiveness of C-FABP-WT stimulated 
cells was significantly higher than those of C-FABP-R109A stimulated cells, C-
FABP-R109/129A stimulated cells and the control cells. The results are the mean ± 
SD of three individual experiments.  
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5.2.4 Soft agar colony formation assay of recombinant C-FABP proteins  
The tumorigenicity of the LNCaP, 22RV1 and LNCaP-C42 cell lines stimulated by 
C-FABP proteins were tested by examining their anchorage-independent growth in a 
soft agar. 
 
5.2.4.1 LNCaP cell line  
The images of soft agar for each cell stimulated by C-FABP proteins were shown in 
Figure 5.11 and the results of the soft agar were shown in Figure 5.12. The accurate 
quantitative assessment and P values of Student t-test for each tested cell line 
compared to control were presented in Table 5.5. 
The number of colonies produced in the soft agar by LNCaP cells stimulated with C-
FABP-WT, C-FABP-R109A, C-FABP-R109/129A and control cells were 
1050±132.29, 283±76.38, 157±38.1 and 155±68.74, respectively. In comparison with 
the control, the number of colonies produced by C-FABP-R109A stimulated cells 
was significantly increased by 45% (Student t-test, P=0.0183) whereas the number of 
colonies produced by C-FABP-R109/129A stimulated cells was at same level as the 
control (Student t-test, P=0.5737). The most significant change was observed in C-
FABP-WT stimulated cells which produced more than 6.7-fold increase in the 
number of colonies formed in soft agar when compared to control. Further analysis 
showed that a significant difference was found between the number of colonies 
produced by control C-FABP-R109A stimulated cells and the number of colonies 
produced by C-FABP-R109/129A stimulated cells (Student t-test, P=0.0258). 
However, the differences between the colony numbers produced by C-FABP-R109A 
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and C-FABP-109/129A stimulated cells were significantly reduced by 73% and 85% 
when compared to C-FABP-WT stimulated cells (Student t-test, P=0.0043 and 
P=0.0077, respectively).  
 
      
Figure 5.11: The colonies produced in soft agar by LNCaP cell stimulated with 
different C-FABPs 
After incubation for 5 weeks, 2 hours staining by MTT was performed on colonies 
developed from C-FABP-WT (Panel A), C-FABP-R109A (Panel B), C-FABP-
R109/129A (Panel C) and Control (Panel D) were displayed above. All plates were 
stimulated by natural fatty acid (Myristic acid).  Experiments were tested in three 
plates. 
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Figure 5.12: The effect of wild and mutants C-FABPs on colonies formation 
ability of LNCaP cells in soft agar 
The number of colonies was counted using GelCount with optimised setting: Edge 
detaction: 30; Centre detaction: 50; Colony diameter: 150µm-800µm; Circularity: 
60; Density: 0.75. C-FABP-WT (Column A), C-FABP-R109A (Column B), C-FABP-
R109/129A (Column C) and Control (Column D).  
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Table 5.5: The numbers of colonies produced in soft agar by LNCaP cells 
stimulated by different C-FABPs 
Numbers of colonies (mean ± SD) produced by LNCaP cells stimulated with different 
C-FABP proteins in three separate soft agar assays were shown above and P values 
were obtained by comparing sample groups to control group (paired t test).  
 
5.2.4.2 22RV1 cells line  
The images of soft agar for cell stimulated by C-FABP proteins were shown in 
Figure 5.13 and the results of the soft agar assays were shown in Figure 5.14. The 
accurate quantitative assessment and P values of Student t-test for each tested cell 
line compared to control were presented in Table 5.6.  
The number of colonies produced in the soft agar by 22RV1 cells stimulated with C-
FABP-WT, C-FABP-R109A, C-FABP-R109/129A and control cells were 
1183.33±160.73, 408.33±38.19, 197±92.50 and 216.67±73.38, respectively. In 
LNCaP cells 
Mean number of colonies ± 
SD 
P Value 
C-FABP-WT 1050 ± 132.29 0.0005 
C-FABP-R109A 283 ± 76.38 0.0183 
C-FABP-R109/129A 157 ± 38.1 0.5737 
Control 155 ± 68.74 --- 
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comparison with the control, the number of colonies produced by C-FABP-R109A 
stimulated cells was significantly increased by 47% (Student t-test, P=0.0130) 
whereas the number of colonies produced by C-FABP-R109/129A stimulated cells 
was at same level as control (Student t-test, P=0.1836). The most significant change 
was observed in C-FABP-WT stimulated cells which produced more than 5.4-fold 
increase in the number of colonies formed in soft agar when compared to control. 
Further analysis showed that a significant difference was found between the number 
of colonies produced by control C-FABP-R109A stimulated cells and the number of 
colonies produced by C-FABP-R109/129A stimulated cells (Student t-test, 
P=0.0214). However, the differences between the colony numbers produced by C-
FABP-R109A and C-FABP-109/129A stimulated cells were significantly reduced by 
65% and 83% when compared to C-FABP-WT stimulated cells (Student t-test, 
P=0.0092 and P=0.0035, respectively).  
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Figure 5.13: The colonies produced in soft agar by 22RV1 cells stimulated with 
different C-FABPs 
After incubation for 4 weeks, 2 hours staining by MTT was performed on colonies 
developed from C-FABP-WT (Panel A), C-FABP-R109A (Panel B), C-FABP-
R109/129A (Panel C) and Control (Panel D) were displayed above. All plates were 
stimulated by natural fatty acid (Myristic acid).  Experiments were tested in three 
plates. 
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Figure 5.14: The effect of wild and mutants C-FABPs on colonies formation 
ability of 22RV1 cells in soft agar 
The number of colonies was counted using GelCount with optimised setting: Edge 
detaction: 30; Centre detaction: 50; Colony diameter: 150µm-800µm; Circularity: 
60; Density: 0.75. C-FABP-WT (Column A), C-FABP-R109A (Column B), C-FABP-
R109/129A (Column C) and Control (Column D).  
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Table 5.6: The numbers of colonies produced in soft agar by 22RV1 cells 
stimulated with different C-FABPs 
Numbers of colonies (mean ± SD) produced by 22RV1 stimulated with different C-
FABP proteins in three separate soft agar assays were shown above and P values 
were obtained by comparing sample groups to control group (paired t test).  
 
5.2.4.3 LNCaP-C42 cell line  
The images of soft agar assay for LNCaP-C42 stimulated with C-FABP proteins were 
shown in Figure 5.15 and the results of the soft agar assays were shown in Figure 
5.16. The accurate quantitative assessment and P values of Student t-test for each 
tested cell line compared to control were presented in Table 5.7.  
 
 
22RV1 cells Mean number of colonies ± SD P Value 
C-FABP-WT 1183.33 ± 160.73 0.0038 
C-FABP-R109A 408.33 ± 38.19 0.0130 
C-FABP-R109/129A 197 ± 92.50 0.1836 
Control 216.67 ± 73.38 --- 
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The number of colonies produced in the soft agar by LNCaP-c42 cells stimulated 
with C-FABP-WT, C-FABP-R109A, C-FABP-R109/129A and Control were 
1233±208.17, 443.33±60.28, 216.67±76.38 and 180.33±65.12, respectively. In 
comparison with the control, the number of colonies produced by C-FABP-R109A 
stimulated cells was significantly increased by 59% (Student t-test, P=0.0068) 
whereas the number of colonies produced by C-FABP-R109/129A stimulated cells 
was at same level as the control (Student t-test, P=0.5647). The most significant 
change was observed in C-FABP-WT stimulated cells which produced more than 7-
fold increased in the number of colonies formed in soft agar when compared to 
control. Further analysis showed that a significant difference was found between the 
number of colonies produced by control C-FABP-R109A stimulated cells and the 
number of colonies produced by C-FABP-R109/129A stimulated cells (Student t-
test, P=0.0157). However, the differences between the colony numbers produced by 
C-FABP-R109A and C-FABP-109/129A stimulated cells were significantly reduced 
by 65% and 82% when compared to C-FABP-WT stimulated cells (Student t-test, 
P=0.0032 and P=0.0014, respectively).  
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Figure 5.15: The colonies produced in soft agar by LNCaP-C42 cells stimulated 
with different C-FABPs  
After incubation for 4 weeks, 2 hours staining by MTT was performed on colonies 
developed from C-FABP-WT (Panel A), C-FABP-R109A (Panel B), C-FABP-
R109/129A (Panel C) and Control (Panel D) were displayed above. All plates were 
stimulated by natural fatty acid (Myristic acid).  Experiments were tested in three 
plates. 
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Figure 5.16: The effect of wild type and mutants FABPs on colonies formation 
ability of LNCaP-C42 in soft agar  
The number of colonies was counted using GelCount with optimised setting: Edge 
detaction: 30; Centre detaction: 50; Colony diameter: 150µm-800µm; Circularity: 
60; Density: 0.75. C-FABP-WT (Column A), C-FABP-R109A (Column B), C-FABP-
R109/129A (Column C) and Control (Column D).  
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Table 5.7: The numbers of colonies produced in soft agar by LNCaP-C42 
stimulated with different C-FABPs 
Numbers of colonies (mean ± SD) produced by different C-FABP proteins in three 
separate soft agar assays were shown above and P values were obtained by 
comparing sample groups to control group (paired t test).  
 
 
 
 
 
 
 
LNCaP-C42 Mean number of colonies± SD P Value 
C-FABP-WT 1233 ± 208.17 0.0011 
C-FABP-R109A 443.33 ± 60.28 0.0068 
C-FABP-R109/129A 216.67 ± 76.38 0.5647 
Control 180.33 ± 65.12 --- 
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5.3 Discussion  
In this chapter, the relationship between the tumourigenicity-promoting function of 
C-FABP and its fatty acid-binding ability was monitored. C-FABP binds to fatty 
acids through a binding motif which consists of three key amino acids (Arg
109
, 
Arg
129
, and Tyr
131
) and replacing any one of these key amino acids with another 
almost completely deprives C-FABP of its fatty acid binding ability (Vorum et al, 
1998). Fatty acid uptake is a strictly regulated process and it is related to the levels of 
certain FABPs in LNCaP cells (Pinthus et al, 2007). The fatty acid uptake assay 
investigated in this chapter, our results showed that the fatty acid uptake capacity of 
LNCaP stimulated with C-FABP-WT was significantly increased when C-FABP was 
forced to be overexpressed. In contrast, the fatty acid uptake capacities stayed at 
same level between either LNCaP cells stimulated with single point mutated C-
FABP (C-FABP-R109A) and control cells (LNCaP) or LNCaP cells stimulated with 
double points mutated C-FABP (C-FABP-R109/129A) and LNCaP cells. These 
results indicated that elevate the expression of C-FABP-WT in LNCaP cells can 
result in enhancing its fatty acid uptake capability. Moreover, it has been also 
demonstrated that expression of mutated recombinant C-FABPs generated by site-
directed mutagenesis can not increase the fatty acid uptake capability compared to 
the control cells, which suggested that the ability of C-FABP to bind and to transport 
fatty acids into these cells depends on the structural integrity of its fatty acid-binding 
motif and changing amino acids in this part can result losing most fatty acid-binding 
and transporting capability. 
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To study the importance of the structural integrity of the fatty acid binding motif to 
the tumorigenicity-promoting activity of C-FABP in prostate cancer, the effect of 
wild type and mutant C-FABPs on cell proliferation, invasion and colony formation 
as indication of tumourigencity were investigated.  The average growth rate of cells 
stimulated with C-FABP-WT was significantly increased by 17% (Student t-test, 
P<0.05) when compared to control cells. Whereas, the average growth rate of cells 
stimulated with C-FABP-R109A and C-FABP-R109/129A were significantly 
reduced by 33% and 47%, respectively (Student t-test, P<0.005) when compared to 
control cells. Further statistical analysis showed that the proliferation rate of cells 
stimulated by C-FABPs plus natural fatty acids were significantly increased by 27% 
(C-FABP-WT), 19% (C-FABP-R109A) and 17% (C-FABP-R109/129A) when 
compared with cells stimulated by C-FABPs only (Student t-test, P>0.05). The 
invasiveness of cells stimulated with C-FABP-WT, C-FABP-R109, C-FABP-
R109/129A and the control cells were 256±40, 163±32, 80±26 and 96.6±15.2, 
respectively. The number of invaded cells stimulated with C-FABP-WT was the 
highest in all cell lines and more than 2.6-fold higher than the number of invaded 
cells from control (Student t-test, P<0.05). The average number of colonies produced 
in the soft agar by selected cells stimulated with C-FABP-WT, C-FABP-R109A, C-
FABP-R109/129A and control were 1050±132.29, 283±76.38, 157±38.1 and 
155±68.74, respectively. In comparison with the control, the average number of 
colonies produced by C-FABP-R109A stimulated cells was increased by 45% 
(Student t-test, P<0.01) whereas the average number of colonies produced by C-
FABP-R109/129A stimulated cells was at same level as the control cells (Student t-
test, P>0.5). The most significant change was observed in C-FABP-WT stimulated 
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cells which produced more than 6.7-fold (85%) increase in the number of colonies 
formed in soft agar assay comparing to the control (Student t-test, P<0.001). These 
results showed that, the increased wild type C-FABP stimulation in prostate cell lines 
significantly increased cell proliferation, invasiveness, and tumorigenicity. Whereas, 
the increased expression of both mutant forms of C-FABP did not significantly effect 
these characteristics. 
 
In-vitro findings in this chapter were consistent with our recently in-vivo results, 
when inoculated in nude mice, 7 out of 8 (88.9%) mice inoculated with LNCaP-WT 
cells developed tumours, but only 3 out of 8 (37.5%) mice inoculated with LNCaP-
R109/129A and LNCaP-V cells respectively produced tumours. At the end of the 
test, the average weight of the tumours produced by LNCaP-WT was 5.8- and 7.3- 
times of those produced respectively by LNCaP-R109/129A and LNCaP-V cells 
(Malki et al, 2011). This result showed that not only that the wild type C-FABP-
expressing cells produced more but also larger tumours than those cells either not 
expressing C-FABP or expressing mutated C-FABP which was not able to bind and 
transport fatty acids. Furthermore, consistent with this finding, our previous work 
established that suppressing expression of C-FABP by either antisense mRNA or 
RNA interference in the highly malignant prostate cancer cell line PC3M has greatly 
inhibited its ability of forming tumours in nude mouse (Adamson et al, 2003; 
Forootan et al, 2010; Morgan et al, 2008). Therefore, The results of the current and 
previous work in-vitro and in-vivo further confirmed that C-FABP promotes 
malignant progression of prostate cancer by its binding and transporting intracellular 
fatty acids into the cancer cells. 
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6 GENERAL DISCUSSION AND CONCLUSION 
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6.1 Discussion  
Prostate cancer is the most frequently diagnosed non-cutaneous male malignancy and 
is the second cause of cancer-related death in men in most Western countries. In the 
UK, more than 35,000 men are diagnosed with prostate cancer and around 10,000 
men die from prostate cancer each year. Current understanding of the molecular 
pathology of prostate cancer is limited. At present, clinical therapy focuses on 
androgen blockage by physical or pharmaceutical castration. However, prostate 
cancer often returns exhibiting more aggressive hormone independent phenotype. 
Therefore, it is important to improve the understanding of the specific molecular 
mechanisms involved in the malignant progression of prostate cancer in order to 
develop new therapies. 
 
The risk factors for prostate cancer include age, ethnicity, family history and diet. It 
has been reported that prostate cancer onset may be attributed to a variety of dietary 
factors ranging from lack of selenium supplementations (Quiner et al, 2011) to 
vitamin D (Stewart et al, 2005) and high dairy fat intake was also associated with 
increased risk of prostate cancer (Crowe et al, 2008; Kurahashi et al, 2008). A long-
term study demonstrated high blood levels of trans-fatty acids to be associated with 
an increased prostate cancer risk (Chavarro et al, 2008). 
 
C-FABP is a 15 KDa cytosolic protein within the family of fatty acid binding 
protein. It binds with high affinity to long chain fatty acid. Increased expression of 
C-FABP has been detected in malignant tumours of breast, bladder and pancreas 
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(Celis et al, 1999; Sinha et al, 1999). Our previous studies in the molecular 
pathology laboratory have established the relationship between over-expression of C-
FABP in breast and prostate cancer cells. A study by (Jing et al, 2000) found the C-
FABP gene to be over-expressed in malignant breast and prostate epithelial cell lines.  
When the C-FABP gene was transfected into the rat benign Rama 37 model cells and 
the tranfectants subsequently inoculated into Wistar Furth rats, a significant number 
of animals developed metastasis. Suppression of C-FABP expression by antisense 
transfection in PC-3M cells decreased the invasive capacity in vitro and reduced the 
tumourigencity in vivo. Moreover, suppression of VEGF has also been detected in 
these transfected cell lines (Adamson et al, 2003). These results indicated that over-
expression of C-FABP may stimulate the expression of VEGF and subsequently 
promote the angiogenesis to facilitate tumour formation and metastasis. Recent 
studies by Morgan et.al (2008) confirmed that suppressing the expression of C-FABP 
in PC-3M cells using  siRNA silencing technique resulted the significant reduction of 
tumourigencity both in-vitro and in-vivo (Morgan et al, 2008). However, the 
mechanism of C-FABP elevating the expression of VEGF remains unclear. 
 
Overall, the aims of this thesis were to investigate the relationship between the 
tumorigenicity-promoting function of C-FABP and its fatty acid-binding ability, so 
as to ascertain that the tumorigenicity promoting activity of C-FABP depends on its 
structural integrity of its fatty acid-binding motif and hence its fatty acid-binding 
ability in prostate cancer cells.  
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In common with other FABP family proteins, C-FABP binds to fatty acids through a 
binding motif which consists of 3 key amino acids (Arg
109
, Arg
129
, and Tyr
131
). We 
used site-directed mutagenesis to convert Arg
109
or Arg
109
 and Arg
129
 into Ala
109
 or 
Ala
109
 and Ala
129
 to generate two mutant cDNAs (Figure 3.1) and transfected them 
together with wild type cDNA into the LNCaP cells to generate modified transfectant 
cell lines. Real-time PCR measurement on C-FABP mRNA showed that the C-FABP 
mRNA level in LNCaP-WT cells to be increased 137.5-fold comparing with control 
cells (Figure 3.5). Western blot also confirmed the overexpression of C-FABP in 
LNCaP-WT cells (Figure 3.6). From the results obtained by our previous studies, it 
was demonstrated that the biological function of C-FABP is promote malignant 
progression of cancer cells. In this study, the effect of high level increment of C-
FABP expression on cell malignant properties such as proliferation rate, invasiveness 
and anchorage-independent growth as an indication of tumourigenecicy, was 
investigated. It is also showed that the mutant C-FABP mRNA levels expressed, 
respectively, in LNCaP-R109A and LNCaP-R109/129A cells were also increased to 
levels similar to that in LNCaP-WT cells. Thus these transfectants were ideal cell 
lines used for comparing biological functions exerted by wild type and mutant C-
FABPs. 
 
The wild type and mutant C-FABP cDNAs were contained in the pIRES2-EGFP 
vector. When the wild type and mutant C-FABP cNDAs were cloned into an 
expression vector to produce recombinant C-FABPs, it was found that in the multiple 
cloning sites of this construct, there was no complimentary restriction site for the 
expression vector pQE. Therefore, before the C-FABP cDNAs were inserted into to 
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the expression vector pQEs, it was necessary to generate complimentary restriction 
sites at both ends of the cDNAs. Thus, the C-FABP-cDNAs were excised from 
pIRES2-EGFP with restriction enzymes XhoI and PstI (Figure 4.1 - Figure 4.3) and 
inserted into cloning vector pBluescript that contains the multiple restriction sites 
(KpnI and PstI). Sequences analysis successfully confirmed the insertion of C-FABP 
cDNAs into the cloning vector pBluescript (Figure 4.4 - Figure 4.6). The C-FABP 
cDNAs were then excised out from the pBluescript vector with KpnI and PstI (Figure 
4.7 and Figure 4.8) and then inserted into the expression vector pQEs to form three 
constructions which will express the wild type and mutant C-FABPs (C-FABP-WT, 
C-FABP-R109A and C-FABP-R109/129A, respectively). Sequence analysis 
successfully confirmed the insertion of C-FABP cDNAs into the pQEs expression 
vector (Figure 4.11 - Figure 4.13). Further analysis confirmed that pQE32 is the only 
vector that remains the ATG codon unchanged as shown in Figure 4.10. Therefore, 
PQE32 was identifies and chosen as the construct to produce recombinant proteins. 
When the recombinant proteins are synthesised in E.coli cells, different expression 
systems exhibit different efficiencies. Thus, it is necessary to establish the time point 
at which the maximum yield of protein is synthesised in E.coli cells.  In this work, it 
was found that protein synthesis is increased with increased incubation time, and 
reached a maximum at five hours after IPTG induction. Once at the maximum, any 
further induction and incubation was not accompanied with any further increment in 
protein synthesis. Instead, the yield of recombinant protein was reduced. This could 
be due to either the cessation of production inside the E. coli cells or the degradation 
of the completed synthesised proteins. Therefore, the optimal time at which the 
maximum yield of protein production was achieved was 5 hours after IPTG 
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induction (Figure 4.14). After C-FABP was separate from the 6xhis-tagged using Ni-
NTA Fast Start column and subjected to Western blot analysis, a single band at the 
correct site of the blot was visualised (Figure 4.15).  This result indicated that the 
separation of the recombinant C-FABP proteins from the E. coli bacterial proteins 
was very successful and the recombinant proteins obtained from purification 
procedures were very pure.  
 
To test whether the recombinant proteins produced were biologically active, the fatty 
acid binding ability of wild type and mutant C-FABPs were tested. The fatty acid 
binding ability of the C-FABP-WT was on average 85% when exposed to natural 
fatty acids (myristic, palmitic, oleic and linoleic acids). However, the average fatty 
acid binding ability of the C-FABP-R109A was significantly reduced to 33% 
(Student t-test, P<0.001) when exposed to natural fatty acids and the average fatty 
acid binding ability of the C-FABP-R109/129A was further significantly reduced to 
10% (Student t-test, P<0.001) (Figure 4.17). These results suggested that fatty acid 
binding ability of C-FABP depends on its structural integrity of the binding motif. 
Therefore, changing one amino acid in motif by site-directed point mutation 
significantly reduced the fatty acid binding ability and changing two amino acids by 
sites-directed mutations almost completely deprived the fatty acid binding ability of 
C-FABP. These findings are comparable to the results of the study by Hagan et al 
(2008) who tested the fatty acid binding ability of wild type and mutant Liver fatty 
acid binding protein (L-FABP) (Hagan et al, 2008).  The study concluded that the 
fatty acid binding ability of mutant L28W and M74W were significantly reduced by 
80% and 87%, respectively, when exposed to linoleic acids comparing to wild type 
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protein. Therefore mutant forms of fatty acid binding proteins seemed to reduce the 
ability to bind to fatty acids compared to wild type proteins as found in this work and 
by others. 
 
To analyze the possible expression of C-FABP proteins in prostate carcinogenesis 
and tumour progression, we examined the effect of wild type and mutant C-FABPs 
on cell proliferation, invasiveness and soft agar colony formation assays as indication 
of tumorigenicity of prostate cells. The average proliferation rate of C-FABP-WT 
stimulated LNCaP cells was significantly increased by 19% when compared to 
control cells (Student t-test, P=0.03). However, the average proliferation rate of C-
FABP-R109 and C-FABPR109/129A stimulated LNCaP cells were significantly 
reduced by 33% and 47% when compared to the control cells (Student t-test, 
P<0.005) (Figure 5.4). Similarly, the average proliferation rate of C-FABP-WT 
stimulated 22RV1 and LNCaP-C42 were significantly increased by 25% and 20%, 
respectively, when compared with control cells (Student t-test, P<0.005 and 
P<0.001, respectively) (Figure 5.6 and Figure 5.7). To analyze the differences 
between the growth rate of selected cells stimulated by C-FABP proteins plus fatty 
acid and selected cells stimulated by recombinant protein only, further statistical 
analysis showed that the average proliferation rate of tested cells stimulated by C-
FABPs plus selected natural fatty acids were significantly increased by 23% (C-
FABP-WT), 18% (C-FABP-R109A) and 16 % (C-FABP-R109/129A) compared 
with cells stimulated by C-FABPs only (Student t-test, P<0.05). Thus, this finding 
may support the hypothesis that the elevated expression of C-FABP may give rise to 
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an increased total uptake of fatty acids, and hence an enhanced fatty acid signalling 
activity.  
 
With respect to cell invasions, the number of LNCaP cells stimulated with C-FABP-
WT that invaded through the trans-well membrane was 2.6-fold higher (student t-
test, P<0.05) than the number of cells in the LNCaP control group (Figure 5.9). The 
invasiveness of C-FABP-R109A stimulated cells was higher than C-FABP-
R109/129A stimulated cells and control group, but was significantly lower than that 
of C-FABP-WT stimulated cells (Student t-test, P<0.01) (Figure 5.10). The 
invasiveness C-FABP-R109/129A stimulated LNCaP cells was at similar level to 
that of the control cells (Student t-test, P=0.44). Further statistic showed that the 
invasiveness of LNCaP cells stimulated with C-FABP-R109A was significantly 
increased by 2-fold than the number of invaded cells in the LNCaP stimulated with 
C-FABP-R109/129A (Student t-test, P<0.05) (Table 5.4). The expression level of 
three C-FABP proteins in prostate cancer cells was proportional to their invasive 
abilities, which suggests that the change one or two amino acids by site-directed 
point mutation might be associated with the metastatic potential of prostate cancer 
cells. These findings are consistent with previously reported associations of C-FABP 
with tumorigenesis and metastasis in prostate cancer and breast cancer in-vitro and 
in-vivo (Adamson et al, 2003; Fang et al, 2010; Fujii et al, 2005; Jing et al, 2000; 
Morgan et al, 2008). Over-expression of the C-FABP gene in non-metastatic rat-cell 
models induced the metastatic phenotype (Jing et al, 2000). Transfecting a vector 
expressing an antisense C-FABP transcript into PC-3M prostatic cancer cells 
significantly inhibited tumorigenicity in-vivo (Adamson et al, 2003).  
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Several studies have reported that FABP expression regulates cell proliferation. Alter 
one or two amino acids of liver-FABP resulted in remarkably inhibited cell 
proliferation and induced apoptosis of prostate and breast cancer cells (Hammamieh 
et al, 2005; Hammamieh et al, 2004). Several genes correlating with cell growth and 
proliferation were down-regulated, and antiproliferative genes were up-regulated in 
response to L-FABP antisense oligonucleotide (Hammamieh et al, 2005). 
Conversely, overexpressed adipocyte-FABP in DU145 prostate cancer cells caused 
apoptosis, perhaps because it down-regulated essential autocrine growth factors, such 
as transforming growth factor-alpha, and upregulated pro-apoptotic factors, such as 
tumour necrosis factor-alpha (De Santis et al, 2004). Antisense oligonucleotide 
blocking C-FABP expression has increased proliferation in DU145 prostate cancer 
cells (Das et al, 2001). Homozygous C-FABP-null mouse keratinocytes showed no 
difference in proliferation compared with wild-type mouse keratinocytes (Kusakari et 
al, 2006). However, the transport and metabolism of fatty acids in prostate cancer 
cells might be important to maintain cell growth, and altered lipid metabolism may 
affect proliferation. The exact mechanism used by C-FABP in increased cell 
proliferation and invasion is worthy of further investigation in-vitro and clarification 
in-vivo.  
 
The tumorigenicity of the LNCaP, 22RV1 and LNCaP-C42 cells stimulated by wild 
type and mutant C-FABPs were tested by examining their anchorage-independent 
growth in soft agar. The number of colonies produced by in soft agar by LNCaP cells 
stimulated with C-FABP-WT was significantly increased by 85% comparing to the 
control cells (Student t-test, P<0.001) (Figure 5.11 and Figure 5.12). Similarly, the 
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number of colonies produced by LNCaP cells stimulated with C-FABP-R109 was 
significantly increased by 45% comparing to the control cells (Student t-test, 
P<0.05). Nevertheless, it was significantly reduced by 3.7-fold comparing to C-
FABP-WT stimulated cells (Student t-test, P<0.005) (Table 5.5). No statistically 
significant difference were observed between the number of colonies produced by 
LNCaP cells stimulated with C-FABP-R109/129A and the number of colonies 
produced by control group (Student t-test, P=0.57). At same time points, the numbers 
of colonies produced by 22RV1 cells stimulated with C-FABP-WT, and C-FABP-
R109A were significantly increased by 82% and 47%, respectively, comparing to the 
control group (Student t-test, P<0.005, P<0.05, respectively) (Figure 5.13 and Figure 
5.14). Whereas, no differences were found between the number of colonies produced 
by C-FABP-R109/129A stimulated cells and the number of colonies produced by the 
control group (Student t-test, P=0.18) (Table 5.6). Further statistic showed that the 
number of colonies produced by 22RV1 stimulated with C-FABP-R109A and C-
FABPR109/129A were significantly reduced by 2.9-fold and 6-fold, respectively, 
when compared to the number of colonies produced by 22RV1 cells stimulated with 
C-FABP-WT (Student t-test, P<0.05, P<0.005, respectively). The number of 
colonies produced by LNCaP-C42 cells stimulated with C-FABP-WT and C-FABP-
R109A were significantly increased by 85% and 59%, respectively, when compared 
to the control group (Student t-test, P<0.001 and P<0.05, respectively) (Figure 5.15 
and Figure 5.16). Whereas, no differences were found between the number of 
colonies produced by LNCaP-C42 cells stimulated with C-FABP-R109/129A and the 
number of colonies produced by the control group (Student t-test, P=0.56) (Table 
5.7). Further statistic showed that the number of colonies produced by LNCaP-C42 
Chapter 6: General Discussion       P a g e  | 253 
 
 
 
 
stimulated with C-FABP-R109A and C-FABPR109/129A were significantly reduced 
by 2.8-fold and 5.7-fold, respectively, when compared to the number of colonies 
produced by LNCaP-C42 cells stimulated with C-FABP-WT (Student t-test, 
P<0.005, P<0.001, respectively). These results suggested that changing one or two 
amino acids in motif of C-FABP by site-directed point mutation significantly 
reduced the tumorigenicity of prostate cancer cells.  
 
The results obtained from in-vitro assays in this work were consistent with our recent 
in-vivo assays, when inoculated with LNCaP-WT cells, 88.9% nude mice developed 
tumours. In contrast, only 50%, 37.5% and 37.5% of the mice inoculated with 
LNCaP-R109A, LNCaP-R109/129A and LNCaP-V cells respectively yielded 
tumours. The average weight of the tumours produced by LNCaP-WT was 5.8- and 
7.3- times of those produced respectively by LNCaP-R109/129A and LNCaP-V cells 
(Malki et al, 2011). This result showed that not only that the wild type C-FABP-
expressing cells produced more but also larger tumours than those cells either not 
expressing C-FABP or expressing mutated C-FABP which was not able to bind and 
transport fatty acids. Furthermore, consistent with this finding, our previous work 
established that suppressing expression of C-FABP by either antisense mRNA or 
RNA interference in the highly malignant prostate cancer cell line PC3M has greatly 
inhibited its ability of forming tumours in nude mouse (Adamson et al, 2003; 
Forootan et al, 2010; Morgan et al, 2008). Therefore, The results of the current and 
previous work in-vitro and in-vivo further confirmed that C-FABP promotes 
malignant progression of prostate cancer by its binding and transporting intracellular 
fatty acids into the cancer cells. 
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Angiogenesis is a process involving the growth of new capillaries from pre-existing 
blood vessels. It has been difficult to identify and characterize the earliest molecular 
changes that facilitate angiogenesis in clinical prostate cancer mostly because of the 
limited availability and access to human tissue representing early-stage disease. A 
number of studies have demonstrated that human prostate tumours and cell lines can 
express VEGF; however, VEGF has also been detected in normal prostate and BPH, 
which reveals the difficulty inherent in a comprehensive analysis of human prostate 
cancer specimens. For example, in one study, the level of VEGF mRNA was found 
to be overexpressed 3-fold or more in 29% of prostate cancer when compared with 
normal prostate (Montecinos et al, 2012). In another study, VEGF protein was 
detected in 90% of prostate cancers and 100% of BPH specimens (Lynch et al, 
2012). However, in a separate study, VEGF protein was detected in 80% of prostate 
cancer, 18% of BPH, and 0% normal prostate samples (Huss et al, 2001). Clearly 
there is some degree of controversy regarding the relationship between VEGF 
expression and prostate disease, complicated by the fact that prostate cancer is a 
heterogeneous disease of a heterogeneous population. Clinical studies revealed that 
the level of VEGF expression in serum, plasma or urine was correlated with higher 
Gleason grade, metastasis and disease-specific survival (Bok et al, 2001; Hudson et 
al, 2012). On the other hand, inhibition of VEGFR-1 and VEGFR-2 using AZD-2171 
(Cediranib, AstraZeneca) induced tumour shrinkage in 56.5% of patients (13 out of 
23 patients with measurable disease) with 4 meeting the criteria
 
for partial response 
(Aragon-Ching & Dahut, 2009). These results indicated that VEGF played a dual 
role in prostate cancer at both the early initiating stage and the later stage for tumour 
progression and metastasis. VEGF interacts with VEGF-2 to stimulate endothelial 
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cell proliferation through the mitogen activated protein kinase (MAPK) pathway and 
promote vascular permeability, and subsequently with VEGFR-1 to assist the 
organization of new capillary tubes. The current studies showed that angiogenesis-
associated genes such as VEGF significantly increased the prostate cancer risk. Our 
recent unpublished data (Malki et al, 2011) showed that increased expression of 
biologically active VEGF was detected in wild type C-FABP transfectants, but not in 
the mutant types of the transfectant cells. These results suggested that increased 
VEGF expression may be caused by wild type C-FABP and that the ability of C-
FABP to increase VEGF depends on its fatty acid-binding ability.  
 
Indeed, we have showed that increased wild type C-FABP stimulation in prostate cell 
line significantly increased cell invasiveness which correlates well with the 
metastasis potential of prostate cancer cells. Cancer metastasis is a complicated 
process, which involves a number of changes in the expression patterns of different 
genes. These changes include the diminished activity of metastasis-suppressing 
genes or the increased activity of metastasis-inducing genes. One such metastasis-
inducing gene identified recently is that for C-FABP, which, when over-expressed, is 
able to cause Rama 37 cells to metastasize. Our current and previous work showed 
that transfection of the C-FABP gene into non-metastatic rat mammary Rama 37 
model cells (Jing et al, 2000) and inoculation of the transfectants into syngeneic 
Wistar Furth rats demonstrated that over-expression of the C-FABP gene can induce 
the non-metastatic Rama 37 cells to metastasize to the lungs and lymph nodes. 
Therefore, the C-FABP gene is suggested to be a metastasis-inducing gene (Jing et 
al, 2001). In addition to blocking invasion, angiogenesis and metastasis, targeting C-
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FABP blocked the growth and proliferation of prostate cancer cells. The growth 
inhibition seen in PC3M cells expressing C-FABP RNAi suggests that, not only does 
targeting C-FABP block the ability of PC3M cells to metastasize, but also the ability 
of primary tumours to expand and secondary metastases to establish at distant sites 
(Lynch et al, 2012). It is possible that reducing C-FABP in prostate cancer cells 
induced defects in growth, invasion and angiogenesis, all contributing to inhibition of 
bone metastasis. C-FABP silencing in the mouse breast cancer cell line 4T1 inhibited 
metastatic nodules to lungs but, did not inhibit primary tumour growth (Liu et al, 
2011). Thusly, targeting C-FABP therapeutically may impair growth at the primary 
tumour site, the ability of cancer cells to escape primary tumours, as well as the 
ability of cancer cells to establish and colonize secondary sites.  A recent study 
showed that C-FABP was over-expressed in oral squamous cell carcinoma (OSCC) 
during early carcinogenesis and tumour metastasis. By increasing or silencing C-
FABP expression in OSCC cells, they found that C-FABP levels were positively 
correlated with in-vitro cell growth, MMP-9 expression and invasiveness (Fang et al, 
2010). MMPs, a family of metalloproteases that degrade extracellular matrix 
proteins, have been associated with cancer cell invasion and metastasis (Deryugina & 
Quigley, 2006). The expression of MMPs, particularly the gelatinases (MMP-2 and 
MMP-9), has been associated with a high potential for metastasis in several human 
carcinomas, including prostate cancer (Shin & Kim, 2012). Fang et al (2010) 
demonstrated that C-FABP overexpression increases MMP-9 expression and OSCC 
invasion. However, the molecular mechanisms through which C-FABP regulates 
MMP-9 expression and OSCC invasion remain unknown. Other studies have shown 
that C-FABP interacted directly with PPAR and S100A7 (Psoriasin) and then 
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modulated their activities (Kwon et al, 2010; Schug et al, 2007b). C-FABP regulated 
the transcriptional activities of PPAR by governing their ligands to target the 
receptor, thereby enabling PPAR to exert its biological functions, such as the PPAR-
betamediated induction of keratinocyte differentiation (Lee et al, 2011). Activated 
PPARs by their ligands or agonists inhibited K562 human erythroleukemia cells and 
the adhesion and invasion of HL-60 human leukaemia cell as well as down-regulated 
the expression of MMP-9 and MMP-2 (Eberhardt et al, 2002). Down-regulation of 
S100A7 expression by RNA silencing in a human invasive breast carcinomas cell 
line up-regulates MMP-13 expression and increases cell migration and invasion 
(Krop et al, 2005; West & Watson, 2010). These data suggested that the effects of C-
FABP on the enhanced MMP-9 production and cancer cells invasion might not be 
associated with these interactions. Therefore, the exact molecular mechanisms of the 
role of C-FABP on cancer invasion and metastasis remain to be explored. 
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6.2 Conclusion   
Subsequent to the results of this study, it is reasonable to hypothesise that there may 
be fatty acid-initiated signalling pathways are involved in the malignant progression 
of prostate cancer cells. The order of these pathways is suggested as: the elevated 
expression of C-FABP gives rise to increased total uptake of fatty acid thus 
enhancing the fatty acid signalling activity. Therefore, it may be possible that 
elevated levels of free fatty acids are transported by C-FABP into the cancer cell 
nuclei to activate downstream mechanisms that might initiate a chain of molecular 
reactions resulting in promotion of cancer growth and expansion. One of such actions 
regulated through this unknown mechanism is to up-regulate some important down-
stream “cancer-promoting” genes, such as VEGF (Adamson et al, 2003; Chen et al, 
2000; Forootan et al, 2010), and hence contribute to carcinogenesis. Thus C-FABP 
which acted as an intercellular fatty acids transporter may play a key role during this 
process. A schematic hypothesis for the involvement of C-FABP in cancer malignant 
progression is shown in Figure 6.1.       
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Figure 6.1: Model for possible C-FABP signalling pathways in prostate cancer 
malignant progression. 
Upon binding to a cognate ligand, C-FABP translocates to the nucleus where it 
directly delivers the ligand to its cognate nuclear receptor, PPARβ/δ. Activation of 
PPARβ/δ results in upregulation of C-FABP. A positive feedback loop is thus 
established: PPARβ/δ activation induces the expression of C-FABP which, in turn, 
enhances the transcriptional activity of the receptor. The FABP5/PPARβ/δ pathway 
induces the expression of PPARβ/δ target genes involved in cell survival, for 
example, PDK1, and growth and angiogenesis, for example, VEGF, and thus 
contributes to prostate cancer development. 
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The free fatty acids move into the blood stream where they are bound by serum 
albumin and transported to the tissue needing fuel (Hajri & Abumrad, 2002). In these 
cells, excessive level  C-FABP binds to and to transport intracellular fatty acids into 
cells, its tumor-promoting activity may be related to its fatty acid-transportting 
ability. Fatty acids have been identified as signalling molecules which can be 
recognised by their nuclear receptor PPARs (Morgan et al, 2010). The elevated 
expression of C-FABP may give rise to an increased total uptake of fatty acids, and 
hence an enhanced fatty acid signalling activity. Moreover, excessive levels of free 
fatty acids may be translocated into the nucleus to activate target genes by PPARs 
through their PPAR recognition (AGGGCANAGGTCA) elements (PPRE). Thus, the 
roles played by FABPs and medium and long chain fatty acids in modulating nuclear 
receptors and gene transcription may have contributed significantly to carcinogenesis 
(Schug et al, 2007b). One of such actions regulated through this unknown 
mechanism is to up-regulate some important down-stream “cancer-promoting” 
genes, such as VEGF (Adamson et al, 2003; Chen et al, 2000; Forootan et al, 2010), 
and hence to facilitate angiogenesis and contribute to carcinogenesis. Angiogenesis 
plays an important role in growth, malignant progression and metastasis by 
promoting endothelial cell proliferation, invasion and capillary differentiation. In 
addition, it has reported that the pathological surrogate for angiogenesis (microvessel 
density) is correlated with malignancy of prostate cancer. The current studies showed 
that angiogenesis-associated genes such as VEGF significantly increased the prostate 
cancer risk. Our recent unpublished data showed that increased expression of 
biologically active VEGF was detected in wild type C-FABP transfectants, but not in 
the mutant types of the transfectant cells. These results suggested that increased 
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VEGF expression may be caused by wild type C-FABP and that the ability of C-
FABP to increase VEGF depends on its fatty acid-binding ability. Other down-
stream genes leading to suppression of apoptosis through up-regulation of PDK/AKT 
pathway may be involving in this pathway, strong evidence suggests that ligand 
activation of PPAR β/δ can enhance the expression of 3-phosphoinositide dependent 
protein kinase 1 (PDK1) and subsequently activate the downstream protein kinase B 
(AKT) by phosphorylation (Di Paola et al, 2011). Activation of the PDK1/AKT 
signalling pathway has a direct effect on cell apoptosis through phosphorylation of 
the BCL-2 family member BCL-2 associated death promoter (BAD) thereby 
suppressing cell apoptosis and promoting cell survival. Schug et al. also suggested 
that PDK1/AKT anti-apoptosis signalling pathway regulated by PPAR β/δ (Schug et 
al, 2007a).    
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6.3 Future work  
As a first step towards testing the hypothesis, we investigated the relationship 
between the tumorigenicity-promoting function of C-FABP and its ability of binding 
to and transporting fatty acid and demonstrated that fatty acid binding and 
transporting ability is essential for C-FABP to promote tumour growth and 
expansion. To fully establish this proposed route of fatty acids signalling pathways, 
further studies are needed to: 
 Investigate how exactly PPAR regulated VEGF leading to angiogenesis. To 
achieve the answer to this question, gene targeting and reporter gene 
technique will be employed to establish whether PPAR can directly activate 
VEGF through its PPAR responsible element (PPRE) located in 5’- un-
translated region.  
 Studies also needed to investigate how PPAR regulate down-stream genes 
leading to suppression of apoptosis in prostate cancer cells. This can be 
achieved by identification of the major down-stream genes through Gene-
Chip micro-array analysis.  
 When assessing the results from micro-array, effort should also be made to 
investigate whether there are any other cancer-promoting molecules up-
regulated.  
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8.1 Appendix 1 
8.1.1 Materials for general molecular Biology 
Reagents      Supplier 
 
Absolute ethanol     BDH 
Agarose      Geneflow 
Bromophenol blue     Sigma 
Calcium Chloride     Sigma 
DEPC       Sigma 
DNA Marker III     Roche 
DNA Marker XIV     Roche 
Ethidium bromide     Sigma 
Glycerol      Sigma 
Isopropanol      BDH 
Microcentrifuge     Beckman Coulter 
NanoDrop ND-1000     NanoDrop Technologies 
Potassium acetate     Sigma 
Potassium chloride     Sigma 
QIAprep Spin Miniprep Kit    Qiagen 
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QIAprep Spin Midiprep Kit    Qiagen 
QIAShredder spin column    Qiagen 
Restriction enzymes     New England BioLabs 
Restriction enzyme buffers    New England BioLabs 
SDS       Sigma 
Sodium chloride     Sigma 
Sodium acetate     Sigma 
Sonicator      Bandelin 
Wizard DNA Clean-up System   Promega 
Xylene cyanol FF     Sigma 
Ni-NTA fast start kit     Qiagen  
 
8.1.2 Materials for transformation of competent bacteria 
Reagents      Supplier 
 
Ampicillin      Sigma 
Bacto-tryptone     Sigma 
DH5  E.coli bacteria     Invitrogen 
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Glucose       Sigma 
Kanamycin      Sigma 
LB agar       Sigma 
LB broth      Sigma 
Magnesium chloride     Sigma 
Magnesium sulphate     Sigma 
MOPS       Sigma 
Yeast extract      Fisher Scientific  
 
8.1.3 Materials for point mutation 
Reagents      Supplier 
 
10x annealing solution    Ambion 
10x T4 DNA ligase buffer    Ambion 
10x T4 Polynucleotide Kinase Buffer  New England BioLabs 
IPTG       Sigma 
Mutagenic and selection primers   Invitrogen 
T4 DNA ligase     Ambion 
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T4 DNA polymerase     Clontech 
T4 Polynucleotide Kinase     New England BioLabs 
Transformer
tm 
Site-Directed Mutagenesis Kit Clontech 
 
8.1.4 Materials for PCR, RT-PCR and Real-time PCR 
Reagents      Supplier 
 
5x First strand buffer     Stratagene 
10x PCR buffer     Promega 
Brilliant II SYBR green Q-PCR master mix  Stratagene 
dNTPs       ABgene 
DTT       Invitrogen 
Oligo (dT)20      Stratagene 
PCR primers      Invitrogen 
RNaseOUT      Invitrogen 
SuperScriptIII reverse transcriptase   Stratagene 
Taq DNA polymerase     Promega 
Thermo-Cycler PTC-200    MJ Research 
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8.1.5 Materials for cell culture 
Reagents      Supplier 
 
Cell culture plates and filter cap flasks  Nunc 
Labofuge 400R (Centrifuge)     Heraeus 
Cryogenic vials     Nunc 
DMSO       Sigma 
EndoGRO basal medium    Millipore 
EndoGRO LS supplement kit    Millipore 
Eppendorf tubes (1.5ml)    Sarstedt 
Fetal calf serum     Biosera 
PixCell II (fluorescence microscope)   Arcturus    
GeneJammer transfection reagent   Stratagene 
Geneticin (G418)     PAA 
Hemocytometer slide     Weber scientific international 
Hydrocotisone      Sigma 
Incubator (Cell culture)    Thermo Scientific 
L-Glutamine      BioWhittaker 
Penicillin/Streptomycin    BioWhittaker 
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Phosphate buffered saline (Tablet)   Gibco  
XGI 1640      PAA 
Sodium pyruvate     Sigma 
Testosterone      Sigma 
Tissue culture pipettes (5ml – 25ml)   Greiner bio-one 
Trypsin      Gibco 
Universal tube  (25ml)    Greiner bio-one 
Versene      Gibco 
Water bath      Grant Instruments 
 
8.1.6 Materials for Western blot 
Reagents      Supplier 
 
-mercaptoethanol     Sigma 
Next gel 12.5%     Pro Pure 
Next gel running buffer     Pro Pure  
Bradford reagent     Sigma 
CelLytic-M      Sigma 
Coomassie brilliant blue    Bio-Rad 
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ECL detaction kit     GE Healthcare 
Hyper films      Amersham Biosciences 
Kodak Developer     Sigma 
Reagents      Supplier 
Kodak Fixer      Sigma 
Pro Sieve colour protein marker   Cambrex 
Methanol      Fisher Scientific 
Nitrocellulose membrane    Amersham biosciences 
Protoblock reagent A &B    ACTG (National diagnostics) 
Roller mixer SRT1     Stuart 
TEMED      Sigma 
Tween-20      Sigma 
 
8.1.7 Materials for fatty acid uptake assay 
Reagents      Supplier 
 
BSA       Sigma 
BODIPY 558/568C12     Invitrogen 
EPICS XL Flow Cytometer    Beckman Coulter 
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8.1.8 Materials for fatty acid Binding assay  
Reagents      Supplier 
 
Myristc acid      Sigma 
Palmitic acid      Sigma  
Oliec acid      Sigma  
Linoleic acid       Sigma  
DAUDA      Cayman Chemical 
 
8.1.9 Materials for cell proliferation assay 
Reagents      Supplier 
 
96-well plate      Nunc 
MTT       Sigma 
Multiscan plate reader    Labsystem 
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8.1.10 Materials for cell invasion assay 
Reagents      Supplier 
  
   
Multiwell 24-well Boyden chamber plate  BD 
Boyden chamber     BD 
Crystal violet      Sigma 
Matrigel      BD 
 
8.1.11 Materials for soft agar assay 
Reagents      Supplier 
 
GelCount      Oxford Optronix 
Low melting point agarose    Geneflow 
Autoclave      Boxer Laboratory Equipment  
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8.2 Appendix 2 
8.2.1 Media and Stock Solutions  
8.2.1.1 Tissue culture  
 
Routine cell culture medium 
 XGI medium 1640    500ml 
 Foetal calf serum     10% (v/v) 
 Pen-Strep (5000U/ml)   5ml 
 L-Glutamine (200mM)   5ml 
 Testosterone (5µg/ml)   5ml 
 Sodium pyruvate  (100mM)   5ml 
 
Freezing medium  
 Routin cell culture medium    92% (v/v)  
 DMSO     8% (v/v) 
 
Trypsin/EDTA solution (2.5%) 
 Versene      100ml 
 Trypsin      2.5ml 
 
MTT solution (5mg/ml) 
 MTT      50mg 
 PBS      10ml 
 
 
Molecular Biology  
 
LB medium  
 LB broth     10g 
 dH2O      500ml 
 
LB agar 
 LB agar     17.5g 
 dH2O      500ml 
 
RF1 buffer (pH 6.8) 
 KCl      100mM 
 MgCl2.4H2O     50mM 
 K-acetate     30mM 
 CaCl2      10mM 
 Glycerol     15% v/v 
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RF2 buffer (pH 6.8) 
 MOPS      10mM 
 KCl      10mM 
 CaCl2.2H2O     75mM 
 Glycerol     15% v/v 
 
SOB medium (pH 7.0) 
 Trypon      2% (w/v) 
 Yeast Extract     0.5% (w/v) 
 NaCl      10mM 
 KCl      2.5mM 
 MgCl2      10mM 
 MgSO4      10mM 
 
SOC medium (pH 7.0) 
 Trypon      2% (w/v) 
 Yeast Extract     0.5% (w/v) 
 NaCl      10mM 
 KCl      2.5mM 
 MgCl2      10mM 
 MgSO4      10mM 
 Glucose     20mM 
 
Stock medium for bacteria 
 Glycerol     50% (v/v) 
 LB medium with bacteria   50% (v/v) 
 
 
8.2.1.2 Qiagen Midi-prep plasmid extraction buffers 
 
Buffer P1 – Resuspension buffer 
 Tris-HCl (pH 8.0)     50mM 
 EDTA      10mM 
 RNaseA     100μg/ml 
 
Buffer P2 – Lysis buffer 
 NaOH      200mM 
 SDS       1% (w/v) 
 
Buffer P3 – Neutralising buffer 
 K-acetate (pH 5.5)     3.0M 
 
Buffer QBT – Equilibration buffer 
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 NaCl      750mM 
 MOPS (pH 7.0)     50mM 
 Isopropanol     15% (v/v) 
 Triton X-100     15% (v/v) 
 
Buffer QC – Wash buffer 
 NaCl      1.0M 
 MOPS (pH7.0)     50mM 
 Isopropanol     15% (v/v) 
 
Buffer QF – Elution buffer 
 NaCl      1.25M 
 Tris-HCl (pH 8.5)    50mM 
 Isopropano     15% (v/v) 
 
TE buffer (pH 7.5) 
 Tris-HCl     10 mM 
 EDTA      1 mM 
 
 
8.2.1.3 Wizard SV gel and PCR clean-up system buffers 
 
Membrane binding solution  
 Guanidine isothiocyante   4.5M 
 K-acetate (pH5.0)     0.5M 
 
Membrane wash solution 
 K-acetate (pH5.0)     10mM 
 Ethanol     80% (v/v) 
 EDTA (pH8.0)     16.7μM 
 
DNA loading buffer 
 Bromophenol blue    0.25% (w/v) 
 Xylene cyanol FF    0.25% (w/v) 
 Glycerol     30% (v/v) 
 dH2O      70% (v/v) 
 
10x TBE buffer (pH 8.0) 
 Tris base      890mM 
 Boric acid     890mM 
 EDTA      20mM 
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8.2.1.4 Western blot buffers 
 
5x SDS-PAGE sample loading buffer 
 1M Tris-HCl (pH 6.8)    1.25ml 
 40% (v/v) Glycerol    15ml 
 10% SDS     5ml 
 1% (w/v) Bromophenol blue   2.5ml 
 -mercaptoethanol    1.25ml 
 
Running Buffer 
 Next gel running buffer    25ml   
 Distilled water    500ml 
 
Transfer Buffer 
 Glycine     192mM 
 Methanol     20% (v/v) 
 Tris base     25mM 
 
10x TBS (pH 7.5) 
 Tris base     500mM 
 NaCl      1500mM 
 
TBS-Tween (Washing Buffer) 
 1x TBS     1000ml 
 Tween 20      1ml 
 
Blocking Buffer  
 5% Skimmed milk    5mg 
 TBST      100ml 
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8.3 Appendix 3 
Sequences alignment of the wild type and mutant C-FABP cDNAs  
Score = 1212 bits (656),  Expect = 0.0 
 Identities = 662/662 (100%), Gaps = 0/662 (0%) 
 Strand=Plus/Plus 
 
Query  250  CGCCGACGCAGACCCCTCTCTGCACGCCAGCCCGCCCGCACCCACCATGGCCACAGTTCA  309 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  68   CGCCGACGCAGACCCCTCTCTGCACGCCAGCCCGCCCGCACCCACCATGGCCACAGTTCA  127 
 
Query  310  GCAGCTGGAAGGAAGATGGCGCCTGGTGGACAGCAAAGGCTTTGATGAATACATGAAGGA  369 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  128  GCAGCTGGAAGGAAGATGGCGCCTGGTGGACAGCAAAGGCTTTGATGAATACATGAAGGA  187 
 
Query  370  GCTAGGAGTGGGAATAGCTTTGCGAAAAATGGGCGCAATGGCCAAGCCAGATTGTATCAT  429 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  188  GCTAGGAGTGGGAATAGCTTTGCGAAAAATGGGCGCAATGGCCAAGCCAGATTGTATCAT  247 
 
Query  430  CACTTGTGATGGTAAAAACCTCACCATAAAAACTGAGAGCACTTTGAAAACAACACAGTT  489 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  248  CACTTGTGATGGTAAAAACCTCACCATAAAAACTGAGAGCACTTTGAAAACAACACAGTT  307 
 
Query  490  TTCTTGTACCCTGGGAGAGAAGTTTGAAGAAACCACAGCTGATGGCAGAAAAACTCAGAC  549 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  308  TTCTTGTACCCTGGGAGAGAAGTTTGAAGAAACCACAGCTGATGGCAGAAAAACTCAGAC  367 
 
Query  550  TGTCTGCAACTTTACAGATGGTGCATTGGTTCAGCATCAGGAGTGGGATGGGAAGGAAAG  609 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  368  TGTCTGCAACTTTACAGATGGTGCATTGGTTCAGCATCAGGAGTGGGATGGGAAGGAAAG  427 
 
Query  610  CACAATAACAAGAAAATTGAAAGATGGGAAATTAGTGGTGGAGTGTGTCATGAACAATGT  669 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  428  CACAATAACAAGAAAATTGAAAGATGGGAAATTAGTGGTGGAGTGTGTCATGAACAATGT  487 
 
Query  670  CACCTGTACTCGGATCTATGAAAAAGTAGAATAAAAATTCCATCATCACTTTGGACAGGA  729 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  488  CACCTGTACTCGGATCTATGAAAAAGTAGAATAAAAATTCCATCATCACTTTGGACAGGA  547 
 
Query  730  GTTAATTAAGAGAATGACCAAGCTCAGTTCAATGAGCAAATCTCCATACTGTTTCTTTCT  789 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  548  GTTAATTAAGAGAATGACCAAGCTCAGTTCAATGAGCAAATCTCCATACTGTTTCTTTCT  607 
 
Query  790  TTTTTTTTTCATTACTGTGTTCAATTATCTTTATCATAAACATTTTACATGCAGCTATTT  849 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  608  TTTTTTTTTCATTACTGTGTTCAATTATCTTTATCATAAACATTTTACATGCAGCTATTT  667 
 
Query  850  CAAAGTGTGTTGGATTAATTAGGATCATCCCTTTGGTTAATAAATAAATGTGTTTGTGCT  909 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  668  CAAAGTGTGTTGGATTAATTAGGATCATCCCTTTGGTTAATAAATAAATGTGTTTGTGCT  727 
 
Query  910  AA  911 
            || 
Sbjct  728  AA  729 
 
 
Figure 8.1: Confirmation of insertion of C-FABP-WT cDNA into pQE32 
Sequence alignment was determined by using BioEdit for searching Genbank 
(BLAST).The sequences alignment showed a 100% sequences match between Query 
(C-FABP-WT) and subject (database sequence).           
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Score = 1201 bits (650),  Expect = 0.0 
 Identities = 661/663 (99.5%), Gaps = 2/663 (0%) 
 Strand=Plus/Plus 
 
Query  252  CGCCGACGCAGACCCCTCTCTGCACGCCAGCCCGCCCGCACCCACCATGGCCACAGTTCA  311 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  68   CGCCGACGCAGACCCCTCTCTGCACGCCAGCCCGCCCGCACCCACCATGGCCACAGTTCA  127 
 
Query  312  GCAGCTGGAAGGAAGATGGCGCCTGGTGGACAGCAAAGGCTTTGATGAATACATGAAGGA  371 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  128  GCAGCTGGAAGGAAGATGGCGCCTGGTGGACAGCAAAGGCTTTGATGAATACATGAAGGA  187 
 
Query  372  GCTAGGAGTGGGAATAGCTTTGCGAAAAATGGGCGCAATGGCCAAGCCAGATTGTATCAT  431 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  188  GCTAGGAGTGGGAATAGCTTTGCGAAAAATGGGCGCAATGGCCAAGCCAGATTGTATCAT  247 
 
Query  432  CACTTGTGATGGTAAAAACCTCACCATAAAAACTGAGAGCACTTTGAAAACAACACAGTT  491 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  248  CACTTGTGATGGTAAAAACCTCACCATAAAAACTGAGAGCACTTTGAAAACAACACAGTT  307 
 
Query  492  TTCTTGTACCCTGGGAGAGAAGTTTGAAGAAACCACAGCTGATGGCAGAAAAACTCAGAC  551 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  308  TTCTTGTACCCTGGGAGAGAAGTTTGAAGAAACCACAGCTGATGGCAGAAAAACTCAGAC  367 
 
Query  552  TGTCTGCAACTTTACAGATGGTGCATTGGTTCAGCATCAGGAGTGGGATGGGAAGGAAAG  611 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  368  TGTCTGCAACTTTACAGATGGTGCATTGGTTCAGCATCAGGAGTGGGATGGGAAGGAAAG  427 
 
Query  612  CACAATAACAGCAAAAATTGAAAGATGGGAAACTAGTGGTGGAGTGTGTCATGAACAATG  670 
            ||||||||||  |||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  428  CACAATAACAAGAAAAATTGAAAGATGGGAAATTAGTGGTGGAGTGTGTCATGAACAATG  486 
 
Query  671  TCACCTGTACTCGGATCTATGAAAAAGTAGAATAAAAATTCCATCATCACTTTGGACAGG  730 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  487  TCACCTGTACTCGGATCTATGAAAAAGTAGAATAAAAATTCCATCATCACTTTGGACAGG  546 
 
Query  731  AGTTAATTAAGAGAATGACCAAGCTCAGTTCAATGAGCAAATCTCCATACTGTTTCTTTC  790 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  547  AGTTAATTAAGAGAATGACCAAGCTCAGTTCAATGAGCAAATCTCCATACTGTTTCTTTC  606 
 
Query  791  TTTTTTTTTTCATTACTGTGTTCAATTATCTTTATCATAAACATTTTACATGCAGCTATT  850 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  607  TTTTTTTTTTCATTACTGTGTTCAATTATCTTTATCATAAACATTTTACATGCAGCTATT  666 
 
Query  851  TCAAAGTGTGTTGGATTAATTAGGATCATCCCTTTGGTTAATAAATAAATGTGTTTGTGC  910 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  667  TCAAAGTGTGTTGGATTAATTAGGATCATCCCTTTGGTTAATAAATAAATGTGTTTGTGC  726 
 
Query  911  TAA  913 
            ||| 
Sbjct  727  TAA  729 
 
Figure 8.2: Confirmation of insertion of C-FABP-R109A cDNA into pQE32  
Sequence alignment was determined by using BioEdit for searching Genbank 
(BLAST) (appendix 3). The sequences marked in red colour confirmed the location of 
single mutation (The Alanine GCA, mutated from Arginine AGA). The sequences 
alignment showed a 99.5% sequences match between Query (C-FABP-R109A) and 
subject (database sequence). The 0.5% gap confirmed the location of Single mutant.           
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Score = 1190 bits (644),  Expect = 0.0 
 Identities = 660/664 (99%), Gaps = 4/664 (1%) 
 Strand=Plus/Plus 
 
Query  258  CGCCGACGCAGACCCCTCTCTGCACGCCAGCCCGCCCGCACCCACCATGGCCACAGTTCA  317 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  68   CGCCGACGCAGACCCCTCTCTGCACGCCAGCCCGCCCGCACCCACCATGGCCACAGTTCA  127 
 
Query  318  GCAGCTGGAAGGAAGATGGCGCCTGGTGGACAGCAAAGGCTTTGATGAATACATGAAGGA  377 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  128  GCAGCTGGAAGGAAGATGGCGCCTGGTGGACAGCAAAGGCTTTGATGAATACATGAAGGA  187 
 
Query  378  GCTAGGAGTGGGAATAGCTTTGCGAAAAATGGGCGCAATGGCCAAGCCAGATTGTATCAT  437 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  188  GCTAGGAGTGGGAATAGCTTTGCGAAAAATGGGCGCAATGGCCAAGCCAGATTGTATCAT  247 
 
Query  438  CACTTGTGATGGTAAAAACCTCACCATAAAAACTGAGAGCACTTTGAAAACAACACAGTT  497 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  248  CACTTGTGATGGTAAAAACCTCACCATAAAAACTGAGAGCACTTTGAAAACAACACAGTT  307 
 
Query  498  TTCTTGTACCCTGGGAGAGAAGTTTGAAGAAACCACAGCTGATGGCAGAAAAACTCAGAC  557 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  308  TTCTTGTACCCTGGGAGAGAAGTTTGAAGAAACCACAGCTGATGGCAGAAAAACTCAGAC  367 
 
Query  558  TGTCTGCAACTTTACAGATGGTGCATTGGTTCAGCATCAGGAGTGGGATGGGAAGGAAAG  617 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  368  TGTCTGCAACTTTACAGATGGTGCATTGGTTCAGCATCAGGAGTGGGATGGGAAGGAAAG  427 
 
Query  618  CACAATAACAGCAAAAATTGAAAGATGGGAAACTAGTGGTGGAGTGTGTCATGAACAATG  676 
            ||||||||||  |||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  428  CACAATAACAAGAAAAATTGAAAGATGGGAAATTAGTGGTGGAGTGTGTCATGAACAATG  486 
 
Query  677  TCACCTGTACT--GATCTATGAAAAAGTAGAATAAAAATTCCATCATCACTTTGGACAGG  735 
            ||||||||||| || ||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  487  TCACCTGTACTCGGATCTATGAAAAAGTAGAATAAAAATTCCATCATCACTTTGGACAGG  545 
 
Query  736  GAGTTAATTAAGAGAACGACCAAGCTCAGTTCAATGAGCAAATCTCCATACTGTTTCTTT  795 
            |||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  546  GAGTTAATTAAGAGAATGACCAAGCTCAGTTCAATGAGCAAATCTCCATACTGTTTCTTT  605 
 
Query  796  CTTTTTTTTTTCATTACTGTGTTCAATTATCTTTATCATAAACATTTTACATGCAGCTAT  855 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  606  CTTTTTTTTTTCATTACTGTGTTCAATTATCTTTATCATAAACATTTTACATGCAGCTAT  665 
 
Query  856  TTCAAAGTGTGTTGGATTAATTAGGATCATCCCTTTGGTTAATAAATAAATGTGTTTGTG  915 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  666  TTCAAAGTGTGTTGGATTAATTAGGATCATCCCTTTGGTTAATAAATAAATGTGTTTGTG  725 
 
Query  916  CTAA  919 
            |||| 
Sbjct  726  CTAA  729 
 
Figure 8.3: Confirmation of insertion of C-FABP-R109/129A into pQE32  
Sequence alignment was determined by using BioEdit for searching Genbank 
(BLAST). The sequences marked in red colour confirmed the location of the double 
mutations (The Alanine GCA, mutated from Arginine AGA and the Alanine GCG, 
converted from Arginine CGG). The sequences alignment showed a 99% sequences 
match between Query (C-FABP-R109/129A) and subject (database sequence). The 
1% gap confirmed the location of Single and double mutations.  
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